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Abstract 
Increased levels of systemic immune activation are strongly associated with disease 
progression in HIV-1 infection, but the mechanisms causing it are not well understood. 
This work investigated the TH17 subset in the gastrointestinal tract of HIV-1 infected 
patients and looked for evidence that mucosal barrier breaches and microbial 
translocation contribute to peripheral immune activation. We found significant 
disruption in the expression of mucosal tight junction proteins in HIV-1 infection that 
only partially resolved on ART. This mucosal damage was positively correlated to plasma 
HIV viral load and 16s rDNA. Increased microbial translocation in viraemic infection 
correlated to elevated T cell activation and viral load. We found no evidence of reduced 
mucosal TH17-associated cytokines (IL-17a, IL-17f and IL-22) in our HIV cohort, but 
did observe reduced mucosal TH17 precursor cells (CD4+CD161+) in viraemic 
infection. Precursor TH17 loss was associated with increased tight junction breaches and 
T cell activation.  
 
To investigate the dual role of TH17 cells in promoting inflammation and maintaining 
barrier function in the gut mucosa we also studied inflammatory bowel disease. Tight 
junction disruption was observed in both active ulcerative colitis (UC) and Crohn’s 
disease (CD) and occurred at a similar level as in viraemic HIV infection. Unlike HIV 
patients we found no evidence of microbial products in the periphery of IBD patients. 
Some T cell activation was seen in active UC but none found in CD patients. In active 
UC there was evidence of TH17 cytokine driven pathology with increased levels of blood 
and mucosal IL-22 and IL-17f production by CD4 T cells. Blood and mucosal IL-17f 
proportions were positively correlated to the ulcerative colitis severity score (UCSS) and 
blood CD4+ IL-17f levels positively correlated with T cell activation. In contrast to UC 
we found little evidence of TH17 dysregulation in the blood or mucosa of CD patients.  
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In conclusion this work found that there was a reduction in mucosal integrity, loss of 
mucosal CD4 T cells and precursor TH17 cells in HIV-1 infection. Loss of mucosal 
integrity in HIV was associated with microbial translocation and systemic T cell 
activation. We identified a correlation between reduced levels of mucosal precursor 
TH17 cells and increased mucosal damage in HIV infection, supporting the theory that 
this subset has a role in HIV-1 pathogenesis. However in UC, the inverse observation - 
elevated levels of precursor TH17 cells associated with increased mucosal damage - was 
made, reinforcing the paradoxical theory that this subset plays directly contrasting roles 
in different pathogenic environments. 
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Chapter 1  Introduction 
 
1.1 General Introduction 
 
Since 1981 Human Immunodeficiency Virus (HIV) infection has claimed the lives of 38 
million people worldwide. It was identified in 1983 as a T lymphotrophic retrovirus 
(Barré-Sinoussi et al. 1983). HIV infection results in depletion of the CD4 T cell, 
dysregulation of other immune cells and ultimate loss of control of multiple pathogens 
leading to the Acquired Immunodeficiency Syndrome (AIDS). After the introduction of 
highly active antiretroviral therapy (ART) in 1996 deaths from AIDS declined rapidly in 
high-income countries. Life expectancy of HIV infected patients in the UK increased by 
more than 15 years between 1996-2008 but is still more than 10 years below that of the 
uninfected UK population (May et al. 2011).  HIV comorbidities including 
cardiovascular, renal, hepatic and gastrointestinal diseases have increased in the ART-
treated population. 
 
Immune activation is now recognised as a central feature of HIV infection and a major 
cause of progression to AIDS (Hazenberg et al. 2003). Ongoing immune activation in the 
ART setting has also been implicated in the development of comorbidities. The leakage 
of microbes from the gut into systemic circulation has been identified as a cause of 
immune activation (Brenchley et al. 2006b) and the preferential loss of the TH17 subset 
from the gastrointestinal associated mucosal tissues (GALT) during infection, has been 
suggested as a cause of microbial translocation (Brenchley et al. 2008). In this work we 
investigated associations between mucosal damage and mucosal T cell subsets with 
markers of microbial damage and immune activation.     
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1.2 Immune Response to Infection 
1.2.1 The Innate Immune System 
 
The innate immune system represents the first arm of defense against pathogens that have 
breached the skin and mucosal barriers of the human body. It is activated in an antigen 
nonspecific manner within minutes of first contact.  
 
Pathogen sensing by the immune system occurs after pattern recognition receptors 
(PRRs) expressed on dendritic cells, macrophages, neutrophils and epithelial cells 
recognise pathogen-associated molecular patterns (PAMPs) (Medzhitov and Janeway 
2002), such as lipopolysaccharide on gram-negative bacteria. This rapidly triggers a wide 
array of inflammatory cytokines, chemokines and type 1 interferons that lead to 
neutrophil and macrophage recruitment to infection sites. Several families of PRRs exist 
including Toll-Like Receptors (TLRs), Nucleotide oligomerisation domain (NOD) like 
receptors, retinoic acid-inducible gene I (RIG-I) like receptors, DNA receptors, C-Type 
lectin receptors and secreted PRRs such as pentraxins and collectins. 
 
1.2.1.1 Toll-like receptors 
TLRs are a family of ten transmembrane receptors that can be split into two families 
(Table 1-1, (Kumar et al. 2011)). TLR 1,2,4,5,6 and 11 are expressed in plasma 
membranes where they sense bacterial, fungal and protozoal product leading to 
inflammatory cytokine production, and TLR 3, 7, 8 and 9 are expressed in endosomal 
membranes and sense viral nucleic acids leading to the induction of type 1 IFNs.  
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TLR Recognition Expression 
1, 2, 6 Triacylated lipopetides (TLR1/TLR2 dimer) 
Diacylated lipopetides (TLR2/TLR6 dimer) 
Gram negative bacterial cell wall (peptidoglycan, 
lipoteichoic acid, lipoprotein) (TLR2) 
Macrophages, dendritic cells, B cells, 
regulatory T cells 
3 Viral dsRNA Endosomes of macrophages, dendritic 
cells, CD8+ dendritic cells 
4 Lipopolysaccharide (LPS), RSV fusion protein, 
Ebola virus glycoprotein 
Macrophages, dendritic cells, 
neutrophils, endothelium 
5 Bacterial flagellin Dendritic cells 
7 Group B streptococci, viral RNA Endosomes of plasmacytoid dendritic 
cells 
8 Viral RNA, bacterial RNA Endosomes Macrophages, myeloid 
dendritic cells 
9 Bacterial or viral CpG dsDNA Endosomes of Plasmacytoid dendritic 
cells, macrophages, epithelium 
Table 1-1 Toll-like Receptor recognition and expression overview.  
 
TLR4 is the most prodigious activator of macrophages known and once activated it can 
lead to septic shock in the host. The recognition of lipopolysacharide by TLR4 is 
therefore necessarily complex requiring a co-receptor, MD-2, and two accessory 
proteins, LPS- binding protein (LBP) and CD14 (Figure 1-1, Chow et al. 1999). LBP is 
produced by gastrointestinal and hepatic epithelial cells and CD14 by hepatic cells and 
secreted by macrophages in response to LPS stimulation (Hailman et al. 1994).  
 
 
 
 
 
 
 
 
 
 
 Figure 1-1 LPS binding to TLR4. LPS binds LBP in serum and the LPS-LBP complex binds CD14 on monocytes. 
CD14 then associates with TLR4 and its accessory protein MD2 leading to signal transduction.  
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1.2.1.2 Innate Recognition of Viral Infection 
Viral double stranded (ds) RNA is sensed in an infected cell by TLR3, TLR7/8 
recognises single-stranded RNA and TLR9 recognises unmethylated CpG motifs within 
viral DNA. Viral recognition leads to the activation of IFN regulatory factor (IRF) 3, 
IRF5 and IRF7. These then form homo- or heterodimers that enter the nucleus and 
activate the transcription of the type 1 interferons, IFNα and IFNβ. Type 1 interferons 
bind the IFN-receptor on infected cells and those nearby to activate the Janus Kinase-
Signal Transducing Activators of Transcription (JAK-STAT) pathway leading to the 
synthesis of antiviral proteins (protein kinase R, oligoadenylate synthetase). IFNs also 
induce the expression of co-stimulatory molecules on antigen-presenting cells enhancing 
presentation to T cells and increasing MHC class I expression on cells leading to 
increased recognition by cytotoxic CD8 T cells (Xagorari and Chlichlia 2008).   
 
1.2.1.3 NOD-like receptors (NLRs) 
The second major family of PRRs are the cytosolic NLRs, of which there are three main 
subfamilies defined by their additional domains, Nlrb, Nlrp and Nlrc. The Nlrc groups 
are defined by the presence of the caspase recruitment domain (CARD) and include 
NOD1 and NOD2 (Kumar et al. 2011). These NLRs sense bacterial peptidoglycan, a 
component of the cell wall of both gram negative and positive bacteria. They also play a 
role in autophagy, a process whereby an autophagosome digests material in the cytosol 
leading to presentation on MHC class II molecules. 
 
1.2.2 Adaptive Immunity 
 
Antigen recognition by T cells is central to the generation and regulation of an effective 
immune response. The primary role of a CD8 T cell (cytotoxic T lymphocyte, CTL) is 
to identify and destroy an infected cell. CD4 T (T Helper, TH) cells enhance and 
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maintain CD8 responses and are required by B cells for help to produce antibody (T 
follicular helper cells, TfH), they are also important mediators of immunologic memory.  
 
1.2.2.1 T cell Maturation and Activation 
A CD4-CD8- α/β T cell precursor enters the thymus from the bone marrow where at 
the cortex it becomes double positive and expresses both CD4 and CD8. Positive 
selection of functional TCRs occurs via MHC expression on epithelial cortical cells, if a T 
cell does not have sufficient affinity for self-MHC peptides it is deleted. If the T cell has 
sufficient affinity for MHC class I a CD4-CD8+ T cell is generated and if the affinity is 
for MHC class II a CD8-CD4+ T cell is produced (Figure 1-2).  
 
 
 
 
 
 
 
 
 
 
Figure 1-2 Positive and negative selection of T cells in the thymus. 
 
CD4+ or CD8+ T cells with a strong affinity for self-peptides are deleted at the cortico-
medullary junction. Self-peptides are presented in this region by thymic epithelial cells 
under the control of the Autoimmune Regulator (AIRE) and by dendritic cells via cross 
presentation. Only around 10% of total T cells that enter the thymus survive positive 
and negative selection. Once these cells reach the medulla they are mature antigen-naïve 
CD4+ or CD8+ T cells that go on to circulate between the lymph nodes, spleen and 
mucosal lymphoid organs.  
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Differentiation of naïve CD4 or CD8 T cells into effector T cells occurs after stimulation 
by their cognate antigen presented to them by MHC class I/II on antigen-presenting cells 
(APCs). Antigen recognition results in signal transduction via the CD3 complex, which 
together with co-stimulatory signals on APCs (CD80/CD86) leads to proliferation, IL-2 
secretion and effector cell function development. Activation is tightly controlled by 
CTLA-4, which is co-expressed on an APC after T cell activation and binds CD28 on T 
cells to limit activation.  
 
Naïve CD8 T cells are activated in the T cell rich zone of lymphatic tissue. CD8 T cells 
are crucial in controlling viral infections by direct lysis of infected cells using granzyme 
and perforin or through FAS and CD95 interaction leading to apoptosis. They also 
produce various antiviral cytokines (IFNγ, IL-2, TNF, MIP1α, MIP1β) that upregulate 
antigen processing and MHC I expression and inhibit viral replication. 
 
1.2.2.2 CD4 Subset differentiation 
The cytokine environments present during TCR-mediated activation of CD4 T cells 
activates the Signaling Transducer and Activator of Transcription (STAT) signaling 
pathways, which induce the master regulators and play a central role in the 
differentiation of the T Helper (TH) lineage. The current accepted subsets of TH cells 
are TH1, TH2, iTreg, TfH (T follicular helper), TH17 and TH22 cells (Figure 1-3). 
Each TH cell subset produces an effector cytokine that further promotes differentiation 
to its lineage, providing a positive amplification loop.  
 
TH1 
A TH1 phenotype is conferred on a naïve CD4 cell in the presence of the cytokines IFNγ 
and IL-12 produced by dendritic cells. TH1 cells are characterised by the secretion of 
IFNγ but also produce high levels of IL-2, GM-CSF and TNF. They have a major role in 
cell-mediated immunity against intracellular viruses, bacteria and protozoa and confer 
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help to NK cells and CD8 T cells promoting cytotoxicity. Their differentiation process 
involves up-regulation of the master transcription regulator T-bet due to activation of 
STAT-4.  STAT-4 and STAT-1 are involved in maintaining and amplifying the TH1 
response, activated STAT-4 directly induces IFNγ secretion and T-bet expression 
(Mullen et al. 2001).  
 
TH2 
TH2 cells direct humoral immunity and are involved in clearing extracellular pathogens. 
Their signature cytokine is IL-4 and they also produce IL-5 and IL-13. They drive B cells 
to produce IgE and are involved in the selective maturation of eosinophils and the 
degranulation of mast cells and basophils. The TH2 phenotype is induced by an IL-4 and 
IL-10 cytokine environment and is under the control of the master regulator GATA3 via 
STAT-6 activation. GATA3 promotes TH2 differentiation by suppressing TH1 
differentiation and selectively stimulating TH2 growth.  
 
Treg 
T regulatory cells are critical in controlling the immune response to infection and in 
maintaining tolerance to self. Naturally occurring Tregs (nTregs) originate in the thymus 
and are characterised by production of high levels of the master transcription factor 
FOXP3 (forkhead transcription factor 3). T regulatory functions can also be induced 
from a naïve T cell in the periphery exposed to a TGFβ/IL-10 cytokine environment 
which leads to its develops into an iTreg (inducible T regulatory cell). Natural Tregs 
express the IL-2 receptor α chain CD25, CD45RO, CTLA-4 and CD27, but none of 
these markers are specific for Tregs. Foxp3 can also be transiently expressed on activated 
T cells (Mantel et al. 2006) making Treg identification difficult in an inflammatory 
setting.  
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TFH 
T follicular helper cells reside in the B cell areas of secondary lymphoid tissue and 
support the activation and differentiation of B cells via expression of CD40L and 
production of IL-21. They develop under the direction of the transcriptional repressor 
Bcl6 and express CXCR5, the B cell zone homing chemokine receptor, and ICOS 
(inducible T cell co-stimulator) (Ma et al. 2012).  
 
TH17 
TH17 cells are characterised by expression of the lineage specific transcription factor 
retinoic orphan receptor-γt (RORγt), STAT-3, the chemokine receptors CCR4 and 
CCR6 and IL-23R (Acosta-Rodriguez et al. 2007).  
 
A TH17 cell exclusively originates from a CD161+ CD4+ naïve T cell precursor pool 
(Cosmi et al. 2008). CD161 is a member of the killer cell lectin-like receptor 
superfamily and is expressed on most NK and NKT cells, in precursor TH17 and TH17 
cells it may have a role in transendothelial migration (Annunziato et al. 2010). TH17 
precursor cells are detectable in the thymus and umbilical cord and can also give rise to 
TH1 and TH2 subsets under certain polarising conditions (Cosmi et al. 2008).  
 
Differentiation to TH17 occurs via STAT3 activation in a TGFβ, IL-6 and IL-21 rich 
environment. STAT3 binds the il17 and il21 genes and induces RORγt and IL-23R 
expression, activation by IL-6 also promotes down regulation of foxp3 in Tregs. IL-23 is 
important in the priming and maintenance of the TH17 phenotype, it is inhibited by high 
concentrations of TGFβ and in the absence of IL-6 Treg differentiation will occur, TH17 
and Tregs therefore have a reciprocal relationship. The signature cytokines produced by 
TH17 cells are IL-17a, IL-17f and IL-22, they also produce IL-6, IL-21, CCL20 and 
TNF. IL-17a and IL-17f can also be produced by γδ T cells, natural killer T cells, NK 
cells and eosinophils (Korn et al. 2009). 
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The TH17 subset has a central role in host defense against extracellular pathogens, in 
particular at the mucosal surfaces. They also promote inflammation, and have been 
implicated in a variety of inflammatory and autoimmune diseases (Caprioli et al. 2008, 
Cosmi et al. 2014, Lee et al. 2014). IL-17a acts on a broad range of cells to induce 
proinflammatory cytokine and chemokine production, it has also been shown to enhance 
the expression of antimicrobial peptides. IL-17a and IL-17f have a central role in 
recruitment of neutrophils to mucosal sites, directly by IL-8 production (Pelletier et al. 
2010) and indirectly by induction of G-CSF and CXCL8 in other cells.  IL-17a also acts 
to maintain mucosal barriers by inducing the expression of the claudin tight junction 
proteins in intestinal epithelial cells and stimulating epithelial cell proliferation and 
mucin production to enhance the intestinal barrier (Kinugasa et al. 2000). IL-17f can 
form heterodimers with, and has a similar function to, IL-17a though perhaps has a 
reduced inflammatory role (Dubin and Kolls 2008).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-3 T helper cell subset differentiation from a naïve CD4 T cell. Cytokines in green, transcription factor and 
activation pathway in black. 
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TH22 
TH22 cells differentiate under the control of the aryl hydrocarbon transcription factor in 
the presence of IL-6 and TNF. They express the chemokine receptors CCR4, CCR6 and 
CCR10 and secrete IL-22, TNF and IL-13.  Similar to IL-17a, IL-22 promotes mucosal 
healing through epithelial cell proliferation and increased mucin production. In the skin 
IL-22 promotes expression of antimicrobial peptides such as β defensins and has a role in 
wound repair (Akdis et al. 2012). 
 
Plasticity 
T helper cell responses are flexible and the ability to secrete signature cytokines of one 
TH population may be acquired by other TH cells in certain situations. For instance TH2 
and TH17 cells can acquire the ability to produce IFNγ (Lee et al. 2009). Expression of 
the master transcription factors is also more complicated than previously thought, after 
viral infection some TH2 cells coexpress T-bet with GATA3 and adopt features of TH2 
and TH1 cells. T cells coexpressing T-bet and Bcl6 have also been described as have Treg 
cells expressing Foxp3 together with T-bet, GATA3 and Bcl6, which may be important 
in the control of the TH1, TH2 and TFH response (Hirahara et al. 2013). TH1TH17 
cells expressing T-bet and ROR-c have also been described (Acosta-Rodriguez et al. 
2007) and TH17 cells can also differentiate fully into TH1 cells in inflammatory 
environments.  
 
1.2.2.3 T cell Memory 
After activation a T cell proliferates and acquires effector functions. The majority of 
these cells then die but a small proportion differentiate into effector memory (EM) T 
cells, or long-lived central memory (CM) T cells. Effector memory T cells (CCR7-
CD62L-) reside in peripheral tissues and mediate direct effector functions (cytokine 
production and cytotoxicity) against pathogens. The central memory subset expresses 
 32 
the lymph node homing receptors CCR7 and CD62L and produces IL-2 but has limited 
effector function.  
 
CD27 can be used to divide the T cell memory pool into responding/effector versus 
resting/central memory T cells. The effector memory CD27- population is short-lived, 
more differentiated, with high level secretion of a broad range of effector cytokines (e.g. 
IFNγ and TNF) and a strong antigen recall response whereas the CD27+ subset has a 
lower proliferative response (Schiött et al. 2004). CM cells may act as memory stem 
cells, capable of self-renewal and continuously producing effector cells to replenish the 
EM pool (Lanzavecchia and Sallusto 2005).  Recently tissue resident memory T cells 
have been described, these CCR7-CD69+ represent the predominant T cell subsets in 
the lungs, intestine, skin and bone marrow (Farber et al. 2014).  Continuous antigenic 
stimulation can lead to the progressive loss of memory potential and reduced cytokine 
secretion resulting in a terminally differentiated (TERM) T cell. This cell is short-lived, 
produces IFNγ alone and is characterised by a CCR7-CD27-CD45RO- phenotype (Seder 
et al. 2008).  
 
1.3 Mucosal Immunity 
1.3.1 Mucosal Immune structures  
 
The mucosal immune system is composed of the gastrointestinal (GI), urogenital, and 
upper and lower respiratory tract. It is the largest immune tissue in the body with more 
than 60% of total body lymphocytes contained within the Mucosal-Associated Lymphoid 
Tissue (MALT) (Wittkopf et al. 2014). The MALT maintains protective immunity while 
preventing unnecessary and damaging responses against commensal microorganisms and 
food antigens. 
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The GI tract comprises the stomach, duodenum, jejunem, ileum, colon, rectum and anal 
canal. It has the largest surface area in direct contact with external antigens and it is also 
colonised by large numbers (around 1014 microorganisms) of non-pathogenic bacteria 
known as the microbiota (Goto and Kiyono 2012). The primary defense against 
pathogenic species in the GI tract is the anatomical barrier, the gut epithelium, made up 
of a single layer of polarised epithelial cells that are joined by tight junction proteins.  
Below the epithelium lies the lamia propria and muscularis mucosae and these structures 
make up the mucosa. The intestinal mucosa increases surface area by the formation of 
villi and microvilli. Between the villi lie the crypts of Lieberkuhn that extend through the 
lamina propria. At the bottom of the crypts are undifferentiated cells, involved in 
epithelial cell regeneration and paneth cells, which release antimicrobial peptides 
(lysozyme, defensins, C-type lectin). The lamina propria consists of scattered immune 
cells and more organised lymphoid structures such as the mesenteric lymph nodes 
(MLNs), Peyer’s patches, and inducible isolated lymphoid follicles (ILFs). Peyer’s 
patches are lymphoid aggregates containing IgA producing B cell follicles and T cells. 
Microfold (M) cells, located on the epithelium of lymphoid follicles, ingest lumen 
antigens by endocytosis and phagocytosis to release at the basal surface where they can be 
recognized by dendritic cells. 
 
1.3.2 The Colon 
 
The colon is divided into four sections; the ascending colon on the right hand side of the 
abdomen, the transverse colon which runs across the abdomen, the descending colon on 
the left hand side and the sigmoid colon which leads to the rectum. Histologically it is 
similar to the rest of the GI tract but has deeper crypts of Lieberkuhn, no intestinal villi 
and increased numbers of goblet cells (Figure 1-4).  
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Figure 1-4 Haematoxylin and Eosin (H&E) stain of colonic mucosa section (x100 magnification) 
 
1.3.3 Mucosal Barrier Function and Microbial Exclusion 
 
The mucosal immune system maintains a balance between the presevation of commensal 
gut flora and the protection from invasive pathogenic organisms. Gut flora is separated 
from the immune system by the epithelial barrier; a single polarised layer of epithelial 
cells connected through the tight junction network (Suzuki et al. 2013). In the lumen 
microbes are further separated from the gut epithelium (microbial exclusion) by a thick 
layer of mucus, which contain antimicrobial peptides, enzymes (defensins, lysozymes) 
and secretory IgA (Goto and Kiyono 2012). Secretory IgA promotes the clearance of 
microbes, blocks their access to receptors and is capable of directly quelling bacterial 
virulence factors (Mantis et al. 2011). 
 
The loss of barrier function has been shown to be a driver of intestinal inflammation in 
the mouse model. Muc2-deficient mice, which lack an inner mucus layer, have abnormal 
bacterial colonisation and develop acute then chronic intestinal inflammation (Van der 
Sluis et al. 2006). Mice lacking tight junction proteins also display intestinal 
inflammation (see below). There is some evidence that loss of barrier function leading to 
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microbial translocation may be present in health without accompanying pathology 
(Sedman et al. 1994). This may lead to a local immune response and devlopment of 
tolerance (Vaishnavi 2013).  
 
1.3.4 Tight Junction Proteins 
 
The intestinal epithelium maintains tissue integrity while regulating gut permeability 
using a network of proteins in complexes between epithelial cells. The major 
constituents are tight junctions, adhesion junctions and desmosomes (Figure 1-5).  
 
 
 
 
 
 
 
 
 
 
 
Figure 1-5 Intercellular junction of intestinal epithelial cells. Adapted from (Suzuki 2013) 
 
Tight junctions are dynamic structures present on the apical and lateral membrane of 
polarised epithelial cells. The first tight junction described was occludin which is crucial 
for maintaining tight junction structure and permeability. It creates a barrier against 
macromolecules but not small ions and interacts with ZO proteins that provide links to 
the actin cytoskeleton (Suzuki 2013). Occludin knockout mice have chronic 
inflammation, hyperplasia of the gastric epithelium (Saitou et al. 2000) and increased 
paracellular permeability (Al-Sadi et al. 2011).  
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The claudin protein family is the largest group of tight junction proteins with 27 
members, each with different but overlapping functions that are found at different 
concentrations across different tissue. Claudins are the key component of the sealing 
tight junction, as addition of claudin 1 and 2 to fibroblast cell lines is sufficient to induce 
tight junction formation (Furuse et al. 1998) and claudin 1 knockout mice die within a 
day of birth due to loss of fluid and electrolytes (Furuse et al. 2002). Expression of 
different claudins is under the control of different signal transduction pathways and the 
coexpression of one claudin with another can change the individual claudin function. As 
well as providing a barrier function the tight junctions have a role in paracellular ion 
transport and claudin 2, 7, 12, and 15 have pore-forming functions (Suzuki 2013). 
 
Aberrant expression of inflammatory cytokines can affect tight junctions at the mucosal 
barrier. IFNγ has been shown to induce cellular internalisation of tight junction proteins 
resulting in decreased transepithelial resistance (TER) in intestinal cell lines (Bruewer et 
al. 2005). TNF induces apoptosis and inflammation in intestinal epithelial cells and 
directly impairs tight junction barriers (Suzuki 2013). IL1β decreases occludin 
expression (Al-Sadi et al. 2008) and IL-6 increases expression of the pore-forming 
claudin 2 (Suzuki et al. 2011). IL-17a and TGFβ however, have been shown to induce 
claudin formation and increase TER (Kinugasa et al. 2000, Suzuki 2013). 
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1.4 Human Immunodeficiency Virus 
 
35 million people are infected with human immunodeficiency virus (HIV) worldwide. 
Despite the introduction of highly active antiretroviral treatment (ART) in 1996 there 
were 1.5 million deaths from AIDS and 2.1 million new HIV infections in 2013, mostly 
in Sub-Saharan Africa. 
 
Two strains of HIV cause infection in humans; HIV-1 (HIV), which arises from three 
distinct transmissions (clades M, N, O) of simian immunodeficiency virus (SIV) in 
chimpanzees and HIV-2, which arises from multiple transmissions of SIV from sooty 
mangabeys (Ho and Bieniasz 2008). The transmission event leading to the pandemic 
strain of HIV-1 (Clade M) occurred around Southern Cameroon 60 to 80 years ago 
(Keele et al. 2006). 
 
1.4.1 Structure and Replication of HIV-1 
 
HIV is a double-stranded RNA retrovirus that belongs to the lentiviral family. The HIV 
virion has a spherical envelope containing two proteins, transmembrane gp41 and 
glycoprotein gp120. The envelope surrounds a conical-shaped capsid (p24) containing 
two copies of single stranded (ss)RNA and the enzymes reverse transcriptase and 
integrase. HIV ssRNA encode genes for structural proteins (gag, env, pol), regulatory 
proteins (tat, rev, nef) and accessory proteins (vif, vpr, vpu). 
 
The first step in viral replication is the attachment of HIV gp120 to the CD4 receptor on 
a host cell. This leads to a conformational change in viral envelope that exposes the 
chemokine receptor-binding site. After CCR5 co-receptor binding gp41 mediates fusion 
and entry (Barré-Sinoussi et al. 2013). Once inside the cytoplasm, the capsid uncoats and 
HIV reverse transcriptase converts viral RNA into DNA.  
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Viral DNA is then transported to the nucleus and spliced into the host DNA using HIV 
integrase forming the ‘provirus’. The cell then has the ability to make viral proteins 
(Klimas et al. 2008).  Capsid proteins (encoded by gag), viral enzymes (encoded by pol) 
and two ssRNA genomes are transported to the host cell membrane. Construction of 
gp160 occurs in the endoplasmic reticulum followed by glycosylation in the golgi before 
it is cleaved into gp120 and gp140. The virion is then released via budding and proteases 
cleave the structural polyprotein to form mature Gag proteins (Figure 1-6). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-6 The life cycle of HIV. Adapted from (Barré-Sinoussi et al. 2013) 
 
1.4.2 Transmission and Acute HIV-1 Infection 
 
At viral transmission a founding virus crosses the mucosal epithelial barrier and infects 
‘resting’ CCR5+ CD4+ T cells (Haase 2010). Recently a gut-homing integrin, α4β7, 
has been found to bind gp120 and facilitate cell-to-cell spread.	   α4β7 is involved in 
intestinal trafficking via its interaction with mucosal addressin cell adhesion molecule-1 
(MAdCAM-1) expressed on lamina propria cells. It has been proposed that this 
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interaction could therefore increase viral transfer between cells (Arthos et al. 2008) and 
CCR5+CD4+ T cells also expressing this integrin are thought to be important targets 
for efficient transmission. HIV integration into host DNA occurs around 6 hours post 
infection and infected cells then undergo local expansion for around 7-10 days. These 
cells then disseminate via the draining lymph nodes to the gastrointestinal lymphoid 
tissue where the majority of activated CD4 T cells reside. These cells are rapidly 
depleted (Anton et al. 2000), infection quickly spreads to the periphery and viral latency 
is established. 
 
Acute HIV infection, when viraemia peaks, is often accompanied by fever, a sore throat 
and swollen lymph nodes. After around 6 months the viral set-point is reached and there 
is gradual peripheral CD4 T cell decline and rising viral load defining the chronic 
infection stage (Figure 1-7). Clinical AIDS occurs approximately 10 years post infection 
when CD4 counts are less then 200 cells/µl or AIDS defining illnesses manifest. AIDS 
defining illness include opportunistic infections (Pneumocystis jiroveci pneumonia (PCP), 
cytomegalovirus disease, toxoplasmosis of the brain and mycobacterial infection) and 
cancer (Karposi’s sarcoma and lymphoma). 
 
 
 
 
 
 
 
 
 
 
Figure 1-7 Natural history of HIV-1 infection charting viral load and CD4 counts (blue dashed lines indicate weeks 
post infection when p24 and then HIV antibodies can be detected). 
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Acute HIV infection initially provokes a surge of inflammatory cytokines (IL-15, IFNα, 
TNF, IFNγ) produced by DCs and then by monocytes, macrophages, NK cells and T 
cells (McMichael et al. 2010). Protective antibodies, directed against gp120, develop 
weeks after infection, too late to influence disease course.  
 
CD8 responses are initially directed against nef epitopes and appear before plasma 
viraemia, responses to gag, pol and env do not develop until the chronic phase of 
infection. Perforin and granzyme B mediate the apoptosis of HIV infected cells, and CD8 
chemokines (macrophage inflammatory protein1 (MIP1)-α,-ß, CCL5) suppress viral 
entry and replication. This response is insufficient to clear infection, partly due to escape 
mutants (McMichael et al. 2010).   
 
1.4.3 Chronic HIV-1 Infection  
 
1.4.3.1 Immune activation 
The chronic phase of infection is characterised by a broad systemic immune activation 
involving T cell activation and increased turnover and exhaustion (Hazenberg et al. 
2000), polyclonal B cell activation (Lane et al. 1983) and raised pro-inflammatory 
cytokines (Valdez and Lederman 1997). T cell activation in particular has been shown to 
be a stronger predictor of disease progression than CD4 counts or viral load (VL, Giorgi 
et al. 1999) and plasma levels of IL-6 and markers of coagulation (d-dimer) predict 
mortality in treated HIV infection (Lackner et al. 2012). 
 
There are likely many factors contributing to immune activation. HIV may directly 
influence immune activation through binding of envelope gp120 to CD4 leading to 
intracellular signaling. Viral recognition by TLR7 and TLR8 induces type 1 IFN and TNF 
secretion by dendritic cells and NK cells. Polymorphisms in IRF7, a signaling protein 
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downstream of TLR7 and 9, have been found in natural hosts of SIV that despite high 
viral loads do not develop immune activation. In this model IRF7 polymorphisms result 
in reduced type I IFN production and control of SIV-induced inflammation (Miedema et 
al. 2013). Immune activation may also arise through host recognition of HIV capsid 
proteins or viral DNA (Lackner et al. 2012).  
 
The loss of mucosal T cells has also been associated with elevated immune activation in 
HIV infection. Depletion of CD4 T cells reduces mucosal integrity and is linked to the 
leakage of immunostimulatory microbes or microbial products (LPS, LTA, bacterial 
DNA) from the intestinal lumen into the circulation. Microbial translocation is defined as 
the non-physiological passage of gut microbes through the mucosal epithelial barrier and 
lamina propria and eventually into systemic circulation. Microbial translocation may be 
another mechanism that contributes to immune activation via TLR2,4,5, and 6 
stimulation (Brenchley et al. 2006b). Immune activation may also be driven by peptide 
recognition of opportunistic microbes, such as cytomegalovirus (CMV), that replicate 
more effectively in a HIV-immune deficient setting. There is also evidence of dysfunction 
of regulatory T cells (Treg) in HIV infection that may contribute to increased immune 
activation, though conversely an increase in these cells may also lead to an ineffective 
anti-HIV T cell response (Sodora and Silvestri 2008).  
 
Immune activation may also be driven by increased secretion of pro-inflammatory 
cytokines. This may lead to bystander activation of lymphocytes and the upregulation of 
apoptosis markers (CD95, TRAIL) leading to activation induced cell death. The need to 
replenish lymphocyte populations at effector sites may also contribute to activation. T 
cell cycling (measured by Ki-67 or bromodeoxyuridine) is especially raised in central 
memory T cells during chronic HIV infection and activated cycling CD4 T cells are more 
susceptible to HIV infection (Lackner et al. 2012).  Recently abortive infection of CD4 T 
cells by HIV has been shown to lead to pyroptosis, a highly inflammatory form of 
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programmed cell death that induces proinflammatory cytokines and CD4 T cell death 
(Doitsh et al. 2014).  
1.4.3.2 Mucosal Immunity and HIV   
Histologically, HIV-associated damage to the gastrointestinal tract includes CD8 
lymphocyte infiltration, crypt hyperplasia, villous atrophy and villous blunting with 
increased apoptosis of enterocytes (Cummins et al. 1990). The mechanism for the loss of 
barrier function is incompletely understood but may result from epithelial damage (Estes 
et al. 2010), the down regulation of genes regulating epithelial barrier maintenance 
(Sankaran et al. 2008) and increased proinflammatory cytokines (Epple et al. 2009). HIV 
viral antigens have also been shown to directly reduce barrier function (Schmitz et al. 
2012, Nazli et al. 2010).  
 
Loss of mucosal barrier function in HIV is thought to lead to microbial translocation, 
which is also a feature of inflammatory bowel disease and hepatitis B and C infection 
(Brenchley et al. 2012). Microbial translocation, the leakage of gut microbes into 
systemic circulation, has been suggested as a cause of immune activation in HIV 
(Brenchley et al. 2006b). Causes of microbial translocation in HIV include disruption of 
the epithelial barrier together with the loss of TH17 cells and the reduced capacity of 
phagocytes to remove microbial products (Sandler and Douek 2012). In HIV microbial 
translocation has been measured indirectly by assessing levels of LPS-binding protein 
(LBP), antibodies directed against LPS core antigen, and soluble CD14 in plasma. 
Bacterial products have also been measured directly by detection of lipopolysaccharide 
(LPS), the outer membrane of gram-negative bacteria and by measurement of 16srDNA, 
common to many bacteria, in plasma samples by PCR (Marchetti et al. 2013). 
 
Brenchley et al first described the association between immune activation, measured by 
CD38+HLA DR+ CD8 T cells and microbial translocation, using the LAL assay to 
measure LPS. The group found HIV infected patients has higher levels of LPS than 
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controls and that LPS levels increased after rhesus macaques are infected with SIV 
(Brenchley et al. 2006b).  A further study in 2008 found LPS levels were also raised in 
ART-treated patients who had failed to restore CD4 counts (immunological non-
responders) and this correlated with Ki-67+ proliferating CD8 T cells (Marchetti et al. 
2008). A longitudinal study saw decreased16s rDNA levels after ART which were 
associated with T cell activation and inversely with CD4 T cell restoration (Jiang et al. 
2009). The level of T cell activation in the gut has been positively correlated to plasma 
LPS levels (Ciccone et al. 2010) and elevated LPS levels in the lamina propria of SIV 
infected macaques have been associated with epithelial barrier disruption (Estes et al. 
2010).  
1.4.3.3 T cells in chronic HIV infection 
Chronic HIV infection is defined by the slow loss of peripheral CD4 T cells, the 
mechanism of which is still not fully understood. HIV-specific CD4 T cells are 
preferentially infected leading to loss of help to B cells and HIV-specific CD8 T cells 
resulting in the early loss of HIV specific immune responses (Douek et al. 2002).  There 
is increased T cell turnover resulting in T cell exhaustion and CD4 T cells have impaired 
responses to recall antigens such as tetanus toxoid and T cell mitogens such as 
phytohaemagglutinin (PHA) (Blazevic et al. 2000).  There is also loss of functional TH 
cells responses to mycobacterial proteins with loss of specific TH subsets identified as a 
risk factor for the development of active TB (Clark et al. 2011). Inflammation caused by 
immune activation leads to collagen deposition and fibrosis in lymphatic tissue thus 
limiting T cell regenerative capacity and reducing the frequency of naïve T cells 
(Schacker et al. 2006, Zeng et al. 2012).  
 
Chronic immune activation sustains viral replication by providing further targets for HIV 
infection. It results in increased frequencies of short-lived effector CD4 T cells 
producing inflammatory and pro-apoptotic cytokines, which then contribute to, and 
sustain immune activation. This expansion is at the expense of naïve and memory T cell 
 45 
pools and chronic HIV infection is associated with a skewing of T cell phenotype and 
increased frequencies of terminally differentiated cells.  
 
CD8 T cells in patients infected with HIV express the exhaustion marker PD-1, and have 
reduced anti-viral protein secretion and reduced perforin and granzyme B mediated 
apoptosis. Despite this there is evidence that CD8 T cells are important for the control of 
HIV replication, as peak viraemia reduces after the expansion of HIV-specific CD8 T 
cells, the emergence of viral escape mutants are associated with HIV specific CD8 T cells 
and specific MHC class I alleles confer resistance to infection (Demers et al. 2013). CD4 
T cell loss in HIV coincides with a rise in CD8 T cell proportions and a skewing of 
CD4/CD8 ratios. Unlike peripheral CD4 counts, which usually return to normal levels 
during ART, CD8 counts remain elevated (Leung et al. 2013). 
 
1.4.3.4 TH17 cells 
TH17 cells are enriched in the gut and express the HIV co-receptor CCR5, the gut-
homing chemokine CCR6 and the integrin α4β7. CCR6+CD4+ T-cells have been 
shown to be targets for HIV-1 infection (Gosselin et al. 2010) and HIV virus-specific IL-
17a producing CD4+ T cells are detectable in early HIV-1 infection (Yue et al. 2008). 
Loss of TH17 cells from the blood and mucosal tissue has been reported in SIV infection 
(Cecchinato and Franchini 2010) but studies in HIV are more conflicted (discussed 
further in chapter 3 introduction). The loss of TH17 cells during HIV infection may 
contribute to systemic immune activation. Microbial translocation and depletion of the 
TH17 subset from peripheral blood have been correlated (Brenchley et al. 2008). The 
loss of TH17 in SIV-macaques has been also been linked to impairment of the mucosal 
barrier and shown to lead to dissemination of salmonella from the gut (Raffatellu et al. 
2008).  
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1.5 Inflammatory Bowel Disease 
The inflammatory bowel diseases are chronic relapsing inflammatory disorders of the 
gastrointestinal tract that can be divided into two major clinical forms: ulcerative colitis 
(UC) and Crohn's disease (CD). In the UK IBD prevalence is around 400/100,000 with 
a peak onset between 15 and 30 years of age and UC is twice as common as CD (Rubin 
et al. 2000). Ulcerative colitis is characterised by inflammation and ulceration that begins 
at the rectum and is restricted to the colon whereas Crohn’s disease features transmural 
inflammation that can occur in patches throughout any part of the gastrointestinal tract 
but is most commonly seen in the terminal ileum.  Both CD and UC carry with them a 
six-fold increased risk of developing colon cancer (Mattar et al. 2011).  
 
1.5.1 Diagnosis and Disease Scoring in IBD 
The diagnosis of IBD is based on the clinical symptoms and endoscopic appearance of the 
bowel combined with typical IBD histology. Symptoms of IBD include rectal bleeding, 
abdominal pain, and severe diarrhoea, fevers and weight loss. Histology samples taken 
from patients with active disease characteristically show a large leukocyte infiltrate in the 
intestine (Kaser et al. 2010). Ulcerative colitis features superficial inflammatory changes 
that are limited to the mucosa and submucosa together with cryptitis (inflammation of 
the intestinal crypts) and crypt abscesses. Crohns disease features thickened submucosa, 
inflammation across the full thickness of the bowel with the formation of non-caseating 
granulomas and fistulas.  
 
CD can be clinically subdivided using the 2005 Montreal classification system, which 
assesses age at onset of disease, the location of inflammation and the behaviour of disease. 
CD disease severity is measured using the Harvey-Bradshaw Index, which assesses five 
variables (Table 1-2, (Sehgal and Koltun 2010). 
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Montreal Score CD Harvey-Bradshaw Index (Cumulative Score) 
Age at 
Onset 
 
A1: <16 years General well-being 0: Very well 
A2: 17-40 years 1: Slightly below par 
A3>40 years 2: Poor 
Disease 
location 
 
L1: Ileal 3: Very Poor 
L2: colonic 4: Terrible 
L3: ileocolonic Abdominal pain 0: None 
L4: isolated upper disease 1: Mild 
Disease 
behaviour 
B1:nonstricturing, 
nonpenetrating 
2: Moderate 
B2: stricturing 3: Severe 
B3: penetrating Abdominal mass 0: None 
‘p’ perianal disease  1: Dubious 
 2: Definite 
3: Definite and tender 
Liquid stools Number/day 
Complications  Arthralgia, uveitis, erythema nodosum, 
aphthous ulcers, pyoderma gangrenosum, 
anal fissue, new fistula, abscess,  
Table 1-2 Crohn's disease classification and disease scoring 
 
Ulcerative colitis is classified using the UC Montreal classification system which assesses 
the extent and severity of disease, further disease scoring is performed using the 
ulcerative colitis severity score (UCSS) (Sehgal and Koltun 2010). 
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Montreal Score UC UCSS (Cumulative Score) 
Extent 
 
E1: ulcerative proctitis 
(limited to the rectum) 
Stool frequency 0: Normal 
E2: left-sided UC 
(limited to colorectum 
distal to splenic flexure) 
1: 1-2 stools/day more than normal 
E3: extensive UC 2: 3-4 stools/day more than normal 
3: 4 stools/day more than normal 
Severity 
 
S0: clinical remission 
S1:mild UC Rectal bleeding 0: None 
S2: moderate UC 1: Visible blood with stool less than half the 
time 
S3: severe UC 2: Visible blood with stool half of the time 
 3: Passing blood alone 
Mucosal appearance 
at endoscopy 
0: Normal 
1: Mild (erythema, decreased vascular 
pattern, mild friability) 
2: Moderate (marked erythema, absent 
vascular pattern, friability, erosions) 
3: Severe disease (spontaneous bleeding, 
ulceration). 
Physician rating of 
disease  
 0: normal 
1: mild 
2: moderate 
3: severe 
Table 1-3 Ulcerative colitis classification and disease scoring 
 
1.5.2 Pathogenesis of IBD 
IBD is thought to result from a dysregulated immune response to environmental factors 
within genetically susceptible hosts however the precise cause of the disease has not been 
fully established.   
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1.5.2.1 Pathogenesis of IBD: Genetics 
Up to 23% of IBD patients have one family member or more that also have the disease 
and monozygotic twin studies have demonstrated concordance rates of 50% in CD and 
20% in UC.  Genome-wide association studies (GWAS) have successfully identified 163 
genetic risk loci for IBD, with 30 specific for CD and 23 for UC (Jostins et al. 2012). 
Susceptibility to UC is conferred by genetic mutations in mucosal barrier function genes 
whereas CD susceptibility genes include those involved in innate immunity, autophagy 
and phagocytosis (Corridoni et al. 2014).  
 
Loss of function polymorphisms in the toll-like receptor NOD2 are found in 35% of CD 
patients. NOD2 initiates innate immunity after recognition of a breakdown product of 
bacterial peptidoglycan (muramyl-dipeptide) and it also has a role in autophagy induction 
and MHC cross-presentation. Mutations in ATG16L1 and IRGM, genes involved in 
forming the autophagosome have also been reported in CD (Naser et al. 2012). 
Autophagy is a process whereby bacterial and self-organelles are ingested intracellularly 
via lysosomal degradation. CD associated mutations in this pathway result in reduced 
bacterial elimination. The recent identification of polymorphisms in both CD and UC 
associated with TH17 development, including those in the IL-23R, IL12B, JAK2 and 
STAT3 genes have focused attention on the role of this subset in IBD pathogenesis. 
Mutations in IL-12B, which encodes the p40 subunit of IL-12 and IL-23, have also been 
described in various autoimmune disorders. Genetic susceptibility to IBD has also been 
linked to the major histocompatibility complex (MHC) and this association is stronger in 
UC than CD. MHC class I risk alleles include HLA-A2 and HLA-B18 for CD and HLA-
B27, HLA B35 and HLA B5 for UC. Class II HLA-DRB1 alleles can be protective (HLA-
DRB1*1501 negatively associates with CD) or confer risk  (HLA-DRB1*1502 associates 
with UC, HLA-DRB1*0103 associates with both CD and UC). Polymorphisms in the 
HLA class III region encoding complement genes and TNF have also been described 
(Rodriguez-Bores et al. 2007).  
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1.5.2.2 Pathogenesis of IBD: Environment 
Environmental factors that have been associated with IBD include increased consumption 
of refined carbohydrates, smoking, social stress and the use of oral contraception (Binder 
2004). Agents that perturb the mucosal barrier, such as non-steroidal anti-inflammatory 
drugs (NSAIDs), antibiotics and viral or bacterial infections are common triggers of IBD 
(Corridoni et al. 2014). The composition of the commensal flora also plays a pivotal role 
in IBD pathogenesis with several studies demonstrating that probiotics can ameliorate 
disease and antibiotics reduce symptoms (Corridoni et al. 2014).  IBD patients have a 
shift in floral phenotype with a relative lack of Firmicutes and Bacteriodetes and increased 
proportions of Enterobacteria such as Escherichia coli (Barnich and Darfeuille-Michaud 
2007).  
 
1.5.2.3 Pathogenesis of IBD: Mucosal barrier dysfunction 
Epithelial barrier disruption has been implicated in IBD pathogenesis. 10-20% CD 
patients have increased intestinal permeability before symptoms of CD develop and 
increased permeability precedes clinical relapse (Kaser et al. 2010). First-degree relatives 
of CD patients also have increased intestinal permeability (Edelblum and Turner 2009). 
Causes of barrier dysfunction include disruption to the tight junction protein network 
and epithelial cell apoptosis (Kaser et al. 2010).   
 
Although there are no known mutations in tight junctions proteins in IBD studies have 
demonstrated they are dysregulated during disease. There is increased expression of the 
pore-forming tight junction claudin 2 (Prasad et al. 2005, Jostins et al. 2012, Heller et 
al. 2005) and reduced expression of sealing tight junctions claudin 3, 4, 5 and 8 in IBD 
(Zeissig et al. 2004, Prasad et al. 2005). Prasad et al found addition of the pro-
inflammatory cytokines TNF and IFNγ reduced expression of all three claudins and trans 
electrical epithelial resistance (TER). Pro-inflammatory cytokines (TNF, IL-1b) promote 
barrier dysfunction by inhibiting transcription and inducing cytoskeleton-mediated 
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redistribution of tight junction proteins. They promote the transcription of myosin light 
chain kinase (MLCK), leading to phosphorylation of myosin II, which then results in the 
reorganisation of tight junction proteins. MLCK has been found to be upregulated in the 
intestinal epithelium of IBD patients (Blair et al. 2006).  
 
1.5.2.4 Pathogenesis of IBD: T Helper Cells 
Cytokine profile analysis in IBD tissue has demonstrated immunological differences 
between the two clinical forms of IBD. Patients with CD have higher levels of the TH1 
related cytokines IFNγ and IL-12 whereas UC patients were originally thought to have a 
predominance of TH2 cytokines. More recent studies in UC have shown that although 
there is increased levels of the TH2 related cytokine IL-13 there is an absence of IL-4 and 
increased levels of IFNγ. Anti-TNF therapy has also shown benefit in these patients 
indicating that the immune response in this disease is more complex than originally 
believed (Bouma and Strober 2003). IL-12 is important in the generation of a TH1-type 
response, and shares a subunit, p40, with another cytokine, IL-23, involved in the 
propagation of the TH17 lineage. Mouse models that were thought to eliminate TH1 
responses by the absence of p40 are now known to have knocked down the TH17 
response too.  
 
Increased IL-17a (Fujino et al. 2003) and increased TH17/TH1 cells (Annunziato et al. 
2007) have been reported in the inflamed mucosa of IBD patients.  IL-17f (Seiderer et al. 
2008) and IL-22 (Brand et al. 2006) are elevated in CD but not in UC. IL-21 is also 
found at increased levels in the gut mucosa of IBD although it is mostly produced by TH1 
cells (Sarra et al. 2010). The role of TH17-associated cytokines in the pathogenesis of 
IBD however remains controversial. IL-17a and IL-22 knockout mice are both more 
susceptible to dextran sodium sulfate (DSS)-induced colitis than wild-type mice, 
highlighting the mucosal protective functions of these cytokines (Strober et al. 2002). In 
contrast, mice models without the IL-17RA, leading to loss of signaling via IL-17a and 
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IL-17f, and IL-17f knockout mice, do not develop colitis (Yang et al. 2008). It is possible 
that IL-17f may have a pathogenic role in the gut and IL-22 and IL-17a may be 
protective. Transfer of IL-17A- or IL-22- deficient T cells into RAG1 mice however 
induces severe colitis indicating that IL-22 and IL-17a may have a role in mucosal 
inflammation in certain circumstances (Leppkes et al. 2009). 
 
1.6 Summary 
 
HIV is associated with mucosal barrier dysfunction that has been linked to the leakage of 
microbial products from the lumen into systemic circulation. Defects in maintaining 
mucosal barrier function have been associated with the loss of mucosal TH17 cells in the 
SIV model but data in HIV infection is limited and conflicting. Microbial translocation 
has been linked to elevated levels of peripheral immune activation, a major cause of HIV 
disease progression, in some studies. The level to which ART can reduce barrier 
dysfunction and microbial translocation is not clearly established. 
 
In contrast to HIV infection, elevated levels of TH17 associated cytokines have been 
found in patients with inflammatory bowel disease. The role of these cytokines in the 
pathogenesis of disease remains controversial. IBD patients have well reported mucosal 
barrier dysfunction and microbial translocation but there is limited data linking this with 
TH17 cell and TH17 related cytokine production.  
 
The protective vs. pathogenic function of TH17 cells are therefore illustrated by these 
two disease states. Comparisons between immune activation state, the levels of mucosal 
damage and evidence of microbial translocation in HIV and IBD may give further insight 
into the mechanisms of disease progression and the role of TH17 cells. 
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1.7 Hypothesis and Aims 
 
Depletion of the mucosal TH17 subset in HIV-1 is associated with impairment of 
mucosal epithelial barrier integrity that results in microbial translocation and systemic 
immune activation. 
 
• Characterise the differences in T cell subsets and cytokine secretions between the 
blood and colonic mucosa of healthy controls. 
 
• Characterise T cell subsets and cytokine production in the blood and mucosa of 
healthy controls compared to HIV-1 infected patients and patients with 
inflammatory bowel disease. 
 
• Determine if there is an association between TH17 frequency, down regulation of 
epithelial gap junction protein expression, increased microbial translocation and 
increased systemic immune activation in HIV-1. 
 
• Using IBD as a disease control assess whether alterations in CD4 TH17 cytokine 
secretions account for differences in the extent of microbial translocation and gap 
junction protein expression. 
 
 
 
 
 
 
Chapter 2  Materials and Methods 
2.1 Ethics 
 
Ethical approval to perform this study was obtained from South West London REC2 
(10/H0706/26). Local Site Specific Approval was obtained from the Research and 
Development Office at Chelsea and Westminster NHS Foundation Trust (R&D 
reference number CW 10/090). Copies are included in the appendix. 
 
2.2 Study Design 
A cross-sectional study of patients receiving colonoscopy as part of their routine clinical 
care. Study groups were as follows: 
 
1. Controls without IBD and not infected with HIV-1 undergoing colonoscopy 
for cancer surveillance due to family history or a personal history of polyps 
2. Chronic HIV-1 infected patients receiving antiretroviral therapy  
3. Chronic HIV-1 infected patients naïve to antiretroviral therapy  
4. Patients with Crohn’s Disease  
5. Patients with Ulcerative Colitis 
 
2.3 Recruitment and Consent 
 
Patients were recruited from the gastroenterology clinic at the Chelsea and Westminster 
Hospital NHS Foundation Trust. Written informed consent was obtained from all 
patients. At enrolment participants underwent colonoscopy for routine clinical 
indications and up to 10 biopsies were collected for the research study. 1 or 2 biopsies 
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were collected into formalin for immunohistochemistry (IHC) staining and the rest 
collected into ice cold MR10 for mucosal mononuclear cell (MMC) isolation and flow 
cytometry. Venesection was also performed to obtain 5ml EDTA blood, 30ml Lithium 
Heparin blood and 10ml of clotted blood. 
 
2.4 Lymphocyte subset quantification and HIV-1 viral load 
Quantification of lymphocyte subsets was performed by the Department of Infection and 
Immunity, Charing Cross Hospital, Imperial College Healthcare NHS Trust and 
determined using four-colour flow cytometry. 100µl of whole blood (EDTA) was 
stained with a panel of monoclonal antibodies (CD3, CD4, CD8, CD45, CD56, and 
CD19, Cyto-Stat TetraCHROME reagents) and lysed in an FP1000 using 
IMMUNOPREP reagents. Absolute counts were evaluated by the addition of 100µl Flow 
Count counting beads and processed using a Navios flow cytometer (All reagents and 
equipment, Beckman Coulter). Plasma HIV-1 RNA quantification was performed by the 
Department of Virology, Barts and The London NHS Trust using a fully automated 
COBAS AmpliPrep/COBAS TaqMan HIV-1 Test (Roche Molecular Diagnostics) with a 
lower detection limit of 40 copies/ml. 
 
2.5 Isolation of mucosal mononuclear cells from colon 
biopsies 
 
A maximum of 10 biopsies were collected 25-30cm from the anal verge of the sigmoid 
colon from macroscopically normal looking tissue using Jumbo EndoJaw 3.7mm forceps. 
Biopsies were collected into ice-cold MR10G medium (RPMI 1640 supplemented with 
2mM L-glutamine (Sigma), 10% HI FBS (PAA), 100 units-0.1mg/ml Penicillin-
Streptomycin, 0.05mg/ml gentamycin (Sigma), 1.25 mg/ml amphotericin (Sigma), 
1mM sodium pyruvate, 10mM HEPES) and processed as previously described with 
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minor modifications (Kaltsidis et al. 2011). Biopsies were washed twice in fresh medium 
and following fine mincing with a scalpel the tissue was digested in 0.5mg/ml 
Collagenase-II (Sigma) for 30 minutes in a shaking water bath (37°C, 220 RPM).   
Mechanical disruption was performed by forcing the sample through a 16-gauge blunt-
ended needle 5 times followed by passage through a 70µm nylon cell strainer to collect 
single cells. Undigested tissue was collected from the cell strainer and subjected to a 
second round of collagenase digestion, mechanical disruption and cell straining.  The 
MMC from both rounds were collected and pooled and count and viability assessed using 
an automated viability and cell counter (ViCell Counter, Beckman Coulter). Cells were 
resuspended to a final concentration of 2.5 million/ml in MR10 (As MR10G without 
Gentanmycin) and rested overnight at 37°C in a humidified incubator with 5% CO2. 
 
2.6 Isolation of peripheral blood mononuclear cells  
 
PBMCs were isolated by gradient centrifugation from heparinised peripheral blood by 
overlaying equal volumes of whole blood directly over Lymphocyte Separation Medium 
(LSM, PAA) in a 50ml conical tube and centrifuging for 20 minutes (1000xg, Brake off). 
The PBMC layer was removed from the plasma/LSM interface and washed twice in fresh 
RPMI-1640 medium. After the final wash the cell pellet was resuspended in MR10 and 
cell count and viability assessed using the ViCell Counter. Cells were resuspended to a 
final concentration of 2 million/ml in MR10.  
 
2.7 PBMC and MMC stimulation with SEB for detection of 
intracellular cytokines 
 
750µl of MMC and PBMC cell suspensions were aliquoted into 8 FACS tubes labeled 
with study ID, MMC or PBMC, and either Control 1, Control 2, Tube 1, or Tube 2. 
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Staphylococcal enterotoxin B (SEB, Sigma S4881) was diluted in MR10 to a 
concentration of 6µg/ml and 750µl of this solution was added to Tube 1 and Tube 2 
giving a final SEB concentration of 3µg/ml. 750µl of MR10 alone was added to Control 
1 and Control 2. 10µg/ml of Brefeldin A was added to every tube. Following gentle 
mixing, tubes were incubated for 6 hours at 37°C in a humidified incubator with 5% 
CO2. After incubation the tubes were centrifuged (400g, 5mins), the supernatant 
decanted and cells washed once with PBS. 
 
2.8 Flow Cytometry 
 
2.8.1 Identification of T cell subsets and cytokine secretions in 
PBMC’s and MMC’s  
2.8.1.1 Staining protocol 
Following stimulation, 100µl of LIVE/DEAD Fixable Violet dead cell dye (Invitrogen) 
diluted 1:1600 in PBS was added to each tube and incubated in the dark for 15 minutes 
at room temperature. After incubation cells were washed once with PBS and cell surface 
staining antibodies added and incubated for 15 minutes at 4°C. 100µl of Fix A 
(Invitrogen) was then added to each tube followed by a 15-minute incubation in the dark 
at room temperature. Cells were then washed in 5%FCS/PBS and cytokine antibodies 
added together with 100µl of Perm B (Invitrogen). After a further 15-minute incubation 
in the dark at room temperature cells were washed once again in 5%FCS/PBS and 
resuspended in 300µl of cell fixative (BD Biosciences). Cells were kept in the fridge until 
acquisition within four hours on a three-laser LSRII (BD Bioscience) (Table 2-1).  
 
 
   
 58 
 PBMC and MMC Whole Blood 
1 Company 
(Clone) 
2 Company 
(Clone) 
3 Company 
(Clone) 
FITC IL-2 BD (MQ1-
17H12) 
CD16 BD (3G8) HLA DR BD (TU38) 
PE IL-17a E Bioscience 
(eBio64Dec17) 
IL-22 E Bioscience 
(22URTI) 
CD38 BD (HIT2) 
PE CY5 CD27 E Bioscience 
(O323) 
CD161 BD (DX12) CD27 E Bioscience 
(O323) 
PE CY7 TNF E Bioscience 
(MAb11) 
IL-17f E Bioscience 
(SHLR17) 
-  
PE TR CD45RO BC (UCHL1) CD45RO BC (UCHL1) CD45RO BC (UCHL1) 
AF700 CD8 BD (RPA-T8) CD8 BD (RPA-T8) CD8 BD (RPA-T8) 
APC -  CCR10 R&D 
(314305) 
-  
APC EF 780 IFNγ E Bioscience 
(4S.B3) 
CD27 E Bioscience 
(O323) 
-  
V450 CD14 
CD19 
Violet dead 
cell dye 
BD (MØPg) 
BD (HIB19) 
Invitrogen 
CD14 
CD19 
Violet dead 
cell dye 
BD (MØPg) 
BD (HIB19) 
Invitrogen 
CD14 
CD19 
Violet dead 
cell dye 
BD (MØPg) 
BD (HIB19) 
Invitrogen 
 
V500 CD3 BD (UCHT1) CD3 BD (UCHT1) CD3 BD (UCHT1) 
QD605 CD4 Invitrogen 
(S3.5) 
CD4 Invitrogen (S3.5) CD4 Invitrogen 
(S3.5) 
Table 2-1 Flow cytometry panel. (BD=Becton Dickinson, R&D=R&D Systems, BC=Beckman Coulter) 
 
2.8.1.2 Gating strategy 
The sequential gating strategy for T cell subset identification and cytokine expression is 
shown below (Figure 2-1). Firstly, using Tube 1, a gate was drawn on a time versus 
QDot 605 plot to exclude fluorochrome aggregates and ensure laser stability. This was 
followed by an area vs. height gate to exclude cell doublets and then a forward vs. side 
scatter plot on which the lymphocytes are gated. Monocytes, B cells and dead cells were 
excluded using CD14 and CD19 and the violet viability dye which are all detected in the 
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V450/pacific blue channel. T cells were then selected using a CD3 vs. TNF plot; this 
was to ensure that any activated T cells expressing TNF with down-regulated expression 
of CD3 are captured in the gate. T cells were divided into CD4+, CD8+ and CD4-
CD8- subsets and further divided using CD45RO and CD27 into naïve T cells 
(CD45RO- CD27+), central memory T cells (CD45RO+CD27+), effector memory T 
cells (CD45RO+ CD27-) and terminally differentiated T cells (CD45RO-CD27-). Tube 
2 gating was similar but replaced the TNF vs. CD3 gate with an IL-17f vs. CD3 gate. 
Tubes 1 and 2 were accompanied by unstimulated control tubes. 
 
Figure 2-1 Gating Strategy for PBMC/MMC Panel. Example shown is PBMC from a healthy control 
 
2.8.2 Measurement of T cell activation in whole blood 
2.8.2.1 Staining protocol 
For whole blood staining (Tube 3) 150µl of blood was aliquoted into 2 tubes (Control 3, 
Tube 3) washed once with PBS (400g, 5 minutes) and incubated with 100µl of diluted 
LIVE/DEAD Fixable Violet dead cell dye for 15 minutes. Following washing, surface 
antibodies were added and cells incubated in the dark at 4 degrees for 30 minutes. Cells 
were lysed and fixed in an automated TQ Prep (Beckman Coulter), washed twice in PBS 
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and resuspended in 300µl of cell fixative (BD Biosciences). Cells were kept in the fridge 
until acquisition within four hours on a LSRII (BD Bioscience).    
2.8.2.2 Gating strategy 
Similar to Tube 1 and 2 we applied a time vs. CD4 gate followed by a doublet 
discrimination gate before selecting lymphocytes. In Tube 3 we then selected live 
CD3+CD14-CD19- events on the V450 vs. CD3 V500 gate before division of T cells 
into CD4+ and CD8+ T cells (Figure 2-2). 
 
 
Figure 2-2 Gating Strategy for whole blood Tube 3 staining. Example shown is from a healthy control. 
 
2.8.3 Flow cytometry panel validation and quality assurance 
2.8.3.1 Antibody titrations 
To minimize spectral overlap and non-specific staining titration experiments were 
performed on all antibodies used. Four different volumes were tested including the 
recommended volume, double the recommended volume and two volumes below 
recommended volume. Gating was performed on the negative and positive population of 
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each tube and the standard deviation of the negative population calculated together with 
the median fluorescent intensity (MFI) of the positive and negative population. Stain 
index was calculated using the formula (MFI(positive) – MFI(negative))/SD(negative) 
and a curve plotted (Figure 2-3). The lowest volume of antibody to give the highest stain 
index was used in the final panel.  
 
 
 
 
 
 
 
 
 
Figure 2-3 Example CD8 AF700 antibody titration data. Left plot shows staining intensity in the AF700 channel as 
CD8 AF700 antibody is increased, right chart shows the calculated staining index. In this example a final volume of 
3µl was selected. 
 
2.8.3.2 Setting control gates 
Fluorescence-minus-one (FMO) tubes were run on the PBMC’s of a healthy control to 
determine approximate positioning of the CCR10, CD161, CD27 (Figure 2-4) and 
CD45RO gates and on whole blood to determine control gates for HLA DR. Subsequent 
gating was based on the FMO gates set on the healthy control and an unstained control. 
As we wanted to identify the expression of different markers on each memory subset 
using CD45RO and CD27 these antibodies were included in the control tubes (to allow 
accurate determination of background vs. positive staining in each subset gated) and 
gating was done by eye with reference to the FMO gates. 
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Figure 2-4 Example CD27 FMO tube gated on CD4 T cells 
 
For the cytokine panels (Tubes One and Two) unstimulated controls were used. These 
tubes were prepared in exactly the same way as the stimulated cells but instead of 
incubation with SEB and BFA they were incubated with BFA alone. After stimulation and 
intracellular permeabilisation the same amount of each cytokine was added to both the 
control and the stimulated tube. Gating on positive cytokine expression was performed 
in reference to the unstimulated control tube with the gate set at a maximum of 0.05% 
positive in the unstimulated tube for PBMC samples (Figure 2-5). Due to the higher 
levels of pre-activation in the MMC populations the control gates were set at 0.5% 
(Figure 2-6). Boolean gating was used to identify polyfunctional cytokine expression. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-5 PBMC cytokine staining in control and SEB stimulated tubes. Example shown is from a UC patient. 
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Figure 2-6 MMC cytokine staining in control and SEB stimulated tubes. Example shown is from an ART-treated HIV 
patient. 
 
 
For the identification of positive staining of the surface markers HLA DR, CD161 and 
CCR10 gates were set at 0.5% positive or less against the corresponding control tube. 
CD38 positive and strong positive gating on T cells was performed in reference to the 
staining of CD38 on granulocytes and monocytes in each patient (Figure 2-7). Using a 
CD38 vs. side scatter contour plot the monocyte and granulocyte populations can be 
selected and provide a strong CD38 positive and moderately CD38 positive biological 
control for T cells (Tilling et al. 2002).    
 
 
 
 
 
 
 
 
Figure 2-7 Gating strategy to identify bright CD38 staining on CD4 and CD8 T cells. Example shown is from a 
healthy control. 
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2.8.3.3 Instrument optimisation and quality assurance 
 
The Perfetto quality assurance protocol for accurate collection of polychromatic flow 
cytometry data was used to calculate optimal PMT (photomultiplier tube) voltages and 
perform cytometer tracking (Perfetto et al. 2006). Briefly, all voltages were set at 350V 
and the MFI and CV of two selected peaks (M1 and M2) from 8-peak Rainbow beads 
(BD Bioscience) were recorded in each detector. One detector at a time the voltage was 
increased by 50V and MFI and CV again recorded until 800V was reached (Figure 2-8). 
This was repeated using unstained CompBeads (BD Bioscience) and the MFI recorded at 
each voltage point (giving the background (B) value). 
 
Figure 2-8 Concatenation plots of 8-peak bead intensity as voltage is increased by 50V in each channel of every 
laser. Grey peaks are negative comp beads at increasing voltage. Vertical axes represent staining intensity and 
horizontal axes show 8-peak staining at 350-800V.  
 
Signal-to-background ratio was calculated as M1/B at each voltage point and PMT 
linearity was calculated as (M2-M1)/M1. Background ratio, linear range and CV of M1 
peak were displayed on one graph and the linear range of each PMT voltage was chosen 
where CV was low and stable, linearity was flat and signal:background ratio was at the 
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highest point (Figure 2-9). Compbeads (BD) were then stained with fluorochromes for 
each individual detector and a voltage within the linear range that corresponded to the 
highest primary fluorescence with minimal MFI in all the secondary detectors was 
selected as the target PMT. Single peak beads were then run at the chosen voltage and the 
MFI of the peak defined as the target value.  
 
Figure 2-9 PMT voltage linear range examples for each laser (APC, PE-CY5, pacific blue). Grey shading indicates 
the chosen linear range of each PMT, red line indicates the PMT target value. 
 
 
The flow cytometer was standardised before each use by adjusting voltages on each PMT 
until the MFI of single peak beads was at the target value range. This allowed real-time 
stability monitoring (Figure 2-10). 
 
Figure 2-10 PMT Voltage monitoring. Example shown is for the blue laser over a 9 month period. 
 
 66 
2.8.3.4 Post-test quality assurance of flow cytometry data    
 
To confirm the robustness of the staining and gating strategy in our panel we compared 
CD4 percentages from Tube 1, where PBMC’s were used, to CD4 percentages from 
Tube 3, the whole blood tube. We found that CD4 percentages were slightly higher in 
the PBMC tube (2.79% bias) and 95% confidence intervals lay between -17.94% and 
23.52%. We also compared differences between tube 1 and tube 2 CD8 percentages in 
the mucosa and saw a bias of 1.28% with 95% confidence intervals between -8.60 and 
+6.05%. Overall there was good reproducibility across the panel (Figure 2-11). 
 
Figure 2-11 Bland Altman plots comparing calculated T cell percentages from different tubes 
 
2.9 Measurement of soluble factors in blood 
2.9.1 Soluble CD14  
A commercially available kit (R&D Systems: Quantikine, Human sCD14 Immunoassay) 
was used to measure sCD14 in plasma samples stored at -80°C. All reagents and samples 
were brought to room temperature. Plasma samples were diluted 200X into calibrator 
diluent. Soluble CD14 standard was reconstituted in 5ml calibrator diluent, giving a 
stock solution of 16,000 pg/ml. The stock solution was gently agitated for 15 minutes 
prior to producing a dilution series. The resulting standard concentrations were as 
follows: 16,000 pg/ml, 8,000 pg/ml, 4,000 pg/ml, 2,000 pg/ml, 1,000 pg/ml, 500 
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pg/ml, 250 pg/ml, 0 pg/ml. 100µl of assay diluent was added to each well, followed by 
100µl of either standard, sample or control in duplicate. A spiked control of known 
sCD14 concentration was run on every plate. The microplate was covered with an 
adhesive plate sealer and incubated at room temperature for 3 hours then aspirated and 
washed 4X before 200µl of sCD14 conjugate was added to each well. The microplate 
was covered with a plate sealer and incubated at room temperature for 1 hour followed 
by a further wash step. 200µl of substrate solution was added to each well and the plate 
was incubated in the dark at room temperature for 30 minutes. The reaction was 
stopped with 50µl of stop solution and read at 450nm.  The standard curve was 
calculated in GraphPad Prism 6 using a 4PL fit and any sample duplicates with CVs 
exceeding 15% were repeated. 
 
2.9.2 LPS-binding protein  
LPS-Binding protein (LBP) was measured in serum samples stored at -80°C using a 
commercial kit (Hycult Biotech: Human LBP ELISA kit, HK315). All reagents and 
samples were brought to room temperature. Samples were diluted 1/1000 in kit buffer. 
LBP standard was prepared by reconstituting the lyophilized vial with the amount of 
wash/dilution buffer specified on the certificate of analysis in the kit, giving a stock 
solution of 50 ng/ml. This was further diluted to produce a dilution series for the 
standard curve (50 ng/ml, 33.3 ng/ml, 22.2 ng/ml, 14.8 ng/ml, 9.9 ng/ml, 6.6 
ng/ml, 3.3 ng/ml, 0 ng/ml). A spiked control of known LBP concentration was run on 
every plate and 100µl of standard, sample or control were added to each well of the 
microplate in duplicate. The plate was covered with an adhesive strip and incubated at 
room temperature for 1 hour. The plate was then aspirated and washed 4X before 100µl 
of diluent tracer (biotin) was added to each well. After a one-hour incubation and wash 
step 100µl of streptavidin-peroxidase was added to each well and incubated for one 
hour. After a final wash, 100µl of TMB substrate solution was added to each well and the 
plate incubated in the dark at room temperature for 30 minutes. The reaction was 
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stopped with 100µl of stop solution and the plate read at 450nm. The standard curve was 
calculated using a log/lin curve fit in Excel 2011 for Mac and any duplicates with CVs 
exceeding 15% were repeated. 
 
2.9.3 Intestinal fatty acid binding protein 
Intestinal fatty acid binding protein (I-FABP) was measured in serum samples stored at -
80°C using a commercial kit (Hycult Biotech: Human I-FABP ELISA kit, HK406). All 
reagents and samples were brought to room temperature. Samples were diluted 1/2 in 
kit sample dilution buffer. I-FABP standard was prepared by reconstituting the 
lyophilised vial with the amount of sample dilution buffer specified on the certificate of 
analysis sheet in the kit giving a stock solution of 3000 pg/ml. This was further diluted to 
produce a dilution series for the standard curve (1500pg/ml, 750pg/ml, 375pg/ml, 
187pg/ml, 94pg/ml, 47pg/ml, 0pg/ml). A spiked control of known I-FABP 
concentration was run on every plate. 100µl of standard, sample or control were added 
to each well of the microplate in duplicate. The plate was covered with a plate sealer and 
incubated at room temperature for 1 hour. The plate was then aspirated and washed 4X 
before 100µl of diluent tracer (biotin) was added to each well. After a one-hour 
incubation and wash step 100ul of streptavidin-peroxidase was added to each well and 
incubated for one hour. After a final wash, 100µl of TMB substrate solution was added to 
each well and the plate incubated in the dark at room temperature for 30 minutes. The 
reaction was stopped with 100µl of stop solution and the plate read at 450nm. The 
standard curve was calculated using a log/lin curve fit in Excel 2011 for Mac and any 
duplicates exceeding 15% CVs were repeated. 
 
2.9.4 CD163 
A commercially available kit (R&D Systems: Quantikine, Human CD163 Immunoassay) 
was used to measure CD163 in serum samples stored at -80°C. All reagents and samples 
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were brought to room temperature. Plasma samples were diluted 10X into calibrator 
diluent. Lyophilised soluble CD163 standard was reconstituted with 1ml distilled water, 
giving a stock solution of 200ng/ml. The stock solution was gently agitated for 15 
minutes prior to using to produce a dilution series. 100µl of assay diluent was added to 
each of the microplate wells, followed by 50µl of either standard, sample or control per 
well in duplicate. A spiked control of known CD163 concentration was run on every 
plate. The microplate was covered with an adhesive plate sealer and incubated at room 
temperature for 2 hours then aspirated and washed 4X before 200µl of CD163 conjugate 
was added to each well. The microplate was covered with a plate sealer and incubated at 
room temperature for 1 hour followed by a further wash step. 200µl of substrate 
solution was added to each well and the plate was incubated in the dark at room 
temperature for 30 minutes. The reaction was stopped with 50µl of stop solution and 
read at 450nm with a background reading at 540nm.  The standard curve was calculated 
in Excel using a lin-lin fit and any sample duplicates with CVs exceeding 15% were 
repeated.  
 
2.9.5 LAL Assay 
We were unable to validate the LAL assay for use with plasma samples (see appendix). 
 
2.9.6 Measurement of endotoxin using a TLR4-responsive cell line 
 
A reporter-gene cell line for the quantification of endotoxin in human serum was 
developed by Christophe Lallemand (Laboratory of Biotechnology & Applied 
Pharmacology, CNRS, Cachcan, France). The macrophage/monocyte erythroleukaemic 
cell line K562 was transfected with an NFkB regulated firefly luciferase reporter-gene 
construct. Briefly, a synthetic double-stranded oligonucleotide corresponding to a five-
fold tandem repeat of the NFkB recognition sequence controlling a SV40 minimal 
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promoter was cloned upstream of the firefly luciferase (FL) reporter-gene by insertion 
into the HindIII/Xbal site of the pGL2 vector (Promega) and stable transfectants were 
isolated and cloned. These cells were then transfected with a second reporter gene, 
Renilla luciferase, under the control of the constitutive minimal thymidine kinase 
promoter (Promega), which allows for normalisation of transfection efficiency and cell 
number. The cell line, which is deficient for the endogeneous expression of TLR4 was 
further transfected with MD-2 and CD14 and TLR4 to allow an efficient activation of 
NFκB-luciferase reporter gene after LPS binding. 
 
Cells were grown in selective antibiotics (RPMI 1640 + HEPES, 10% fetal calf serum, 
G418 (1mg/ml), hydrogold (0.150mg/ml), puromycin (0.25µg/ml) and blasticidin 
(10µg/ml) in a 37°C incubator at 5% CO2. The WHO 2
nd international Endotoxin 
Standard (NIBSC) was used to create a log standard curve, which ranged from 1000 to 
0.001 IU/ml and serum was spiked with known concentrations of standard to provide 
controls. The assay was performed in 96 well pyrogen and DNA free Luminometer 
plates (Perkin Elmer). 10µl of standard or serum to be tested was added in duplicate to 
the plate followed by 25,000 transfected cells per well (100µl). The plate was incubated 
for 6 hours (37°C, 5% CO2) after which Dual-Glo (Promega) FL reagent was added 
(50µl/well) and a first reading taken in a luminometer (GloMax Multi Detection 
System, Promega). The Dual-Glo RL reagent (50µl/well) was then added and a second 
reading taken after a 10-minute incubation in the luminometer. The readings were 
exported into Excel and FL activity relative to RL activity calculated, results were 
normalized relative to the FL/RL reading in the blank well and a 4PL curve of the 
standard was constructed in GraphPad Prism. Unknown concentrations were 
interpolated from the curve.  
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2.9.7 16s Ribosomal DNA 
Bacterial DNA was measured in plasma samples stored at -80°C using quantitative 
polymerase chain reaction (qPCR). DNA was extracted from 400µl plasma using an EZI 
Advanced robot and kit (Qiagen DNA EZI, DNA EZI mini kit v2.0). PCR was carried 
out with Platinum Syber Green Supermix UDG (Invitrogen) with 16s primers (Eurofons 
MWG Operon (forward (5’-3 ’ – TGG AGC ATG TGG TTT AAT TCG A) reverse (5’- 
3’ – TGC GGG ACT TAA CCC AAC A)) at a final concentration of 0.05 µM. 
Molecular grade water controls and spiked plasma controls were run on each plate. A 
standard curve was made from purified E.coli DNA and ranged from 2 x 107 to 2 x 101 
copies per reaction. Quantitative real time PCR was performed in an Applied Biosystems 
ABI PRISM® 7000 using the following conditions; activation of Taq DNA polymerase 
for 10 minutes 95oC, 40 cycles of denaturing for 40 seconds 94oC, annealing for 45 
seconds 60oC, and extension for 45 seconds 72oC.  A PCR run was accepted if the slope 
of the standard fell between -3.6 and -3.3 representing 90-100% efficiency, and the 
curve fit was 0.985 or above. Samples were run in triplicate and repeated if the standard 
deviation of the quantification cycle (Cq) was over 0.400. 
 
2.10 Immunohistochemistry 
Two biopsies per patient were collected into formalin and processed in batches. Biopsy 
processing was performed by Anna Mroz (Department of Medicine, St Mary’s Campus, 
Imperial College London). Biopsies were dehydrated and embedded into paraffin then 
sectioned into 5µm slices using a microtome. Sections were then mounted onto 
microscope slides and stored at room temperature until required.  
 
2.10.1 Tight Junction Protein staining 
Tight junction staining was performed by Anna Mroz (Department of Medicine, St 
Mary’s Campus, Imperial College London). Slides were stained for the tight junction 
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proteins Claudin 1, Claudin 4 and Occludin with an automated Leica BOND-MAX 
system (Leica Biosystems) using Bond Polymer Refine Detection reagents (Leica 
Biosystems) and unconjugated rabbit polyclonal antibodies (Claudin 1 1:200 dilution 
(ABCAM), Claudin 4 1:800 (Santa Cruz Biotechnology), Occludin 1:100 or 1:800 
(ABCAM)). Slides were deparaffinised in Bond Dewax solution and antigen retrieval was 
performed using EDTA (Claudin 1, 30 minutes: Claudin 4, 40 minutes: Occludin, 20 
minutes). Endogenous peroxidases were then blocked with hydrogen peroxide before 
incubation with the primary antibody (30 minutes). Indirect labeling was performed 
using a rabbit anti-mouse IgG antibody linker (15 minutes) followed by incubation with 
anti-rabbit polyclonal HRP IgG antibody (15 minutes) after three wash steps. 
Visualisation using the chromogen 3,3’-Diaminobenzidine tetrehydrochloride (DAB) was 
performed (10 minutes) before counterstaining with haematoxylin. After automated 
processing, slides were rinsed under running water for 2 minutes, enhanced in copper 
sulfate (CuSO4) for 2 minutes and rinsed again before being dehydrated by hand in baths 
of increasing concentrations of denatured ethanol then xylene before coverslipping.  
 
2.10.2 LPS staining  
Staining was performed as above with a mouse anti-LPS core antibody (Hycult Biotech, 
dilution 1/1000) with citrate antigen retrieval (20 minutes). 
 
2.10.3 Analysis of IHC staining 
Stained slides were scanned at high resolution (x400) on a NanoZoomer 2.0-HT digital 
slide scanner (Hamamatsu) and viewed in NanoZoomer Digital Pathology 2 (NDP2) 
software.  
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2.10.3.1 Tight Junction Analysis 
Breaches in tight junction staining were defined as the absence of the apical staining 
pattern between the epithelial cell and the gut lumen. Lengths of breaches and intact 
staining were measured by drawing freehand lines along the epithelium in NDP Viewer 2 
(Hamamatsu). Breach/Intact ratios were calculated from the sum of the total length of 
the breaches divided by the sum of the total length of the intact staining. All analysis was 
done blind to disease group and 10% of claudin 1 slides were reanalysed to test the 
robustness of the analysis method. Slides for reanalysis were randomly chosen using the 
RANDBETWEEN function in Excel for Mac. The average C.V of the repeated slides was 
29% (SD 1.18). 
2.10.3.2 LPS 
The level of LPS staining was assessed throughout the lamina propria of the whole tissue 
scan at a set magnification of x250. Where LPS staining was present, a score of 1+ to 3+ 
was given according to the intensity and distribution of staining. Confirmation of positive 
LPS staining was performed by Professor Robin Goldin, Consultant histopathologist, St 
Mary’s Hospital London. 
 
2.11 Software and statistical analysis 
 
Flow cytometry analysis was performed using FlowJo v.8.8.7 (TreeStar) and exported 
into Microsoft Excel 2011 for Mac and then into Prism (GraphPad Prism 6). The 
magnitude of staining in an unstimulated control was subtracted for each cytokine 
measured, where this generated negative values these responses were arbitrarily set to 
zero. For the display of polychromatic flow cytometry data excel files were exported and 
analysed in SPICE v5.3 (Simplified Presentation of Incredibly Complex Evaluations 
(Roederer et al. 2011).  Soluble markers were analysed in either GraphPad Prism 6 or in 
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Excel 2011 for Mac. NDP2 Nano zoomer digital software was used to measure breach 
and intact lengths of epithelium and ratios were calculated in Excel.  
 
Differences between 3 groups were analysed using Kruskal-Wallis with Dunn’s post-test 
correction. Comparisons between matched blood and mucosal data within groups was 
performed using Wilcoxon Matched-Pairs signed rank test and differences between two 
non-matched groups was performed using Mann-Whitney test. Correlations were 
performed using Spearman’s Rho. The threshold of statistical significance was set at a p 
value of below 0.05. Multiparametric data was analysed in SPICE using the partial 
permutation test and Mann-Whitney.    
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Chapter 3  Blood and Mucosal T cell subsets in 
health and HIV-1 infection 
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3.1 Introduction 
 
HIV is now understood to be primarily a mucosal disease, with mass depletion of CD4 T 
cells from the lamina propria occurring within a few weeks of infection (Veazey et al. 
1998, Brenchley et al. 2004). This loss may never be fully recovered, even after long 
term ART (Costiniuk and Angel 2012). The loss of memory CD4 T cells in the mucosal 
compartment is, however, insufficient to cause AIDS, as natural hosts of SIV have a 
similar extensive CD4 loss in acute infection but do not progress (Gordon et al. 2007, 
Pandrea et al. 2007).  
 
Preferential depletion of the pro-inflammatory subset TH17 from mucosal sites has been 
described in SIV models and a limited number of studies in HIV. The loss of the gut-
maintaining TH17 subset has been linked to microbial translocation (Cecchinato et al. 
2008, Brenchley et al. 2008), which may contribute to peripheral immune activation, 
the main indicator of HIV disease progression. Supporting a role for TH17 cell loss in 
HIV disease progression, reduced blood TH17 cells have been correlated with increasing 
viral load in HIV infection (Ndhlovu et al. 2008) and mucosal TH17 depletion associated 
with increasing viral load in SIV infection (Cecchinato et al. 2008). Preserved levels of 
blood CD4+ IL-17a cells were found in long-term non-progressors (Ciccone et al. 2011) 
and in non-pathogenic SIV infection (Brenchley et al. 2008) and ART has been shown to 
lead to a gradual increase in TH17 cells in peripheral blood (He et al. 2011).  
 
Although various SIV models have demonstrated TH17 depletion from the GALT and 
the periphery (Kader et al. 2009) in chronic and acute (Cecchinato et al. 2008) infection 
the studies in human cohorts are conflicting. Initial work found increased IL-17a+ CD4 
T cells in the blood of HIV patients compared to healthy controls (Maek-A-Nantawat et 
al. 2007) but various other groups have since found a reduction of TH17 cells in the 
periphery (Prendergast et al. 2010, Ndhlovu et al. 2008, Gosselin et al. 2010). Studies in 
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human mucosa are more limited and include those that found a depletion of IL-
17a+CD4+ T cells (Brenchley et al. 2008, Chege et al. 2011, Kök et al. 2014) however 
others, including the largest study (Kim et al. 2012) failed to confirm this in chronic HIV 
(Macal et al. 2008). The effect of HIV infection on mucosal TH17 cells therefore 
requires further investigation. 
 
To characterise the HIV-1 disease stage of our cohort we measured routine 
immunological parameters on or near the date of colonoscopy. These included absolute 
CD4 count, the most widely used marker of disease progression, CD4:CD8 absolute T 
cell count ratios and nadir CD4 T cell counts. To further describe our disease groups we 
compared the proportion and phenotype of T cells in blood and mucosal tissue to those 
of healthy controls. Naïve CD4 T cells are known to decrease with HIV progression and 
effector CD4 T cells increase in the periphery (Gorochov et al. 1998) but there is little 
information on alterations in mucosal T cell phenotype. We identified functional TH17 
cells in the blood and mucosa as IL-17a producing CD4 T cells, which is the most 
common and original definition. To further explore TH17 cell function we also 
measured IL-17f and IL-22 together with the phenotypic marker of precursor TH17 
cells, CD161. To attempt to identify functional differences in TH17 cells in HIV we also 
examined the memory phenotype and the ability of these cells to produce the 
inflammatory cytokines IFNγ and TNF together with the T cell proliferation cytokine IL-
2 in response to SEB.  
 
To assess whether preferential depletion of TH17 occurs in the blood or mucosa of HIV 
patients we also measured TH1 frequencies (IFNγ producing CD4 T cells), together with 
‘TH17TH1’, Tc17, TH22 and mucosal associated invariant T (MAIT) cells. TH17TH1 
cells are defined here as CD4 T cells producing IL-17a and IFNγ. Similar to TH17 cells 
they are highly permissive to HIV infection and a number of studies have shown that 
these are reduced in the periphery of HIV patients (Gosselin et al. 2010, Clark et al. 
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2011) .To our knowledge these cells have not been studied in the GI tract of HIV 
infected patients. MAIT cells are a recently described innate-like mucosal-homing T cell 
subset which express the semi-invariant TCR Vα7.2, IL-18R and are strongly positive 
for CD161 (Billerbeck et al. 2010).  They play a key role in host immunity against 
bacteria and fungi by recognition of vitamin B metabolites presented by the MHC class 
1b-related protein MR1 (Kjer-Nielsen et al. 2012). Two recent studies have found 
reduced MAIT cell percentages in blood that are not restored on ART (Leeansyah et al. 
2013, Cosgrove et al. 2013). 
 
HIV infection is associated with dysregulation of cytokine production. IL-2 deficiency is 
one of the first immunological defects that can be demonstrated in infection (Kinter and 
Fauci 1996) and increases in TNF have been reported (Vyakarnam et al. 1990). There 
are conflicting reports on the effect HIV infection has on blood IFNγ production, some 
studies have shown it is reduced in vitro after HIV exposure (Fan et al. 1997) and 
reduces further as disease progresses (Hong et al. 1998) but others have found elevated 
levels in serum (Vyakarnam et al. 1990) and no evidence of disturbance to TH1 
(IFNγ+CD4 T cells) proportions (Clark et al. 2011). Mucosal TH1 frequency in HIV are 
thought to be similar to controls (Kim et al. 2013). We measured the capacity of CD4 
and CD8 T cells in the blood and mucosa to produce these cytokines. 
 
3.1.1 Aims 
• Assess the TH17 cell frequency, functionality and distribution in HIV-1 infection. 
• Establish any preferential depletion of TH17 cells by also determining the 
frequencies of TH1, TH17TH1, Tc17, TH22 and MAIT cells in the blood and 
colonic mucosa. 
• Compare inflammatory cytokine expression patterns of CD8 and CD4 T cells in 
the blood and mucosa of HIV infected patients. 
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3.2 Patient characteristics 
 
Of the 23 healthy controls enrolled onto the study, one patient was excluded after 
histological examination showed evidence of severe melanosis coli. One blood and one 
mucosal HC result were excluded due to failed stimulation. 30 HIV infected patients on 
suppressive ART were recruited into the study. Matched blood and mucosal samples 
were collected from 29/30 with one patient providing blood samples only. Mucosal 
cytokine results from one ART patient were excluded due to failed stimulation. 3/30 
ART patients had a pre-existing diagnosis of ulcerative colitis and are not included in this 
chapter. 13 HIV infected patients with detectable viraemia were recruited into the study, 
one of whom commenced ART one week prior to colonoscopy and had a viral load of 
684 copies/ml at this time.  
 
Individuals in the viraemic group were significantly younger than both the healthy 
controls and the ART treated patients (HC=47, Viraemic=33, ART=43 years, 
p=0.0060). There was also a significant difference in gender between HIV groups and 
controls, with 3 females in the control group and none in both HIV groups (Chi 
squared=4.70, p=0.0302).  
 
Median CD4 absolute counts were within the normal range (300 – 1400 cells/µl) and 
we saw no differences between groups (Table 3-1), but there was a significant increase in 
absolute CD8 counts in viraemic and ART-treated HIV infection compared to controls 
(HC=342, Viraemic=1050, ART=806 cells/µl, p=<0.0001). Consequently we also 
found CD4/CD8 ratios were significantly reduced in both HIV groups compared to 
controls (HC=1.60, Viraemic=0.60, ART=0.70, p=<0.0001). 
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 HC (n=22) Viraemic (n=13) ART (n=27) p value 
Age in years 47 (40 – 55) 33 (31 – 44) 43 (36 – 52) 0.0060a 
Gender F:M 3:19 0:13 0:27 0.0302 b 
CD4 cells/µl 
(normal range 
300-1400) 
524 (460 – 827) 536 (400 – 775) 580 (434 - 774) ns 
CD8 cells/µl 
(normal range 
200-900) 
342 (268 – 463) 1050 (819 – 1495) 806 (602 – 995) <0.0001 c 
CD4:CD8 ratio 
(normal range 
1.00-3.60) 
1.60 (1.08 – 2.05) 0.60 (0.40 – 0.75) 0.70 (0.53 – 0.80) <0.0001 d 
Months since 
HIV diagnosis 
- 20 (7– 67) 105 (63 -192)  
HIV viral load 
Copies/ml 
- 30992 (9123 – 90944) <40  
Months on 
ART 
- - 69 (28 -131)  
Nadir CD4 
cells/µl 
- - 161(107-320)  
Table 3-1 Control and HIV Patient characteristics. Median values are reported with interquartile ranges in brackets. 
Differences between groups were assessed using Kruskal Wallis with Dunn’s post-test correction, a p value of less than 
0.05 was considered significant. Normal ranges (Comans-Bitter et al. 1997). a HC vs. viraemic HIV p=0.0047 
post correction (pc), viraemic vs. ART p=0.0458pc. bchi-squared 4.697, p=0.0302. c HC vs. viraemic HIV 
p=<0.0001pc, viraemic vs. ART p=<0.0001pc. d HC vs. viraemic HIV p=<0.0001pc, viraemic vs. ART 
p=<0.0001pc. 
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Median nadir CD4 counts in the ART-treated group were 161 cells/µl (range 7 – 1473 
cells/µl) indicating, together with failure to normalise CD4:CD8 ratios, that the ART-
treated cohort, though on suppressive ART have significant disease burden. Nadir CD4 
counts were positively correlated to CD4:CD8 ratios (p=0.0226, rs=0.4732, Figure 
3-1). 
 
 
 
 
 
 
Figure 3-1 Correlation between nadir CD4 counts and current CD4/CD8 ratios in ART-treated patients. 
Associations were calculated using Spearman’s Rho. 
 
The time since diagnosis in the viraemic cohort ranged from 3 to 112 months, 4 patients 
in total had been diagnosed less than a year at recruitment. Time since diagnosis in the 
viraemic group was inversely correlated to absolute CD4 count (p=0.0268, rs=-0.709). 
Viral load was broad in the viraemic group (ranging from 74 to 131,200 copies/ml) and 
significantly correlated to absolute CD8 count (p=0.0202, rs=0.6713) but not to CD4 
count (Figure 3-2). 
 
 
 
 
 
 
 
Figure 3-2 Correlations between absolute T cell counts, months since diagnosis and viral load in viraemic HIV 
patients. Correlations were performed using Spearman’s Rho. 
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3.3 T cell subsets  
3.3.1 CD4 and CD8 Percentage 
There was a significant reduction in percentage CD4 T cells in viraemia and ART 
compared to controls in the blood (HC=64.10%, Viraemic=49.80%, ART=47.20%, 
p=<0.0001) and the mucosa (HC=64.78%, Viraemic=33.65%, ART=48.50%, 
p=<0.0001, Figure 3-3, Table 3-2). Viraemic mucosal CD4 T cell depletion was more 
severe compared to blood (p=0.0034) and MMC/PBMC CD4 ratios were significantly 
reduced in viraemic HIV-1 infection compared to both ART and controls (HC=0.98, 
Viraemic=0.68, ART=0.99, p=0.0048).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-3 CD4 T cells (as a percentage of CD3) in the blood and mucosa of HC and HIV-1 patients. PBMC = 
peripheral blood mononuclear cells, MMC= mucosal mononuclear cells. Green circles = HC blood, blue triangles = 
Viraemic blood, orange diamonds = ART, Green squares = HC MMC, blue inverted squares = Viraemia MMC, 
orange rings = ART MMC. Differences between groups were assessed using Kruskal Wallis with Dunn’s post-test 
correction (*=p<0.05,**=p<0.01, **=p<0.001,***=p<0.0001). Differences between PBMC and MMC 
within groups were assessed using Wilcoxon matched-pairs signed rank test. Box plots represent the interquartile 
range and whiskers the minimum and maximum ratio of percentage CD4 of MMC divided by percentage CD4 of 
matched blood. 
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Blood and mucosal CD8 T cell percentages were significantly increased in the HIV 
groups compared to controls (PBMC; HC=27.95%, Viraemic=42.30%, ART=44.45%, 
p=<0.0001. MMC; HC=22.20%, Viraemic=60.10%, ART=43.13%, p=<0.0001, 
Figure 3-4). Healthy controls had significantly lower levels of CD8 T cells in the mucosa 
compared to blood, but this pattern was lost in ART and reversed in viraemic HIV-1 
infection. The ratio of percentage CD8 in MMC compared to the blood was significantly 
raised in viraemia compared to both HC and ART (HC=0.80, Viraemic=1.26, 
ART=0.97, p=0.0004). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-4 CD8 T cells (as a percentage of CD3) in the blood and mucosa of HC and HIV-1 patients. PBMC = 
peripheral blood mononuclear cells, MMC= mucosal mononuclear cells. Green circles = HC blood, blue triangles = 
Viraemic blood, orange diamonds = ART blood, Green squares = HC MMC, blue inverted squares = Viraemia 
MMC, orange rings = ART MMC. Differences between groups were assessed using Kruskal Wallis with Dunn’s post-
test correction (*=p<0.05,**=p<0.01, **=p<0.001,***=p<0.0001). Differences between PBMC and MMC 
within groups were assessed using Wilcoxon matched-pairs signed rank test. Box plots represent the interquartile 
range and whiskers the minimum and maximum ratio of percentage CD8 of MMC divided by percentage CD8 of 
matched blood. 
 
Mucosal CD4 T cells correlated to blood CD4 T cells in HIV infection (p=0.0382, 
rs=0.332) but not in controls (p=0.3113, rs=0.2263, Figure 3-5). Mucosal CD8 T cells 
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also correlated to blood CD8 in HIV (p=0.4238, rs=0.0072) but not in HC (p=0.0599, 
rs=0.4073).   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-5 Correlation of mucosal versus blood CD4 and CD8 T cells in HC and HIV-1 patients. Orange diamonds 
= ART HIV, blue triangles=viraemic HIV, green circles = Healthy controls. Correlations were determined using 
Spearman’s Rho. 
 
 
 Site Subset HC Viraemic ART p value 
 
T cells  
(%CD3) 
PBMC CD4 64.10  
(53.00-73.45) 
49.80 
(38.00-57.13) 
47.20 
(41.90-52.20) 
<0.0001
a
 
CD8 27.95 
(20.50-36.61) 
42.30 
(32.95-51.20) 
44.45 
(35.75-47.75) 
<0.0001
b 
MMC CD4 64.78 
(56.66-70.59) 
33.65 
(23.98-40.13) 
48.50 
(38.83-53.05) 
<0.0001
 c 
CD8 22.20 
(16.99-27.95) 
60.10 
(45.03-68.02) 
43.13 
(34.79-50.55) 
<0.0001
 d 
Table 3-2 T cell frequencies in blood and mucosa of controls and HIV infected patients. Median percentages with 
interquartile ranges are shown. P values from Kruskal-Wallis test for differences between groups.a HC vs. Viraemic 
p=0.0012post correction (pc), HC vs. ART p=<0.0001pc. b HC vs. Viraemic p=0.0025pc, HC vs. ART 
p=<0.0001pc. c HC vs. Viraemic p=<0.0001pc, HC vs. ART p=0.0008pc. d HC vs. Viraemic p=<0.0001pc, 
HC vs. ART p=<0.0001pc. 
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3.3.2 CD4 and CD8 Memory Phenotype 
 
Blood CD4 central memory (CD45RO+CD27+, CM) T cells were reduced in viraemia 
compared to ART-treated patients (HC=38.95%, Viraemic=30.80%, ART=48.00%, 
p=0.0481) and HIV groups had significantly more CD4 effector memory 
(CD45RO+CD27-, EM) T cells (HC=3.96%, Viraemic=11.80%, ART=9.92%, 
p=0.0053, Figure 3-6). Terminally differentiated CD4 T cells (CD45RO-CD27-) were 
raised in viraemic infection compared to controls (HC=0.83%, viraemic=3.79%, 
ART=1.68%, p=0.0178). In the mucosa we saw significantly reduced CD4 CM T cells 
in both HIV groups (HC=62.00%, viraemic=35.40%, ART=50.80%, p=0.0004) and 
elevated levels of terminally differentiated CD4 cells compared to controls (HC=4.15%, 
viraemic=18.80%, ART=14.50%, p=<0.0001, Figure 3-6). 
 
 
 
 
 
 
 
 
 
 
Figure 3-6 CD4 Central and effector memory and terminally differentiated T cells in PBMC and MMC of HC and 
HIV-1 patients. Green circles = HC blood, blue triangles = Viraemic blood, orange diamonds = ART, Green 
squares = HC MMC, blue inverted squares = Viraemia MMC, orange rings = ART MMC. Differences between 
groups were assessed using Kruskal Wallis with Dunn’s post-test correction (*=p<0.05, **=p<0.01, 
**=p<0.001, ***=p<0.0001). 
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Comparing healthy blood to matched mucosa (Figure 3-7) we saw reduced naïve CD4 T 
cells and increased levels of terminally differentiated, central memory and effector 
memory CD4 T cells. In viraemic HIV infection there was also reduced naïve CD4 T 
cells and increased terminally differentiated T cells in the mucosa compared to the blood 
but unlike healthy controls we found no significant differences in central or effector CD4 
T cells. ART patients had significantly raised CD4 effector cells in the mucosa compared 
to blood (p=<0.0001) similar to controls but CD4 central memory T cells were at a 
similar level in blood and mucosa.  
 
 
 
 
 
 
   
 
 
 
 
 
 
Figure 3-7 Comparisons between blood and mucosal CD4 phenotype in HC and HIV-1 patients. Green circles = HC 
blood, blue triangles = Viraemic blood, orange diamonds = ART, Green squares = HC MMC, blue inverted squares 
= Viraemia MMC, orange rings = ART MMC Differences between MMC and PBMC within groups were determined 
using Wilcoxon matched pairs signed rank test. 
 
There was a trend for reduced central memory blood CD8 T cells and increased effector 
memory CD8 T cells in viraemia that did not reach significance (Figure 3-8). We found 
increased terminally differentiated CD8 T cells in the blood of both ART and the 
viraemic group compared to controls (HC=9.60%, Viraemic=38.60%, ART=27.70%, 
p=0.0014). However in the mucosa we saw no significant differences in CD8 naïve, 
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terminally differentiated, central memory or effector memory CD8 subsets between 
groups (Table 3-3).  
 
 
Figure 3-8 CD8 central, effector memory and terminally differentiated T cells in PBMC and MMC of HC and HIV-1 
patients. Green circles = HC blood, blue triangles = Viraemic blood, orange diamonds = ART, Green squares = HC 
MMC, blue inverted squares = Viraemia MMC, orange rings = ART MMC. Differences between groups were assessed 
using Kruskal Wallis with Dunn’s post-test correction (*=p<0.05, **=p<0.01, **=p<0.001, 
***=p<0.0001). 
 
Healthy controls had significantly reduced naïve CD8 T cells in the mucosa compared to 
blood (p=<0.0001) and increased levels of both central (p=0.0127) and effector 
(p=<0.0001) memory CD8 T cells (Figure 3-9). Terminally differentiated CD8 T cells 
proportions were similar in the blood and mucosa. In HIV-1 infected patients we 
observed a similar pattern between blood and mucosal memory and naïve T cell 
phenotype but found significantly more terminally differentiated CD8 T cells in the 
blood compared to mucosa (Viraemic p=0.0046, ART p=0.0025). 
 
 88 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-9. Comparisons between blood and mucosal CD8 phenotype in HC and HIV-1 patients. Green circles = 
HC blood, blue triangles = Viraemic blood, orange diamonds = ART, Green squares = HC MMC, blue inverted 
squares = Viraemia MMC, orange rings = ART MMC Differences between MMC and PBMC within groups were 
determined using Wilcoxon matched pairs signed rank test. 
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 Site Subset HC Viraemic ART p value 
 
Naïve  
PBMC %CD4 54.60 
(35.30-66.90) 
48.10 
(42.30-64.60) 
35.00 
(12.90-60.60) 
ns 
%CD8 48.20 
(33.13-61.53) 
35.70 
(20.25-46.90) 
36.10 
(25.00-50.30) 
ns 
MMC %CD4 8.02 
(4.49-13.20) 
18.30 
(6.76-34.75) 
7.78 
(4.12-17.65) 
0.0451
a
 
%CD8 12.10 
(5.52-17.15) 
22.20 
(9.05-26.10) 
12.40 
(8.06-21.25) 
ns 
 
Terminally 
diff.  
PBMC %CD4 0.83 
(0.37-3.40) 
3.79 
(2.31-4.23) 
1.68 
(0.72-6.49) 
0.0178
 b
 
%CD8 9.60 
(1.59-32.05) 
38.60 
(24.30-45.75) 
27.70 
(18.10-37.60) 
0.0014
 c
 
MMC %CD4 4.15 
(1.63-6.81) 
18.80 
(8.16-34.20) 
14.50 
(7.18-22.30) 
< 0.0001
 d
 
%CD8 11.70 
(5.33-18.50) 
14.40 
(7.02-32.75) 
15.40 
(8.26-21.65) 
ns 
 
Central 
Memory  
PBMC %CD4 38.95 
(28.25-50.80) 
30.80 
(24.30-37.55) 
48.00 
(29.70-66.30) 
0.0481
 e
 
%CD8 23.00 
(13.38-38.23) 
12.50 
(10.80-21.70) 
20.20 
(13.10-28.30) 
ns 
MMC %CD4 62.00 
(53.80-74.15) 
35.40 
(25.55-52.45) 
50.80 
(39.85-59.45) 
0.0004
 f
 
%CD8 37.40 
(27.60-57.70) 
30.10 
(26.80-44.40) 
36.80 
(27.50-47.50) 
ns 
 
Effector 
Memory  
 
PBMC %CD4 3.96 
(2.83-7.42) 
11.80 
(6.58-17.95) 
9.92 
(4.96-13.10) 
0.0053
 g
 
%CD8 5.99 
(3.63-7.04) 
9.02 
(6.22-16.05) 
6.69 
(3.91-15.70) 
ns 
MMC %CD4 20.70 
(15.40-30.25) 
15.90 
(10.80-24.15) 
23.20 
(16.10-31.70) 
ns 
%CD8 33.60 
(24.45-43.30) 
22.20 
(14.35-37.20) 
29.60 
(15.00-43.15) 
ns 
Table 3-3 T cell memory phenotype in HC and HIV-1 patients. Median percentages with interquartile ranges are 
shown. P values from Kruskal-Wallis test for differences between groups. . a no significance post correction (pc). b HC 
vs. Viraemic p=0.0136pc,    c HC vs. Viraemic p=0.0015pc, HC vs. ART p=0.0376pc. d HC vs. Viraemic 
p=<0.0001pc, HC vs. ART p=<0.0001pc. eART vs. Viraemic p=0.0412pc. . fHC vs. Viraemic p=0.0004pc, 
HC vs. ART=0.0233pc. . gHC vs. Viraemic p=0.0095pc, HC vs. ART=0.0353pc. 
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3.4 TH17 cells 
3.4.1 Precursor TH17 cells 
We found no significant differences in levels of precursor TH17 (CD4+CD161+) cells 
in the blood of our HIV groups compared to controls (Figure 3-10, Table 3-4). In the 
mucosa however, we saw a reduced precursor TH17 cells in viraemia compared to both 
controls and ART patients (HC=62.37%, Viraemic=38.59%, ART=52.07%, 
p=<0.0001). Overall TH17 precursor cells were enriched in the mucosa, with healthy 
controls having five times the frequency compared to blood. In HIV infection there was a 
significant reduction in MMC/PBMC TH17 precursor ratios in both HIV groups 
compared to controls (HC=5.42, Viraemic=3.13, ART=3.42, p=0.0090). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-10 Precursor TH17 cells in blood and mucosa of HC and HIV-1 patients. Differences between groups were 
assessed using Kruskal Wallis with Dunn’s post-test correction (*=p<0.05,**=p<0.01, 
**=p<0.001,***=p<0.0001). Differences between PBMC and MMC were assessed using Wilcoxon matched-pairs 
signed rank test. Box plots represent the interquartile range and whiskers the minimum and maximum ratio of %CD4 
CD161+ of MMC divided by %CD4 CD161+ of matched blood. 
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Table 3-4 Precursor TH17 cells in blood and mucosa of HIV patients and controls. Median values with interquartile 
ranges are reported. P values from Kruskall-Wallis test for difference between groups. a HC vs. Viraemic 
p=<0.0001pc, Viraemic vs. ART p=0.0109pc. b HC vs. Viraemic p=0.0003pc, HC vs. ART p=0.0219pc.  
 
3.4.2 TH17 Frequency 
 
There was a trend for increased TH17 (IL-17a+CD4+) cells in the blood of HIV patients 
that did not reach significance (Figure 3-11, Table 3-5). TH17 cells in the effector 
memory blood compartment were raised in viraemia but this lost significance post 
correction (HC=0.45%, Viraemic=0.76%, ART=0.65%, p=0.0377, Table 3-5). We 
found no differences in mucosal TH17 percentages between controls and HIV infection. 
Similar to precursor TH17 cells, TH17 cells were enriched in the mucosa compared to 
blood but this pattern was lost in HIV infection and consequently there was a trend for a 
reduced ratio of mucosal to blood TH17 cells in viraemia compared to controls 
(HC=1.97, Viraemic=0.87, ART=1.56, p=0.0523).  
 
 Site Subset HC Viraemic ART p value 
 
CD161 
(Precursor 
TH17) 
 
PBMC %CD4 10.11 
(7.84-14.21) 
9.10 
(8.42-17.25) 
15.01 
(9.12-21.57) 
ns 
%CM 22.60  
(15.10-27.85) 
29.90 
(24.05-35.40) 
26.00 
(21.38-33.48) 
ns 
%EM 25.60 
(15.30-30.85) 
24.10 
(17.70-30.90) 
22.00 
(14.80-29.35) 
ns 
MMC %CD4 62.37 
(52.36-68.85) 
38.59 
(32.57-48.50) 
52.07 
(47.88-57.11) 
<0.0001
a
 
%CM 62.55 
(53.30-67.38) 
53.90 
(47.55-60.75) 
53.40 
(49.75-63.85) 
ns 
%EM 78.45 
(68.20-82.35) 
57.60 
(52.90-70.95) 
66.85 
(58.13-75.50) 
0.0003
 b
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Figure 3-11 TH17 frequency in blood and mucosa of HC and HIV-1 patients. Differences between groups were 
assessed using Kruskal Wallis with Dunn’s post-test correction. Differences between PBMC and MMC were assessed 
using Wilcoxon matched-pairs signed rank test. Box plots represent the interquartile range and whiskers the 
minimum and maximum ratio of MMC %CD4 IL-17a+ divided by PBMC %CD4 IL-17a. 
 
3.4.3 TH17 Phenotype 
 
We next sought to assess whether TH17 phenotype was altered in HIV-1 infection in the 
periphery or mucosa. We analysed the expression of CD45RO and CD27 on CD4 T 
cells expressing IL-17a in SPICE. Before analysis we excluded samples where fewer than 
50 IL-17a+ events had been collected, as further subdivision of such small populations 
may be unreliable. After exclusion we had data in the blood of 19 HC, 12 viraemic and 
26 ART and in the mucosa 19 HC, 9 viraemic, and 18 ART patients. 
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We observed no significant difference between the overall phenotype of blood TH17 
cells across groups using the partial permutation test in SPICE (Figure 3-12). There was 
a trend for increased effector memory TH17 cells in HIV blood that did not reach 
significance. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-12 TH17 phenotype in HC and HIV-1 patients. Comparisons between pie charts were performed in SPICE 
using a partial permutation test. 
 
In the mucosa however TH17 phenotype was significant differently between controls and 
viraemic HIV infection (p=0.0426) due to significantly increased terminally 
differentiated TH17 cells in viraemia (HC=1.85%, Viraemic=13.00%, ART=6.80%, 
p=0.0113, Figure 3-13). 
 
The phenotype of mucosal TH17 cells in healthy controls had a significantly different 
phenotype to TH17 cells in the blood (p=0.0030), with more effector memory and 
reduced central memory TH17 cells. Unlike controls there was no difference in the 
proportion of effector memory TH17 cells in the mucosa compared to the blood of HIV 
patients but ART patients, similar to controls, had less central memory TH17 compared 
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to blood. Both HIV groups had significantly more terminally differentiated TH17 in the 
mucosa compared to the blood. 
 
 
 
 
 
 
 
Figure 3-13 Percentage terminally differentiated TH17 in the MMC of HC and HIV infection. 
 
3.4.4 TH17 Functionality 
 
As alterations in the functionality of TH17 cells have been shown to occur before TH17 
numbers decline (Kim et al. 2013) we next assessed the polyfunctionality of TH17 cells 
in blood and mucosa using boolean gating and SPICE (For single cytokine production in 
TH17 cells see appendices). In blood the largest population of TH17 cells were those 
producing both IL-2 and TNF (cerise pie slice, Figure 3-14) followed by TH17 cells 
solely producing TNF. We found no significant differences between blood TH17 
polyfunctionality between HIV groups and controls. However in the mucosa we found a 
significant increase in triple negative (IFNγ-IL-2-TNF-) TH17 cells in viraemia 
(p=0.0260) compared to controls.     
 
Mucosal TH17 cells had a significantly different functional profile compared to blood 
TH17 cells. In controls and HIV we found reduced proportions of IL-2+TNF+ TH17 
cells in the mucosa compared to blood. ART patients had significantly reduced TH17 
cells expressing IFNγ+IL-2+TNF+ and increased percentages of TH17 solely producing 
TNF as well as TH17 that did not produce IFNγ, IL-2 or TNF (IFNγ-IL-2-TNF-) in the 
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mucosa compared to blood. Viraemic HIV infection was also associated with increased 
triple negative IFNγ-IL-2-TNF- TH17 cells in the mucosa compared to blood.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-14 Polyfunctional TH17 cells in blood and mucosa of HIV-1 and controls. Comparisons between pie charts 
were performed in SPICE using a partial permutation test. 
 
3.4.5 IL-17f+ CD4 T cells 
 
We then assessed the production of the TH17-associated cytokine IL-17f by CD4 T cells 
(Figure 3-15). Overall IL-17f production was low, however we found a significant 
increase in the blood of both HIV groups compared to controls (HC=0.00%, 
Viraemia=0.10%, ART=0.15%, p=0.0005) and a significant increase of central 
memory CD4 T cells producing IL-17f in viraemia compared to controls (HC=0.05%, 
Viraemia=0.17%, ART=0.11%, p=0.0018). No differences were observed in mucosal 
CD4 IL-17f production. 
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Blood IL-17f production by CD4 T cells was highly correlated to IL-17a CD4 production 
in HIV infection (rs =0.8402, p=<0.0001) and in controls (p=0.004, rs= 0.605) but 
this correlation was lost in the mucosa (HIV p=0.1080, rs=0.276; control p=0.138, 
rs=0.335).  
 
Figure 3-15 IL-17f production by CD4 T cells in the blood and mucosa of HC and HIV-1 patients. Differences 
between groups were assessed using Kruskal Wallis with Dunn’s post-test correction (*=p<0.05, **=p<0.01, 
**=p<0.001, ***=p<0.0001). 
 
3.5 Tc17 cells 
 
CD8 T cells capable of producing TH17-associated cytokines have previously been 
reported. In our cohort there was little evidence of CD8 T cells expressing either IL-17a 
or IL-17f in the blood (Table 3-5). Mucosal IL-17f production by CD8 T cells was also 
largely absent. We did find low levels of CD8 T cells in the mucosa capable of producing 
IL-17a (HC=0.06%, Viraemia=0.10%, ART=0.19%) but there were no significant 
differences between HIV and controls.  
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Table 3-5 TH17-associated cytokines in HC and HIV-1 patients. Median values with interquartile ranges in 
brackets are reported. aNo significance post correction (pc). bHC vs. Viraemic p=0.0051pc, HC vs. ART 
p=0.0017pc. cHC vs. Viraemic p=0.0011pc. dNo significance post correction.   
 
3.6 TH17TH1 cells 
 
The percentage of CD4 T cells producing IL-17a together with IFNγ (TH17TH1) was 
low in the blood and not significantly different between groups (Table 3-6). In the MMC 
there was a weak trend for decreased TH17TH1 cells in HIV patients compared to 
controls that did not reach significance. 
  
Site 
 
Subset 
 
HC 
 
Viraemic 
 
ART 
 
p value 
 
 
IL-17a 
(TH17) 
 
PBMC %CD4 0.32 
(0.14-0.44) 
0.36 
(0.24-0.65) 
0.40 
(0.19-0.82) 
ns 
%CM 0.45 
(0.25-0.67) 
0.76 
(0.47-1.10) 
0.65 
(0.33-0.89) 
0.0377
a
 
%EM 1.55 
(0.69-1.91) 
1.25 
(0.68-1.98) 
1.35 
(0.77-2.39) 
ns 
MMC %CD4 1.05 
(0.80-1.40) 
0.89 
(0.33-1.13) 
0.96 
(0.55-1.66) 
ns 
%CM 0.94 
(0.75-1.51) 
0.77 
(0.49-1.25) 
0.80 
(0.53-1.42) 
ns 
%EM 2.00 
(1.61-3.77) 
1.52 
(0.63-2.56) 
2.08 
(0.79-2.98) 
ns 
 
 
IL-17f 
 
PBMC %CD4 0.00 
(0.00-0.07) 
0.10 
(0.07-0.22) 
0.15  
(0.00-0.24) 
0.0005
 b
 
%CM 0.05 
(0.02-0.11) 
0.17 
(0.14-0.23) 
0.11 
(0.05-0.17) 
0.0018
 c
 
%EM 0.21 
(0.17-0.58) 
0.51 
(0.26-1.31) 
0.60 
(0.30-0.83) 
0.0352
 d
 
MMC %CD4 0.13 
(0.00-0.16) 
0.11 
(0.05-0.30) 
0.09 
(0.05-0.21) 
ns 
%CM 0.09 
(0.04-0.15) 
0.07 
(0.04-0.23) 
0.09 
(0.05-0.17) 
ns 
%EM 0.25 
(0.10-0.43) 
0.25 
(0.11-0.82) 
0.23 
(0.11-0.60) 
ns 
IL-17a PBMC %CD8 0.00 
(0.00-0.00) 
0.00 
(0.00-0.09) 
0.00 
(0.00-0.06) 
ns 
MMC %CD8 0.06 
(0.00-0.28) 
0.10 
(0.00-0.22) 
0.19 
(0.06-0.44) 
ns 
IL-17f PBMC %CD8 0.00 
(0.00-0.00) 
0.00 
(0.00-0.00) 
0.00 
(0.00-0.00) 
ns 
MMC %CD8 0.00 
(0.00-0.03) 
0.00 
(0.00-0.06) 
0.00 
(0.00-0.07) 
ns 
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3.7 IL-22+ CD4 T cells 
 
We found a significant increase in the percentage of blood CD4 T cells producing IL-22 
in the ART group compared to controls (HC=0.12, Viraemic=0.15%, ART=0.25%, 
p=0.0150, Figure 3-16). In the mucosa there was a trend for reduced IL-22 production 
by CD4 T cells in viraemia that did not reach significance. CD4 T cells producing IL-22 
were enriched in the mucosa of controls compared to the blood (p=0.0004). However 
this pattern was lost in HIV infection and MMC/PBMC ratios were significantly reduced 
compared to controls (HC=2.98, Viraemic=0.96, ART=1.50, p=0.0060). 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
Figure 3-16 IL-22 production by CD4 T cells in blood and mucosa of HC and HIV-1 patients. Differences between 
groups were assessed using Kruskal Wallis with Dunn’s post-test correction (*=p<0.05). Differences between PBMC 
and MMC were assessed using Wilcoxon matched-pairs signed rank test. Box plots represent the interquartile range 
and whiskers the minimum and maximum ratio of %CD4 memory IL-22+ in MMC divided by PBMC. 
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3.7.1 TH22 cells 
As IL-22 is produced by both TH17 and TH22 cells we used the TH17 precursor marker 
CD161 to isolate IL-22 production by TH22 cells. The percentage of IL-22+CD161- 
CD4 T cells was low in the blood (HC=0.06%, Viraemic=0.09%, ART=0.11%) and 
the mucosa (HC=0.12%, Viraemic=0.00%, ART=0.08%, Figure 3-17) but not 
significantly different between groups. In contrast to total IL-22 expression, TH22 CD4 
levels in healthy controls were not significantly different between the blood and mucosa 
but viraemic and ART patients had significantly reduced mucosal TH22 cells compared 
to blood (Viraemic PBMC=0.09%, MMC=0.00, p=0.0011. ART PBMC= 0.11%, 
MMC=0.08%, p=0.0059). There was no significant difference in mucosal/blood TH22 
ratios between controls and HIV (HC=1.13, Viraemic=0.59, ART=0.61).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-17 TH22 T cells in the blood and mucosa of HC and HIV-1 patients. Differences between groups were 
assessed using Kruskal Wallis with Dunn’s post-test correction. Differences between memory TH22 PBMC and MMC 
were assessed using Wilcoxon matched-pairs signed rank test. Box plots represent the interquartile range and whiskers 
the minimum and maximum ratio of %CD4 memory TH22 in MMC divided by PBMC. 
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Similar to IL-17a and IL-17f we saw very few IL-22 producing CD8 T cells in any of our 
groups. 
 
 
3.8 MAIT cells  
 
Mucosal invariant T cells (MAIT) are a recently described innate-like lymphocyte with 
anti-bacterial functions. Recent work has suggested their loss may have a role during HIV 
infection. We identified MAIT cells in CD8 T cells by the bright expression of CD161. 
We saw a significant reduction in the proportion of blood CD8 T cells that express 
CD161++ in ART-naive and ART-treated HIV patients compared to healthy controls 
(HC=4.84%, Viraemic=1.60%, ART=1.42%, p=0.0026, Figure 3-18). The expression 
of CD161++ on CD8 T cells isolated from colon samples was also significantly reduced 
in viraemic HIV but similar to controls in patients receiving ART (HC=8.42%, 
Viraemic=3.93%, ART=6.91%, p=0.0059).  
 
 
 
 
 
 
 
 
Figure 3-18 MAIT cells in blood and mucosa of HC and HIV-1 patients. Differences between groups were assessed 
using Kruskal-Wallis with Dunn’s post-test correction. (*=p<0.05, **=p<0.01, **=p<0.001, 
***=p<0.0001). 
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Table 3-6 TH17TH1 cells, IL-22 producing CD4 T cells, TH22 and MAIT cell proportions in the blood and 
mucosa of HC and HIV-1 patients. aHC vs. ART p=0.0120pc.bHC vs. Viraemic p=0.0076pc, HC vs. ART 
p=0.0138pc. cHC vs. Viraemic=0.0043pc. 
 
3.9 CD4 and CD8 Cytokine Responses to SEB 
 
We finally assessed the ability of CD4 and CD8 T cells to produce the cytokines IFNγ, 
IL-2 and TNF in response to the super-antigen Staphylococcal Enterotoxin B (SEB). 
 
3.9.1 CD4 Cytokine Production 
In the blood we found no significant differences in percentage CD4 T cells producing 
IFNγ (TH1 cells), IL-2 or TNF in HIV compared to controls (Figure 3-19). We found a 
 Site Subset HC Viraemic ART p value 
TH17TH1 PBMC %CD4 0.03 
(0.00-0.07) 
0.04 
(0.02-0.08) 
0.03 
(0.02-0.10) 
ns 
MMC %CD4 0.09 
(0.07-0.18) 
0.05 
(0.01-0.13) 
0.06 
(0.02-0.017) 
ns 
 
 
 
IL-22 
 
PBMC %CD4 0.12 
(0.00-0.19) 
0.15 
(0.11-0.32) 
0.25 
(0.08-0.50) 
0.0150
 a
 
%CM 0.18 
(0.08-0.32) 
0.35 
(0.17-0.52) 
0.30 
(0.18-0.50) 
ns 
%EM 0.50 
(0.22-0.96) 
0.72 
(0.21-1.78) 
0.81 
(0.42-1.11) 
ns 
MMC %CD4 0.60 
(0.34-0.78) 
0.19 
(0.10-0.64) 
0.39 
(0.25-0.78) 
ns 
%CM 0.48 
(0.31-0.64) 
0.46 
(0.13-0.59) 
0.39 
(0.21-0.73) 
ns 
%EM 0.98 
(0.61-1.24) 
0.35 
(0.23-2.66) 
0.74 
(0.33-1.59) 
ns 
 
TH22 
PBMC %CD4 0.06 
(0.00-0.12) 
0.09 
(0.03-0.19) 
0.11 
(0.04-0.21) 
ns 
MMC %CD4 0.12 
(0.00-0.20) 
0.00 
(0.00-0.11) 
0.08 
(0.00-0.15) 
ns 
MAIT PBMC %CD8 4.84 
(2.32-9.76) 
1.60 
(0.41-2.92) 
1.42 
(0.53-4.73) 
0.0026
 b
 
MMC %CD8 8.42 
(5.19-13.14) 
3.93 
(1.91-4.40) 
6.91 
(2.73-10.53) 
0.0059
 c
 
 102 
significant increase in IFNγ production by EM CD4 T cells in the ART group compared 
to healthy controls (HC=4.58%, Viraemic=7.83%, ART=9.75%, p=0.0102) and a 
significant reduction in IL-2 production by blood EM CD4 T cells in viraemia compared 
to controls (HC=8.72%, Viraemic=3.18%, ART=6.52%, p=0.0205, Table 3-7).    
 
 
Figure 3-19 Single cytokine production of IFN, IL-2 and TNF in the blood of HC and HIV patients. Differences 
between groups were calculated suing Kruskal-Wallis with Dunn’s post-test correction. (*=p<0.05,**=p<0.01, 
**=p<0.001,***=p<0.0001). 
 
In contrast to the blood, mucosal CD4 production of IFNγ, IL-2 and TNF were all 
significantly reduced in ART and viraemic patients compared to controls (TH1 cells; 
HC=2.99%, Viraemic=0.71%, ART=1.83%, p=<0.0001. IL-2; HC=4.12%, 
Viraemic=1.41%, ART=1.90%, p=<0.0001. TNF; HC=12.51%, Viraemic 4.95%, 
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ART=7.80%, p=<0.0001, Figure 3-20) with ART leading to some incomplete 
restoration of IFNγ+/TH1 cells.  Cytokine production in the central and effector 
memory CD4 T cells subsets was also significantly reduced in HIV compared to controls 
(Table 3-7).     
 
 
Figure 3-20 Single cytokine production of IFN, IL-2 and TNF in the mucosa of HC and HIV patients. Differences 
between groups were calculated suing Kruskal-Wallis with Dunn’s post-test correction. (*=p<0.05,**=p<0.01, 
**=p<0.001,***=p<0.0001). 
 
To compare mucosal to blood cytokine responses we calculated the ratio of 
MMC/PBMC cytokine production in the total memory CD4 subset, as mucosal sites 
have a higher proportion of memory T cells.  We found a significant reduction in 
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mucosal/blood ratios for TH1 cells (HC=1.38, Viraemic=0.33, ART=0.54, 
p=0.0002), IL-2 (0.88, Viraemic =0.38, ART=0.41, p=0.0084) and TNF (HC=1.26, 
Viraemic=0.63, ART=0.77, p=0.0058) producing CD4 T cells in viraemic HIV 
compared to controls  (Figure 3-21). 
 
 
Figure 3-21 MMC/PBMC CD4 cytokine ratios in HC and HIV-1 patients. Box plots represent the interquartile 
range and whiskers the minimum and maximum ratio of percentage CD8 of MMC divided by percentage CD8 of 
matched blood. Comparisons between groups were performed using Kruskal-Wallis with Dunns post-test correction 
(*=p<0.05,**=p<0.01, **=p<0.001,***=p<0.0001). 
 
 
3.9.2 CD8 Cytokine Production 
 
IFNγ production by blood CD8 T cells was significantly raised in ART patients compared 
to controls (HC= 2.61%, Viraemic=4.73%, ART=5.71%, p=0.0209, Figure 3-22). 
This pattern was also found in CD8 central and effector T cell populations (Table 3-7) 
CD8 and CM CD8 IL-2 production was raised in ART compared to viraemic patients 
(CD8: HC=0.83%, Viraemic=0.23%, ART=1.10%, p=0.0169, CD8 CM: 2.43%, 
1.11%, ART=3.25%, p=0.0069). TNF production by total CD8 T cells in the blood 
was similar across the groups but elevated in the central memory CD8 T cells of ART 
patients compared to viraemia (HC=9.38%, Viraemic=6.82%, ART=12.90%, 
p=0.0049).  
 105 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-22 Single inflammatory cytokine production by CD8 T cells in the blood of HC and HIV-1 patients. Green 
circless = HC, blue tirangles = Viraemic, orange circles = ART. Differences between groups were assessed using 
Kruskal Wallis with Dunn’s post-test correction (*=p<0.05,**=p<0.01, **=p<0.001,***=p<0.0001). 
 
In the mucosa there was no difference in total CD8 production of IFNγ across groups 
(Figure 3-23) but we found increased IFNγ production by CD8 central memory T cells 
in viraemic patients compared to controls (HC=5.20%, Viraemic=12.80%, 
ART=6.91%, p=0.0139). Mucosal IL-2 production by CD8 T cells was significantly 
reduced in viraemia compared to both controls and ART patients (HC=1.95%, 
Viraemic=0.76%, ART=2.07%, p=0.0003) and this pattern was found in both the 
central and effector memory compartment. Mucosal TNF production by CD8 T cells 
was also significantly reduced in viraemia compared to controls and ART patients 
(HC=11.19%, Viraemic=4.82%, ART=10.26%, p=0.0002).  
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Figure 3-23 Mucosal single cytokine production by CD8 T cells in HC and HIV-1 patients. Green squares = HC 
MMC, blue inverted squares = Viraemia MMC, orange rings = ART MMC. Differences between groups were assessed 
using Kruskal Wallis with Dunn’s post-test correction (*=p<0.05,**=p<0.01, 
**=p<0.001,***=p<0.0001). 
 
Mucosal/blood ratios of CD8 memory IFNγ production were significantly reduced in 
ART patients compared to controls (HC=1.37, Viraemic=1.13, ART=0.74, p=0.0165, 
Figure 3-24). IL-2 production by CD8 T cells was reduced in both blood and mucosa of 
viraemia resulting in mucosal/blood ratios being similar across the groups (HC=0.99, 
Viraemic=1.07, ART=0.66). TNF production was selectively reduced in mucosal CD8 
T cells compared to blood in viraemic patients leading to significantly lower 
MMC/PBMC TNF ratios compared to controls (HC=1.22, Viraemic=0.49, 
ART=0.68, p=0.0061).  
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Figure 3-24 MMC/PBMC CD8 cytokine ratios in HC and HIV-1 patients. Box plots represent the interquartile 
range and whiskers the minimum and maximum ratio of percentage CD8 of MMC divided by percentage CD8 of 
matched blood. Comparisons between groups were performed using Kruskal-Wallis with Dunns post-test correction 
(*=p<0.05, **=p<0.01, **=p<0.001, ***=p<0.0001). 
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 Site Subset  HC Viraemic ART p value 
 
 
 
 
IFNγ 
 
PBMC  
CD4 
(TH1) 
%CD4 1.35 
(0.50-3.13) 
1.85 
(0.72-3.19) 
2.92 
(0.76-3.30) 
ns 
%CM 1.97 
(0.75-4.62) 
1.62 
(0.92-2.47) 
2.30 
(1.16-2.82) 
ns 
%EM 4.58 
(2.26-6.08) 
7.83 
(4.36-11.10) 
9.75 
(5.03-13.58) 
0.0102
a
 
 
CD8 
%CD8 2.61 
(1.16-4.97) 
4.73 
(2.39-7.53) 
5.71 
(3.15-9.86) 
0.0209
 b
 
%CM 3.88 
(1.92-5.60) 
5.29 
(3.67-7.13) 
6.78 
(5.43-10.10) 
0.0067
 c
 
%EM 4.29 
(3.18-9.69) 
7.65 
(3.97-12.55) 
11.20 
(6.69-19.10) 
0.0148
 d
 
MMC  
CD4 
(TH1) 
%CD4 2.99 
(2.14-3.64) 
0.71 
(0.27-1.58) 
1.83 
(0.88-2.28) 
<0.0001
 e
 
%CM 3.08 
(2.17-4.02) 
1.15 
(0.39-1.99) 
2.12 
(1.11-2.52) 
0.0005
 f
 
%EM 5.22 
(3.83-7.07) 
1.79 
(0.563.19) 
2.39 
(1.33-3.40) 
<0.0001
 g
 
 
CD8 
%CD8 4.04 
(3.24-6.44) 
7.04 
(3.39-8.73) 
5.26 
(2.26-6.84) 
ns 
%CM 5.20 
(4.17-7.67) 
12.80 
(6.60-15.95) 
6.91 
(4.57-9.49) 
0.0139
 h
 
%EM 3.65 
(2.59-6.09) 
3.00 
(2.14-5.44) 
2.70 
(1.99-6.46) 
ns 
 
 
 
 
IL-2 
 
 
PBMC  
CD4 
%CD4 3.39 
(1.04-4.59) 
2.14 
(1.07-3.88) 
3.20 
(1.47-6.37) 
ns 
%CM 6.41 
(2.64-7.80) 
4.13 
(2.60-7.76) 
5.84 
(3.66-8.29) 
ns 
%EM 8.72 
(3.48-12.44) 
3.18 
(1.78-6.53) 
6.52 
(4.85-11.10) 
0.0205
 i
 
 
CD8 
%CD8 0.83 
(0.43-1.74) 
0.23 
(0.21-0.77) 
1.10 
(0.56-1.91) 
0.0169
 j
 
%CM 2.43 
(1.01-4.15) 
1.11 
(0.44-2.23) 
3.25 
(2.00-4.37) 
0.0069
 k
 
%EM 1.61 
(0.53-3.22) 
0.30 
(0.13-1.36) 
1.27 
(0.57-2.77) 
0.0404
 l
 
MMC  
CD4 
%CD4 4.12 
(3.09-5.20) 
1.41 
(0.53-2.46) 
1.90 
(1.23-3.79) 
<0.0001
 m
 
%CM 4.60  
(3.02-5.80) 
1.80 
(0.98-3.50) 
2.66 
(1.94-4.29) 
0.0012
 n
 
%EM 5.22 
(3.83-7.07) 
1.13 
(0.39-2.19) 
2.25 
(1.55-3.10) 
<0.0001
 o
 
 
CD8 
%CD8 1.95 
(0.95-3.45) 
0.50 
(0.28-1.01) 
1.26 
(0.90-2.37) 
0.0003
 p
 
%CM 2.37 
(1.32-4.27) 
0.76 
(0.45-1.22) 
2.07 
(1.37-3.70) 
<0.0001
 q
 
%EM 2.29 
(1.00-3.34) 
0.35 
(0.14-0.71) 
0.88 
(0.54-2.78) 
0.0005
 r
 
 
 
 
PBMC  
CD4 
%CD4 6.91 
(3.87-10.65) 
5.73 
(3.86-8.87) 
8.81 
(5.13-11.34) 
ns 
%CM 11.27 
(5.22-12.87) 
8.56 
(5.12-12.20) 
10.30 
(8.09-12.87) 
ns 
%EM 16.45 
(13.03-21.45) 
15.50 
(11.15-18.68) 
17.50 
(13.70-24.69) 
ns 
 %CD8 5.94 
(3.20-11.05) 
9.84 
(5.14-11.20) 
10.25 
(6.96-13.98) 
ns 
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Table 3-7 Cytokine production by CD4 and CD8 T cells in PBMC and MMC of HC and HIV-1 patients. Median 
values with interquartile ranges are reported, p values from Kruskal-Wallis test for differences.  
a
HC vs. ART p=0.0083pc. bHC vs. ART p=0.0187pc.  cHC vs. ART p=0.0047pc. dHC vs. ART p=0.0119pc. eHC vs. 
Viraemic p=<0.0001pc, HC vs. ART p=0.0045pc, Viraemic vs. ART p=0.0471pc. 
f
HC vs. Viraemic p=0.0006pc, HC vs. 
ART p=0.0195pc. 
g
HC vs. Viraemic p=<0.0001pc, HC vs. ART p=<0.0001pc. 
h
HC vs. Viraemic p=0.0121pc.
i
HC vs. 
Viraemic p=0.0191pc.
j
Viraemic vs. ART p=0.0134pc. 
k
Viraemic vs. ART p=0.0049pc.
l
No significance post correction.  
m
HC vs. Viraemic p=<0.0001pc, HC vs. ART p=0.0011pc. 
n
HC vs. Viraemic p=0.0019pc, HC vs. ART p=0.0194pc. 
o
HC vs. Viraemic p=<0.0001pc, HC vs. ART p=<0.0001pc. 
p
HC vs. Viraemic p=0.0002pc, Viraemic vs. ART 
p=0.0041pc.   
q
HC vs. Viraemic p=0.0001pc, Viraemic vs. ART p=0.0003pc. 
r
HC vs. Viraemic p=0.0003pc, Viraemic vs. 
ART p=0.0200pc.  
s
Viraemic vs. ART p=0.0048pc. 
t 
HC vs. Viraemic p=<0.0001pc, HC vs. ART p=0.0003pc. . 
u
HC vs. 
Viraemic p=0.0017pc, HC vs. ART p=0.0012pc. . 
v
HC vs. Viraemic p=<0.0001pc, HC vs. ART p=0.0019pc.  . 
w
HC vs. 
Viraemic p=0.0002pc, Viraemic vs. ART p=0.0037pc. . 
x
HC vs. Viraemic p=0.0145pc, Viraemic vs. ART p=0.0284pc. 
y
HC vs. Viraemic p=0.0003pc, Viraemic vs. ART p=0.0200pc.                                          
                
                    
                      
      
        
     
 
 
 
TNF 
 
 
CD8 %CM 9.38 
(4.84-11.80) 
6.82 
(4.33-9.15) 
12.90 
(9.90-14.90) 
0.0049
 s
 
%EM 17.80 
(8.27-21.15) 
13.00 
(4.65-21.40) 
18.90 
(13.60-29.00) 
ns 
MMC  
CD4 
%CD4 12.51 
(10.46-14.80) 
4.95 
(3.13-7.72) 
7.80 
(5.81-9.54) 
<0.0001
 t
 
%CM 13.40 
(11.40-15.05) 
7.62 
(5.62-11.05) 
9.05 
(6.91-11.60) 
0.0002
 u
 
%EM 16.30 
(12.65-20.10) 
6.46 
(4.81-7.59) 
9.28 
(7.37-14.00) 
<0.0001
 v
 
 
CD8 
%CD8 11.19 
(8.76-13.02) 
4.82 
(3.87-7.26) 
10.26 
(7.48-13.47) 
0.0002
 w
 
%CM 13.40 
(8.69-16.15) 
8.29 
(6.46-11.10) 
12.40 
(9.07-15.70) 
0.0110
 x
 
%EM 2.29 
(1.00-3.34) 
0.35 
(0.14-0.71) 
0.88 
(0.54-2.78) 
0.0005
 y
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3.9.3 CD4 and CD8 Polyfunctional Cytokine Responses to SEB 
 
To assess the quality of the cytokine response in health and HIV infection in the blood 
and mucosa we next examined the quantity of T cells producing multiple cytokines 
(IFNγ, IL-2 and TNF) in response to SEB using SPICE. 
3.9.3.1 CD4 Polyfunctional T cells 
Using partial permutation analysis in SPICE we found no significant difference in the 
spread of blood polyfunctional CD4 T cells between controls and HIV patients (Figure 
3-25). Mucosal CD4 functional T cell patterns were however significantly different in 
HIV compared to controls. In viraemia there was a significant reduction in IFNγ+IL-
2+TNF+ CD4 T cells (p=<0.0001), IFNγ+TNF+ CD4 T cells (p=0.0050) and IL-
2+TNF+ (p=0.0030) compared to controls.  There was also a significant reduction in 
mucosal CD4 T cells producing TNF only (p=<0.0001). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-25 Polyfunctional CD4 cytokine production in MMC and PBMC of HC and HIV-1 patients. Comparisons 
between pie charts were performed in SPICE using a partial permutation test. 
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ART-treated patients also had significantly reduced mucosal polyfunctional CD4 T cells 
(IFNγ+IL-2+TNF+, p=<0.001), IL-2+TNF+ dual function CD4 T cells (p=0.0030) 
and TNF+ mono-functional CD4 T cells (p=0.0030).  But mucosal IFNγ+TNF+ CD4 T 
cells in ART patients were similar to controls.   
 
3.9.3.2 CD8 Polyfunctional T cells 
There were significant differences in the quality of the CD8 response in the blood of 
viraemic and ART patients compared to controls (Figure 3-26). In both viraemic and 
ART patients we found significant increases of IFNγ+TNF+ dual function CD8 T cells 
(Viraemic p=0.0130, ART p=0.0100) and increases of mono-functional IFNγ CD8 T 
cells (Viraemic p=<0.0001, ART p=0.0120). In viraemic patients there was a 
significant reduction in IL-2+TNF+ (p=0.0190) CD8 T cells and a reduction in mono-
functional IL-2 producing CD8 T cells (p=0.0390). 
 
Mucosal CD8 polyfunctional (IFNγ+IL-2+TNF+) were significantly reduced in viraemia 
compared to controls (p=0.0010). We also observed a reduction in the IL-2+TNF+ 
dual function CD8 subset in viraemia compared to controls (p=<0.0001). Finally mono-
functional IL-2 and TNF CD8 cells were reduced compared to controls and similar to 
the blood, there were increased proportions of mucosal CD8 T cells producing IFNγ 
solely  (p=<0.0001).  
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Figure 3-26 Polyfunctional CD8 T cell responses in blood and mucosa of HC and HIV-1 patients. Comparisons 
between pie charts were performed in SPICE using a partial permutation test. 
 
3.10 Correlations of T cell subsets with Patient Characteristics 
 
3.10.1 Correlations with nadir CD4 counts 
We found no significant correlations between nadir CD4 T cell count and blood T cell 
subsets or cytokine secretions. In the mucosa we saw a positive correlation between 
nadir CD4 counts of the ART group and the frequency of central memory CD8 T cells 
(p=0.005, rs=0.581) and polyfunctional (IFNγ+IL-2+TNF+) TH17 cells (Figure 3-27).  
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Figure 3-27 Correlation of mucosal polyfunctional TH17 cells and nadir CD4 count. Correlations were determined 
using Spearman’s Rho. 
 
3.10.2 Correlations with time on ART 
We found no correlations between blood T cell subsets and months a patient had been 
on ART. However in the mucosa there was a positive correlation between %CD4 and 
time on treatment, and an inverse correlation with %CD8 (Figure 3-28).   
 
 
 
 
 
 
 
Figure 3-28 Correlation of mucosal CD4 and CD8 T cells with time on ART. Correlations were determined using 
Spearman’s Rho. 
 
3.10.3 Correlations with CD4 count and CD4/CD8 ratio 
Absolute CD4 counts positively correlated with the TH17-associated cytokines IL-17a, 
IL-17f and IL-22 on memory CD4 T cells in the blood of HIV patients (Figure 3-29). In 
the mucosa we saw a correlation between absolute CD4 count and IL-2 production by 
memory CD4 T cells (p=0.009, rs=0.417, data not shown). 
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Figure 3-29 Correlation of absolute CD4 with TH17 and TH17-associated cytokines in HIV infection. Correlations 
were determined using Spearman’s Rho. 
 
CD4/CD8 ratios positively correlated with MAIT cells in the blood and with mucosal 
percentage CD4 count and mucosal IFNγ production by memory CD4 T cells (Figure 
3-30).  
 
Figure 3-30 Correlations of CD4/CD8 ratio with blood MAIT cells, mucosal CD4 T cells and IFN production by 
CD4 T cells in HIV infection. Correlations were performed using Spearman’s Rho. 
 
3.10.4 Correlations with time since diagnosis  
Mucosal CD4 production of IFNγ, TNF and the TH17-associated cytokines IL-17f and 
IL-22 were inversely correlated with the length of HIV diagnosis in our viraemic HIV 
patients (Figure 3-31). Blood polyfunctional TH17 cells also declined as time since 
diagnosis increased (rs=-0.6727, p=0.0277, not shown).  
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Figure 3-31 Correlation of mucosal cytokine production with months since diagnosis in viraemic HIV infection 
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3.11 Discussion 
 
3.11.1 Key Findings 
 
Precursor TH17 (CD4+CD161+) cells were significantly reduced in the mucosa of 
viraemic patients but we found no significant depletion of TH17 (IL-17a+CD4+) cells in 
the blood or mucosa of our HIV cohort. There was however, a trend for altered 
blood:mucosal TH17 ratios and evidence of altered functionality in viraemic HIV 
infection. There was a trend for reduced mucosal expression of IL-22+CD4+ in 
viraemic HIV. We saw a significant reduction in the ability of mucosal CD4 T cells to 
produce IL-2, IFNγ and TNF in viraemic and ART-treated infection. We also saw a 
reduction of central memory CD4 T cells and increased proportions of terminally 
differentiated CD4 T cells in HIV infection that was more profound in the mucosa.  
There were significantly reduced mucosal associated invariant T (MAIT) cells in the 
blood and mucosa of viraemic patients.  
 
3.11.2 Discussion 
 
We saw no evidence of reduced precursor TH17/CD161+CD4+ levels in the blood of 
untreated HIV patients. This is in contrast to previous work (Prendergast et al. 2010) 
but supports a more recent study (Gaardbo et al. 2014). These differences may be 
explained by sample preparation techniques, the study finding a significant depletion 
used frozen PBMCs whereas Gaardbo et al. used fresh whole blood. Ours is the first 
study to investigate the CD161+CD4+ subset within the colonic mucosa of HIV infected 
patients, we found precursor TH17 cells are five times more frequent in the mucosa 
compared to the blood of healthy controls but they are significantly reduced in viraemic 
infection. We further found that ART leads to a significant replenishment of mucosal 
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precursor TH17 cells. All TH17 cells have been shown to originate from the CD161+ 
precursor pool (Cosmi et al. 2008) and we suggest that this loss in the mucosa may 
eventually limit the capacity for blood and mucosal TH17 cell regeneration in HIV 
infection.   
 
We confirm an enrichment of TH17 cells in the mucosa compared to the blood of 
healthy controls (Cecchinato et al. 2008). We found no reduction in IL-17a producing 
CD4 T cells in the blood of viraemic infection and in fact found a trend for increased 
TH17 cells within the effector memory CD4 T cell subset compared to controls. We 
also found significantly raised IL-17f production by CD4 T cells in the blood of both 
viraemic and ART patients and significantly raised IL-22 production in ART-treated 
patients compared to controls. The phenotype and cytokine secretion of TH17 cells in 
the blood was similar across the groups. IL-17f and IL-17a both signal through the IL-
17RA and have some similar roles although IL-17f may be less capable of inducing pro-
inflammatory cytokines (Miossec and Kolls 2012). IL-17a and IL-17f may also act in 
opposing roles: in the dextran sulfate sodium (DSS) induced colitis model Il-17a is 
protective whereas IL-17f is pathogenic (Iwakura et al. 2011).  One previous study 
supports our finding that IL-17f is raised in the blood of ART treated HIV-infected 
patients (Salem et al. 2013) but ours is the first study to look at IL-17f in untreated 
infection and in the mucosa of HIV-1 infected patients.  
 
There was no difference in mucosal TH17 proportions in either HIV group compared to 
controls. In viraemic infection however we observed significantly more TH17 cells with 
a terminally differentiated phenotype together with an increased proportion of TH17 
cells that did not secrete IFNγ, IL-2 or TNF suggesting mucosal TH17 function is 
dysregulated in viraemia. Total TNF production by mucosal TH17 cells was also reduced 
in the mucosa. Unlike the blood, we saw no significant differences in mucosal CD4 IL-
17f production across groups. Although some studies have found normal (Yue et al. 
2008, El Hed et al. 2010, Macal et al. 2008, Kim et al. 2012, Jenabian et al. 2013) or 
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increased (Maek-A-Nantawat et al. 2007) frequencies of TH17 cells in chronic HIV 
infection other studies demonstrate significant depletion (Ndhlovu et al. 2008, 
Prendergast et al. 2010), especially from within the mucosa (Brenchley et al. 2008, 
Raffatellu et al. 2008).  
 
We did see a trend for reduced mucosal IL-22+CD4+ in viraemia and this loss was most 
apparent in patients with the longest exposure to HIV infection. One viraemic patient 
recruited onto the study was later diagnosed with anal gonorrhea and had the highest IL-
22 frequency in the mucosa. After excluding this patient from analysis, the difference 
between the viraemic and control group became significant (HC=0.60%, 
Viraemic=0.16%, ART=0.39%, p=0.0203). Reduced IL-22 producing mucosal CD4 T 
cells without a concurrent decline in mucosal TH17 cells has previously been reported 
(Kim et al. 2012). However, this paper identified these cells as the TH22 subset, 
distinguished from TH17 cells by the co-expression of CCR10. We were unable to 
obtain a distinct staining pattern for CCR10 and found little evidence for its co-
expression with IL-22+ CD4 T cells. We instead used the absent expression of the TH17 
precursor marker CD161 to define TH22 cells. TH22 cells were low in all groups with 
levels in viraemic HIV appearing particularly low, however this was not statistically 
significant. 
 
Although we found no significant reduction of TH17 frequency in HIV infection we 
found some evidence that TH17 cells are associated with HIV disease state. Patients on 
ART with the highest nadir counts also had the highest frequency of polyfunctional TH17 
in the mucosa and in untreated HIV those who had been infected for the longest time had 
the lowest levels of the TH17 cytokines IL-17f and IL-22 in the mucosa. HIV patients 
with the highest absolute CD4 counts also had the highest frequency of Il-17a, IL-17f and 
IL-22 CD4 T cell production in the blood. Both our HIV groups had CD4 counts well 
within the normal range (Viraemic=536 (IQR 400-775) cells/µl, ART=580 (434-774) 
cells/µl) and a previous study in viraemic infection found the most significant reductions 
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in blood TH17 cells only when CD4 counts dropped below 350 cells/µl (Ndhlovu et al. 
2008, El Hed et al. 2010). Our failure to establish a significant reduction in TH17-
associated cytokine production in mucosal tissue may therefore be due to the relatively 
early chronic disease state of our viraemic patients. 
 
Unlike TH17-associated cytokines, we saw a profound reduction of CD4 T cells 
producing IFNγ, IL-2 and also TNF in the mucosa of viraemic and ART-treated HIV 
patients. This was apparent in both the central and effector memory CD4 T cell 
compartments and the loss of IFNγ and TNF correlated with the length of exposure to 
HIV infection in untreated patients, supporting the hypothesis that prolonged antigen 
exposure results in functionally exhausted T cells and anergy. TH1 cells (IFNγ+CD4+) 
in the mucosa were also positively correlated to peripheral CD4/CD8 ratios in HIV 
infection. Previous studies found IFNγ production by CD4 T cells was similar to controls 
in the mucosa of HIV patients (Brenchley et al. 2008, Kim et al. 2013) although one 
study in SIV infection of rhesus macaques found reduced mucosal IFNγ+CD4+ 
(Raffatellu et al. 2008). Kim et al also found no difference in CD4+ TNF production 
(Kim et al. 2013).  During HIV-1 infection a progressive loss of TH1 cells, characterised 
by loss of IL-2 and IFNγ, in the periphery has been described (Clerici and Shearer 1993) 
but ours is the first study to demonstrate this in mucosal tissue. We found less evidence 
of blood CD4 T cell dysregulation although IFNγ production by effector memory CD4 T 
cells was raised in ART, supporting previous studies (Clark et al. 2011). We also saw 
blood CD4 effector memory production of IL-2 was reduced in viraemic HIV infection 
compared to controls.  The reduction in CD4 secretion of IL-2 in blood and mucosa of 
HIV patients in our study is similar to a recent study investigating cervical CD4 T cells, 
although this study found no concurrent reduction in IFNγ production (Gumbi et al. 
2011). Control of HIV has been associated with increased frequencies of polyfunctional 
CD4 T cells that produce two or more cytokines (Seder et al. 2008). In our cohort we 
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found reduced polyfunctional CD4 T cells in the mucosa but not the blood of HIV 
patients. 
 
Similar to CD4 T cells we found elevated IFNγ production by blood CD8 T cells in ART 
patients. IFNγ production was also elevated in mucosal central memory CD8 T cells and 
viraemic infection was associated with an expansion of CD8 T cells in blood and mucosa 
that produced IFNγ but not TNF or IL-2. These T cells are likely at the final stage of T 
cell differentiation with limited capacity to be sustained as memory T cells (Seder et al. 
2008). We also found significantly reduced IL-2 and TNF production by CD8 T cells in 
the mucosa of viraemic infection compared to controls.  
 
Our data confirms previous work showing that viraemic HIV infection is associated with 
a depletion of mucosal CD4 and a rise of CD8 T cells that is more severe than in the 
blood (Schneider et al. 1995, Smit-McBride et al. 1998, Brenchley et al. 2004). We 
found a partial restoration of mucosal CD4 percentages in our ART treated group that 
correlated with the length of exposure to ART. There was a significant depletion of 
mucosal central memory CD4 T cells in both HIV groups compared to controls. Central 
memory (CM) T cells have a role in replenishing the effector memory T cell pool 
(Lanzavecchia and Sallusto 2005) and their eventual loss in SIV leads to collapse of the 
effector memory subset and the development of AIDS (Okoye et al. 2007) with the rate 
of decline predicting progression. The Forkhead transcription factor FOXO3a drives the 
loss of CM T cells in HIV and lower transcriptional levels due to higher levels of 
FOXO3a phosphorylation are found in elite controllers. Transfection of memory T cells 
with small interfering RNAs specific for FOXO3a has been shown to protect central 
memory T cells from death and may represent a new therapeutic pathway in the 
treatment of HIV (van Grevenynghe et al. 2008). In our cohort the loss of central 
memory cells was more profound in the mucosa compared to the blood. 
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Increasing numbers of replication senescent/terminally differentiated T cells are seen in 
HIV infection as well as the aged population in the periphery (Appay and Rowland-Jones 
2004, Papagno et al. 2004) and also in mucosal compartments (Gumbi et al. 2011). We 
defined these as CD4 or CD8 T cells lacking both the CD45RO isoform and CD27. 
There were increased levels of terminally differentiated T cells in the blood of viraemic 
patients compared to controls. In the mucosa there was also a significant rise in the ART 
group suggesting restoration of normal CD4 phenotype is more delayed in mucosal 
populations. These cells are destined to die of activation-induced apoptosis and the 
increased frequency in mucosal tissue has been inversely correlated to mucosal CD4 T 
cell proportions (Gumbi et al. 2011). CD8 phenotype in both our HIV groups appeared 
relatively preserved with no significant differences in naïve or memory proportions 
compared to controls in blood or mucosal sites. We did however see a threefold rise in 
terminally differentiated CD8 T cells in the blood of ART and viraemic patients 
compared to controls but no such difference within the mucosal compartment.  
 
Our data confirms results of recent studies showing a significant reduction in the 
proportion of blood CD161++CD8 T (MAIT) cells in viraemic and ART-treated HIV 
patients compared to healthy controls (Cosgrove et al. 2013, Leeansyah et al. 2013, 
Gaardbo et al. 2014). However in contrast to one study we also found a significant 
depletion of MAIT cells isolated from colon biopsies in viraemic HIV patients (Leeansyah 
et al. 2013). Differences in sampling sites, markers used to identify MAIT cells and 
patient characteristics may in part account for discrepancy between the two studies. It 
has been proposed that the rate of loss of MAIT cells in mucosal tissues is much slower 
than that seen in blood and the failure of ART to restore this lymphocyte subset in blood 
argues for treatment of HIV as early as possible to preserve host immunity against 
bacterial and fungal infections (Sandberg et al. 2013).  Our results show that the kinetics 
of MAIT cell loss in untreated HIV infection appears to be similar in the blood and 
mucosa and we demonstrate that ART appears to be effective in restoring the MAIT cell 
population.  
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Finally, despite our viraemic patients having CD4 counts within the normal range, 
CD4:CD8 ratios were significantly distorted and absolute CD8 T cell counts but not 
CD4 count correlated with viral load. There was a positive correlation between nadir 
CD4 counts in our ART group and CD4:CD8 ratios but no correlations with CD4 
counts.  We further saw that blood CD4:CD8 ratios are better correlated to mucosal 
CD4 percentages (p=0.0043, rs=0.4644) than absolute blood CD4 counts alone 
(p=0.0382, rs=0.3332) in our combined HIV cohort providing further evidence for the 
utility of the CD4:CD8 ratio in monitoring disease progression in HIV infection (Sainz et 
al. 2013, Serrano-Villar et al. 2014b, Serrano-Villar et al. 2014a). 
 
3.11.3 Limitations 
 
Our control group was selected from a population that was receiving colonoscopy as part 
of routine monitoring after a family history of bowel cancer or a personal history of 
polyps. Although only those with macroscopically normal colons were recruited it is 
possible that this group had higher levels of bowel inflammation than the healthy 
population. We assessed cytokine production in response to the superantigen SEB, which 
activates up to 20% of all T cells by directly crosslinking MHC class II and the TCR β 
chain. As alterations in the Vβ repertoire have been reported in HIV infection 
(Kharbanda et al. 2003) it is possible that the loss of response seen in CD4 T cells in the 
mucosa of HIV patients may be because of a selective loss of CD4 T cells with TCRs that 
bind SEB (Vβ 3.2, 6.4, 6.9, 15). We also had a smaller number of patients in the HIV-
infected untreated patient group, which may have affected the power of the study. This 
group was also quite heterogeneous and included patients with very early (<6months 
post-diagnosis) chronic disease, and one patient with a very low viral load diagnosed 2.5 
years ago who may eventually be classified as a long term non-progressor. Finally all our 
HIV infected patients had been referred to the colonoscopy clinic due to gastrointestinal 
 123 
symptoms so this study may have a selection bias for patients with more severe 
gastrointestinal disease. 
 
3.11.4 Future Work 
 
This work only investigated three TH17 associated cytokines and their production by T 
cells. Further work could include measuring more TH17 cytokines, such as IL-21 
together with cytokines that drive TH17 differentiation such as IL-23. The assessment of 
TH17 cytokine production by other cell types enriched in mucosal tissue, such as γδ T 
cells, innate lymphoid cells and NKT cells, is also warranted. This study has not 
identified the cause of the reduced capacity of mucosal CD4 T cells to produce cytokines 
in our HIV cohort. First we could use the marker PD-1 to identify T cells with an 
exhausted phenotype. We could assess the level of T cell activation in the mucosa using 
the proliferation marker Ki-67 on biopsy sections. Proviral load in mucosal samples 
should be measured to determine whether viral antigens are directly affecting CD4 T cell 
cytokine production. Regulatory T cells in mucosal tissue could be examined and the 
effect of HIV antigens on T cells from healthy mucosal tissue in vitro could also be 
investigated. Finally a recent publication found that abortive infection of CD4 T cells is a 
major cause of CD4 T cell death by pyroptosis in HIV infection. To investigate this 
pathway in our cohort we could assess caspase 1 activation in blood and mucosal CD4 T 
cells.   
3.11.5 Conclusions 
In conclusion we found evidence of CD4 and CD8 T cell dysregulation in the blood and 
mucosa of HIV infected patients including the loss of TH1, MAIT cells and increased 
terminally differentiated cells T cells. We also saw a significant reduction in precursor 
TH17 cells but no depletion in the TH17 subset or in TH17-associated cytokines.  
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Chapter 4  Mucosal damage, microbial 
translocation and immune activation in HIV-1 
infection 
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4.1 Introduction 
 
Chronic immune activation is a hallmark of HIV infection and a robust predictor of 
progression to AIDS (Giorgi et al. 1999) and death (Liu et al. 1998). It is multifaceted 
and characterised by: polyclonal B cell activation (Lane et al. 1983), increased numbers 
of activated T cells with increased turnover (Hazenberg et al. 2000), increased monocyte 
activation (Anzinger et al. 2014) circulating inflammatory cytokines (IFNα, TNF, IL-6) 
(Valdez and Lederman 1997) and increased serum markers of inflammation (sCD14, 
CRP, D-dimer) (Deeks 2011). 
 
Early work studying acute SIV infection in rhesus macaques showed a severe and rapid 
depletion of memory CD4 T cells from the gastrointestinal tract (Veazey et al. 1998). 
This compromised gut immune system leads to a ‘leaky gut’ and increased bacterial 
lipopolysaccharide (LPS) in the blood. LPS activates innate immunity via TLR4 and levels 
in blood have been associated with T cell activation in HIV infection (Brenchley et al. 
2006b, Jiang et al. 2009). The loss of mucosal CD4 T cell populations leading to 
immune activation via microbial translocation has therefore been suggested as a main 
driver of disease progression (Brenchley et al. 2006a).  
 
Deterioration of the gut epithelium has been described in SIV (Estes et al. 2010) and is a 
feature of pigtail macaques naïve to infection where it correlates with microbial 
translocation and systemic inflammation (Klatt et al. 2010). In HIV there are reports of 
compromised intestinal permeability due to increased epithelial apoptosis (Epple et al. 
2009), increased expression of the pore-forming tight junction claudin 2 (Smith et al. 
2010), and reduced pore-sealing tight junction protein (occludin, claudin 4) expression 
(Chung et al. 2014). 
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However, studies of SIV infection in sooty mangabeys (Gordon et al. 2007) and African 
green monkeys (Pandrea et al. 2007), both natural hosts of the virus who do not progress 
to AIDS, also found substantial mucosal CD4 depletion. Also, the variant attenuated 
pathogenic virus SIVmac239 causes immune activation and AIDS without mucosal CD4 
T cell loss or microbial translocation (Breed et al. 2013). The extent to which mucosal 
CD4 depletion and microbial translocation contribute to immune activation and HIV 
pathogenesis is therefore still under investigation. 
 
In this chapter we measured mucosal damage indirectly via serum levels of intestinal fatty 
acid binding protein (I-FABP), a marker of small intestine epithelial cell death, and 
directly through immunohistochemistry (IHC) staining of colonic biopsies with 
antibodies against the pore-sealing tight junction proteins Claudin 1, Claudin 4 and 
Occludin. 
 
We assessed microbial translocation using the indirect marker LPS-binding protein in 
plasma, then directly by measuring bacterial 16s rDNA in plasma by PCR. LPS-binding 
protein catalytically transfers LPS onto membrane or soluble CD14 and binds toll-like 
receptor 4 (TLR4) leading to downstream proinflammatory cytokine production. We 
measured biologically active endotoxin in serum using a newly developed reporter cell 
line and we also looked for evidence of local LPS translocation into the lamina propria by 
IHC.  
 
Finally we looked for evidence of T cell activation by measuring HLA DR and CD38 
expression on CD4 and CD8 T cells using flow cytometry. We measured sCD163 and 
sCD14 in serum and plasma to assess monocyte activation. Pro-inflammatory stimuli, 
such as LPS, result in the shedding of CD163 from monocytes/macrophages. Increased 
levels of soluble CD163 (sCD163) have been reported in inflammatory conditions 
including HIV, where it has been shown to be a marker of disease activity (Burdo et al. 
2011). Elevated sCD163 is found in HIV patients with neurocognitive and cardiac 
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impairment (Burdo et al. 2013, Walker et al. 2014). Soluble CD14 is produced by the 
liver or shed from monocytes where it binds LPS, peptidoglycan and apoptotic cells. In 
HIV infection it is independently associated with all-cause mortality (Sandler et al. 
2011). 
 
4.1.1 Aims 
• Determine if HIV is associated with disruption in epithelial tight junction protein 
expression. 
• Measure microbial translocation in HIV using LPS-binding protein levels and by 
direct measurement of bacterial product in circulation (16s rDNA, endotoxin). 
Assess leakage of LPS into the lamina propria using immunohistochemistry.   
• Assess peripheral immune activation in HIV by measurement of activated CD4 
and CD8 T cells in blood and sCD14 and CD163 in plasma. 
• Find associations between microbial translocation, mucosal damage and immune 
activation in HIV infection. 
• Determine whether loss of TH17 cells and associated cytokines have a role in 
increased mucosal damage and microbial translocation in HIV-1 infection. 
 
4.2 Patient Recruitment 
 
Tight junction analysis could not be performed on 2/22 healthy control patients (TH17-
113, TH17-42) due to absence of the epithelial layer. In our ART cohort one patient 
could not be analysed for tight junction proteins due to broken epithelium.  
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4.3 Markers of Mucosal Damage 
 
4.3.1 Intestinal Fatty Acid Binding Protein 
 
There was a significant increase in levels of intestinal fatty acid binding protein in the 
serum of ART-treated patients compared to controls (HC=304.60, Viraemic=474.39, 
ART=949.57 pg/ml, p=<0.0001, Figure 4-1). 
 
 
 
 
 
 
 
 
 
Figure 4-1 Serum Intestinal fatty acid binding protein in controls and HIV-1 patients. Differences between groups 
were calculated using Kruskal-Wallis with Dunn’s post-test correction (****=p<0.0001). 
 
 
4.3.2 Tight Junction Protein Expression  
 
Tight junction protein staining was performed on colonic biopsies using antibodies 
directed against claudin-1, claudin-4 and occludin (Figure 4-2 Figure 4-3, Figure 4-4). 
We calculated breach:intact ratios by summation of the total length of breaches along the 
epithelium barrier divided by the total length of intact protein staining in µm using NDP 
viewer2 software in Excel (Figure 4-5).  
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Figure 4-2 Claudin 1 IHC staining on representative control and HIV patients. 
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Figure 4-3 Claudin 4 IHC staining on representative controls and HIV patients. 
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Figure 4-4 Occludin IHC staining in representative control and HIV patients. 
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Figure 4-5 Example measuremens of breach and intact lengths along the epithelium in a control (right) and a HIV 
patient (left). 
 
We observed a significant increase in breach ratios in viraemic and ART-treated HIV 
infection for claudin 1 (HC=0.25, Viraemic=5.29, ART=1.23, p=<0.0001), claudin 4 
(HC=0.64, Viraemic=4.35, ART=1.98, p=0.0003) and occludin protein expression 
(HC=1.15, Viraemic=3.16, ART=3.50, p=<0.0001, (Figure 4-6). Claudin 1 breach 
ratios in ART patients were significantly lower than in viraemia but not restored to 
normal levels. 
 
 
Figure 4-6 Tight junction protein breach:intact ratios in HIV and controls. Differences between groups were assessed 
using Kruskal Wallis with Dunn's post-test correction (*=p<0.05,**=p<0.01, 
**=p<0.001,***=p<0.0001).   
 
Claudin 1 breach:intact ratios were positively correlated to Claudin 4 ratios (p=0.028, 
rs=0.351) but neither claudin 1 or 4 correlated to occludin breach:intact ratios. There 
was no correlation with I-FABP.  
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4.4 Markers of Microbial Translocation 
4.4.1 LPS Binding Protein 
There was a significant increase in plasma levels of LPS binding protein (LBP) in viraemic 
HIV compared to controls, with ART restoring levels to normal (HC=12.42, 
Viraemic=17.72, ART=14.78µg/ml, p=0.0325, Figure 4-7).  
  
 
 
 
 
 
Figure 4-7 LPS Binding Protein in HIV and controls. Differences between groups were calculated using Kruskal-
Wallis with Dunn’s post-test correction *=<0.01). 
 
4.4.2 16s PCR 
We found elevated copies of 16s rDNA in the plasma of our viraemic patients compared 
to ART patients (HC=24.11, Viraemic=35.42, ART=11.03 copies/ml, p=0.0100, 
Figure 4-8). Overall levels of 16s were quite broad in the HIV groups and appeared 
bimodal in the control group.  
 
 
 
 
 
Figure 4-8 Plasma levels of 16s in HIV-1 and controls. Differences between groups were calculated using Kruskal-
Wallis with Dunn’s post-test correction (*=p<0.05). 
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4.4.3 Endotoxin 
There was no significant difference in the levels of serum endotoxin between groups 
(Figure 4-9).  
 
 
 
 
 
 
 
Figure 4-9 Serum endotoxin levels in HIV and HC. Differences between groups was calculated using Kruskal-Wallis 
with Dunn’s post-test correction. 
 
 
4.4.4 LPS Immunohistochemistry 
 
We next stained our colonic biopsies with an anti-LPS antibody to look for evidence of 
localised microbial translocation. We found LPS in the lamina propria of 13/22 (59%) 
controls, 7/13 (54%) viraemic patients and 16/23 (70%) of ART patients.  
 
We scored the positive cases from 1+ to 3+ according to the intensity and distribution 
of staining. In controls 31% had weak LPS staining, 38% moderate LPS and 31% had 
intense and widespread LPS staining (3+). The majority of the positive viraemic patients 
had weak staining (1+ = 50%, 2+=25%, 3+=25%) and we saw no strong positive LPS 
staining in ART treated patients (1+ =75%, 2+=25%, 3+ =0%, Figure 4-10, Figure 
4-11).  
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Figure 4-10 Distribution of LPS IHC scores in HIV infection and HC. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-11 LPS staining on control and HIV-infected colonic biopsies. X250 magnification. 
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We divided our controls and HIV groups according to LPS score and looked at the 
distribution of 16s rDNA levels. We found no significant difference between groups but 
saw increased levels of 16s RNA levels in controls with the most intense LPS staining 
(Figure 4-12). 
 
 
 
 
 
 
 
 
 
 
Figure 4-12 16s rDNA levels divided by LPS IHC score in HC and HIV infection. 
 
 
 Marker HC Viraemic ART P values 
 
 
Microbial 
Translocation 
LBP 
µg/ml 
12.42 
(8.98-16.59) 
 
17.72 
(13.67-28.98) 
14.78 
(9.77-21.57) 
0.0325a 
16s 
copies/ml 
24.11 
(12.28-63.45) 
35.42 
(20.86-64.13) 
11.03 
(5.00-23.31) 
0.0100 b 
Endotoxin 
IU/ml 
0.22 
(0.00-1.24) 
0.45 
(0.11-0.57) 
0.19 
(0.00-0.35) 
ns 
Mucosal 
LPS (+ve) 
13/22 (59%) 7/13 (54%) 16/23 (70%) ns 
 
 
Mucosal 
Damage 
I-FABP 
pg/ml 
304.61 
(146.60-468.27) 
474.39 
(384.47-833.02) 
949.57 
(661.01-1541.88) 
<0.0001 c 
Claudin 1 
B:I ratio 
0.25 
(0.11-0.52) 
5.29 
(3.04-11.04) 
1.23 
(0.32-4.84) 
<0.0001 d 
Claudin 4 
B:I ratio 
0.64 
(0.47-1.79) 
4.35 
(2.79-8.88) 
1.98 
(1.10-6.65) 
0.0003 e 
Occludin 
B:I ratio 
1.15 
(0.53-1.66) 
3.16 
(2.51-7.08) 
3.50 
(1.52-4.44) 
<0.0001 f 
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Table 4-1 Markers of microbial translocation and mucosal damage in HIV-1 infection and HC. Median values with 
interquartile ranges in brackets are reported and p values from Kruskal-Willis test.  
 
. a HC vs. Viraemic p=0.0335pc . b Viraemic vs. ART p=0.0217pc.c HC vs. ART p=<0.0001pc. d HC vs. 
Viraemic p=<0.0001pc, HC vs. ART p=0.0089pc, Viraemic vs. ART p=0.0108pc. e HC vs. Viraemic 
p=0.0003pc, HC vs. ART p=0.0120pc. f HC vs. Viraemic p=0.0003pc, HC vs. ART p=0.0011pc. 
 
 
4.5 Peripheral Immune Activation in HIV 
4.5.1 T cell activation 
 
To assess T cell activation we measured HLA DR and CD38 expression on memory CD4 
and CD8 T cells using whole blood. CD38 bright staining was defined using the 
monocyte and granulocyte populations in each patient.   
 
We found a significant increase in HLA DR+ CD38+ dual positive CD4 (HC=1.48%, 
Viraemic=5.68%, ART=2.73%) and CD8 (HC=3.25%, Viraemic=14.02%, 
ART=4.70%) T cells in viraemic HIV compared to controls, with ART patients having 
significantly less CD8 HLA DR+ CD38+ T cells compared to viraemic patients (Figure 
4-13). CD38 bright staining on CD4 (HC=3.77%, Viraemic=8.34%, ART=5.13%) and 
CD8 (HC=1.51%, Viraemic=12.57%, ART=3.59%) T cells was similarly elevated in 
viraemia compared to controls and significantly reduced in ART compared to viraemia.    
 
There was no correlation between CD4 T cell expression of HLA DR+CD38+ and CD4 
T cell expression of CD38++ but HLA DR+CD38+ expression on CD8 T cells was 
highly correlated to CD38++ expression on CD8 T cells (p=0.0002, rs=0.5573). 
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Figure 4-13 Peripheral T cell activation in HC and HIV-1 patients. T cell activation was measured using dual 
expression of HLA DR and CD38 on memory T cells and by the bright expression of CD38. Differences between 
groups were analysed using Kruskal-Wallis with Dunn’s post-test correction (*=p<0.05, **=p<0.01, 
**=p<0.001, ***=p<0.0001).    
 
4.5.2 Monocyte Activation 
 
We found a significant increase in levels of soluble CD163 in the serum of patients on 
ART compared to controls (HC=0.435 µg/ml, Viraemic=0.598 µg/ml, ART=0.622 
µg/ml, p=0.017) and soluble CD14 levels in plasma were elevated in both viraemia and 
ART compared to controls (HC=1.436 µg/ml, Viraemic=2.124 µg/ml, ART=1.945 
µg/ml, p=0.004, Figure 4-14).  
 
CD163 and sCD14 were not correlated in HIV. In viraemic infection we found a positive 
association between sCD14 and T cell activation (CD38++ %CD4 p=0.0079, 
rs=0.714. HLA DR+ CD38+ %CD4 p=0.0127, rs=0.681. HLA DR+CD38+ %CD8 
p=0.0028, rs=0.775) that was lost in the ART-treated group (data not shown). There 
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was also a positive correlation between sCD163 and CD38++ expression on memory 
CD8 T cells in the combined HIV group (p=0.007, rs=0.447, data not shown). 
 
 
 
 
 
 
 
Figure 4-14 Levels of sCD163 and sCD14 in HIV and healthy control plasma. Differences between groups were 
analysed using Kruskal-Wallis with Dunn’s post-test correction (*=p<0.05,**=p<0.01, 
**=p<0.001,***=p<0.0001).   
 
 
  
Marker 
 
subset 
 
HC 
 
Viraemic 
 
ART 
 
p value 
 
T cell 
Activation 
CD45RO+
HLA DR+ 
CD38+ 
%CD4 1.48 
(1.03-2.59) 
5.68 
(2.10-8.71) 
2.73 
(1.60-4.19) 
0.0094a 
%CD8 3.25 
(1.25-5.41) 
14.02 
(8.65-29.33) 
4.70 
(1.71-12.34) 
0.0024 b 
CD45RO+
CD38++ 
%CD4 3.77 
(2.87-6.14) 
8.34 
(5.92-16.47) 
5.13 
(4.12-6.71) 
0.0010 c 
%CD8 1.51 
(0.94-2.42) 
12.57 
(8.79-23.20) 
3.59 
(1.86-5.24) 
<0.0001 d 
Monocyte 
Activation 
sCD163 serum 0.44 
(0.39-0.60) 
0.60 
(0.46-1.04) 
0.62 
(0.49-0.86) 
0.0172 e 
sCD14 plasma 1.44 
(1.18-1.88) 
2.12 
(1.37-2.58) 
1.95 
(1.61-2.25) 
0.0044 f 
 
Table 4-2 Blood T cell and monocyte activation markers in controls and HIV-1 patients. Median values with 
interquartile ranges in brackets are reported, p values from Kruskal-Wallis. a HC vs. Viraemic p=0.0087 post 
correction (pc).      b HC vs. Viraemic p=0.0017pc, Viraemic vs. ART=0.0314pc. c HC vs. Viraemic p=0.0007pc, 
Viraemic vs. ART=0.0162pc. d HC vs. Viraemic p=<0.0001pc, HC vs. ART=0.0159pc,  Viraemic vs. 
ART=0.0010pc. e HC vs. ART p=0.0375pc. f HC vs. Viraemic p=0.0305, HC vs. ART p=0.0085pc. 
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4.6 Correlations between TH17 cells, mucosal damage, 
microbial translocation and T cell activation 
 
4.6.1 Correlations with Patient Characteristics 
 
We found a positive correlation between breach ratios of claudin 4 and HIV viral load 
(Figure 4-15). Viral load also correlated with the microbial translocation marker 16s 
rDNA (p=0.0251, rs=0.6818, Figure 4-16). 
 
 
 
  
 
 
Figure 4-15 Correlation between Claudin 4 breach:intact ratio and HIV RNA viral load. Associations were 
calculated using Spearman’s Rho. 
 
 
 
 
 
 
 
 
Figure 4-16 Correlation between 16s rDNA levels and HIV viral load. Associations were calculated using 
Spearman’s Rho. 
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There was a significant inverse correlation between the percentage of HLA DR+CD38+ 
CD8 T cells and nadir CD4 T cell counts in ART (p=0.006, rs= -0.542, Figure 4-17). 
 
 
 
 
 
 
 
Figure 4-17 Association between CD8 T cell activation and Nadir CD4 T cell count (cells/µl) in ART-treated HIV 
patients.  Correlations performed using Spearman’s Rho. 
 
Soluble CD14 correlated with CD4/CD8 ratio in the combined HIV group (p=0.014, 
rs=0.399) and also ART nadir CD4 counts (p=0.013, rs=0.501, Figure 4-18). 
 
 
 
 
 
 
 
 
Figure 4-18 Correlation of sCD14 with CD4/CD8 ratio and nadir CD4 count in HIV infection. Correlation was 
calculated using Spearman’s Rho. 
 
 
4.6.2 Correlations between mucosal damage and microbial 
translocation 
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We found a positive correlation between breaches in claudin 4 and plasma levels of 16s 
rDNA (p=0.0082, rs=0.4229, Figure 4-19). There were no other significant 
associations between mucosal damage and markers of microbial translocation. 
 
 
 
 
 
 
 
Figure 4-19 Correlations between 16s rDNA and claudin 4 breach:intact ratios in HIV infection. Correlations were 
calculated using Spearman’s Rho. 
 
4.6.3 Correlations between mucosal damage and T cell subsets and 
cytokines 
 
There was an inverse correlation between blood central memory CD4 T cells with 
claudin 1 (p=0.0149, rs=-0.3871, Figure 4-20) and claudin 4 (p=0.042, rs=-0.327) 
breach:intact ratios. In the mucosa CD4 T cell loss was correlated to increasing claudin 1 
disruption (p=0.0108, rs=-0.4088, Figure 4-20). 
 
 
 
 
 
 
 
Figure 4-20 Correlations between Claudin 1 breaches and blood and mucosal CD4 T cells in HIV infection. 
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Together with the loss of total CD4 cells in the mucosa we also found an association 
between claudin 1 disruption and precursor TH17 cells loss (p=0.007, rs=-0.463, 
Figure 4-21). 
 
 
 
 
 
 
 
Figure 4-21 Correlation between precursor TH17 and claudin 1 breaches in HIV infection. Associations were 
calculated using Spearman’s Rho. 
 
There was also a weak inverse correlation between mucosal TH22 cells in HIV and 
claudin 1 breach:intact ratios (p=0.029, rs=-0.385, Figure 4-22). 
 
 
 
 
 
 
 
Figure 4-22 Correlation between TH22 and Claudin 1 breaches in HIV-1. Associations were calculated using 
Spearman’s Rho. 
 
4.6.4 Correlations between mucosal damage and immune activation 
 
We found a positive, though weak, correlation between claudin 4 breach:intact ratios 
and HLA DR+CD38+ memory CD8 T cells (p=0.0128, rs=0.3951, Figure 4-23). 
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There were no associations between I-FABP or claudin 1 and occludin disruption and T 
cell activation. 
 
 
 
 
 
 
Figure 4-23 Correlation between T cell activation and Claudin 4 disruption in HIV-1. Associations were calculated 
using Spearman’s Rho. 
 
4.6.5 Correlations between microbial translocation and T cell subsets 
and cytokines 
 
In the viraemic cohort there was a significant correlation between LBP, mucosal CD4 T 
cells and terminally differentiated mucosal CD4 T cells (Figure 4-24).  
 
 
 
 
 
 
 
 
Figure 4-24 Correlation between LBP and mucosal CD4 T cells and terminally differentiated CD4 cells in viraemic 
HIV-1 infection. 
 
Mucosal CD4 and CD8 T cell percentages were both associated with plasma levels of 
bacterial 16 rDNA Figure 4-25).  
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Figure 4-25 Correlation between mucosal T cell frequency and 16s rDNA in HIV-1 infection. 
 
Precursor TH17 in the blood and mucosa were also both inversely correlated to levels of 
16s rDNA (Figure 4-26). 
 
 
 
 
 
 
 
Figure 4-26 Correlation between blood and mucosal precursor TH17 cells and 16s rDNA in HIV-1 infection. 
 
We also saw a positive correlation between 16s rDNA and mucosal CD8 production of 
TNF in viraemic infection (p=0.0142, rs=0.6993, not shown). 
 
We found a weak correlation between mucosal TH17 cells and serum endotoxin levels 
(p=0.018, rs=-0.381) in the combined HIV group. The association was strongest in the 
viraemic group alone (p=0.001, rs=-0.791, Figure 4-27).  
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Figure 4-27 Correlation between mucosal TH17 cells and plasma endotoxin in HIV-1 infection. 
 
There was also an inverse correlation between IL-22 production by blood and mucosal 
CD4 T cells and endotoxin levels in viraemic patients (PBMC p=0.0171, rs=-0.6547, 
MMC p=0.0083, rs=-0.7070). Blood IL-17f (p=0.0401, rs=-0.5785) and TH22 
(p=0.0190, rs=-0.6418) levels in viraemic patients were also inversely correlated to 
endotoxin (Figure 4-28). IL-2 production by mucosal CD4 T cells also inversely 
correlated to endotoxin levels in HIV (p=0.025, rs=-0.791, not shown).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-28 Correlations between blood and mucosal IL-22, blood IL-17f and blood TH22 cells with endotoxin in 
viraemic HIV infection 
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4.6.6 Correlations between microbial translocation and immune 
activation 
 
We saw a positive correlation between LBP and CD38++ CD8 memory T cells in HIV 
infection (p=0.0050, rs=0.4457, Figure 4-29). CD38++ CD8 memory T cells also 
correlated to levels of 16s RNA (p=0.0326, rs=0.3428, Figure 4-29) in our HIV cohort.  
 
 
 
 
 
 
 
Figure 4-29 Correlation between microbial translocation markers and T cell activation in HIV infection. 
Correlations were performed using Spearman’s Rho. 
 
 
There was a positive correlation between CD4 T cell activation and levels of endotoxin 
in the serum of viraemic HIV (Figure 4-30) but not ART treated patients. We saw no 
correlations between CD8 T cell or monocyte activation and endotoxin. 
 
 
 
 
 
 
 
 
 
 
Figure 4-30 Correlation between CD4 T cell activation and serum endotoxin in viraemic HIV. Correlation was 
performed using Spearman’s Rho. 
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4.6.7 Correlations between immune activation with T cell subsets 
and cytokines 
 
There was a positive correlation between CD4 T cell activation (HLA DR+CD38+)  and 
terminally differentiated mucosal CD4 cells (p=0.0059, rs=0.438) and an inverse 
correlation with mucosal central memory CD4 T cells (p=0.0049, rs=-0.447, Figure 
4-31).  
 
 
 
 
 
 
Figure 4-31 Correlation between blood CD4 T cell activation and mucosal CD4 phenotype in HIV-1 infection. 
Correlations were performed using Spearman’s Rho. 
 
CD8 T cell activation (HLA DR+CD38+) also correlated to mucosal terminally 
differentiated CD4 (p=0.0252, rs=0.363) and CD4 central memory (p=0.0207, rs=-
0.374) T cells (Figure 4-32). CD38++ expression on memory CD8 T cells was 
inversely correlated to mucosal effector CD4 percentage (p=0.0121, rs=-0.402, not 
shown). 
 
 
 
 
 
 
Figure 4-32 Correlation between blood CD8 T cell activation and mucosal CD4 phenotype in HIV infection.  
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CD38++ CD8 T cells also inversely correlated to levels of polyfunctional (IFNγ+IL-
2+TNF+) CD4 and CD8 T cells in the mucosa of HIV patients (Figure 4-33). Mucosal 
IFNγ production by CD4 T cells was inversely correlated to CD38++ CD4 p=0.0059, 
rs=-0.444) and CD8 (p=0.0001, rs=-0.585) T cell activation (not shown). 
 
 
 
 
 
 
 
Figure 4-33 Correlation between mucosal polyfunctional T cells and T cell activation in HIV infection. 
 
We also found an inverse correlation between peripheral CD8 T cell activation and 
precursor TH17 in the mucosa (p=0.0030, rs=-0.494, Figure 4-34).  
 
 
 
 
 
 
 
Figure 4-34 Correlation between mucosal precursor TH17 and T cell activation in HIV-1 infection. 
 
There was an inverse correlation between activated CD4 (HLA DR+CD38+) T cells 
and mucosal IL-22+ CD4+ cells in HIV (p=0.0111, rs=-0.424, Figure 4-35). In the 
viraemic group there was a correlation between CD38++ CD4+ T cells and mucosal IL-
22 production (p=0.0090, rs=-0.702, Figure 4-36) and a weak inverse association with 
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mucosal TH17 (p=0.0371, rs=-0.582, not shown). Soluble CD14 was also weakly 
correlated to mucosal EM CD4 T cells (p=0.0254, rs=-0.364, not shown). 
 
 
 
 
 
 
 
Figure 4-35 Correlation between mucosal IL-22 and CD4+HLA DR+CD38+ in HIV-1 infection. 
 
 
 
 
 
 
 
Figure 4-36 Correlation between mucosal IL-22 production and CD4+CD38++ in viraemic HIV-1 infection.  
 
There was also an inverse correlation between CD38++ CD8 T cell activation and 
mucosal MAIT cells (p=0.0241, rs=-0.3861, Figure 4-37). 
 
 
 
 
 
 
 
Figure 4-37 Correlation between mucosal MAIT cells and T cell activation in HIV-1 infection. 
 
 151 
4.7 Discussion 
 
4.7.1 Key Findings 
 
We found that HIV infection is associated with disruption to epithelial barrier tight 
junction proteins that is not corrected by ART.  This disruption was highest in untreated 
patients with the highest HIV viral load and positively correlated to markers of microbial 
translocation (16s rDNA) in HIV infection. Tight junction dysregulation was further 
associated with declining mucosal CD4 T cells and specifically loss of the TH17 
precursor and the TH22 subset in the mucosa. The level of breaches in tight junction 
expression also positively correlated with peripheral CD8 T cell activation. We found an 
association between mucosal precursor TH17 loss with peripheral CD8 T cell activation 
and blood and mucosal precursor TH17 loss with microbial translocation. We found that 
rising proportions of terminally differentiated mucosal CD4 T cells was associated with 
increased microbial translocation and raised CD4 and CD8 peripheral T cell activation. 
 
4.7.2 Discussion 
 
We found significant disruption to the pore-sealing tight junction proteins claudin 1, 
claudin 4 and occludin, in both the viraemic and ART HIV groups. Median breach:intact 
ratios were highest in untreated infection but only claudin 1 disruption was significantly 
reduced in ART compared to viraemia, highlighting that ART appears to be insufficient 
at resolving damage to the gastrointestinal tract caused by HIV infection. Epple et al used 
Western Blot analysis to measure tight junctions in duodenal tissue, they found increased 
expression measure of pore-forming claudin 2 with reduced expression of sealing claudin 
1 but no difference in occludin and claudin 4 (Epple et al. 2009). Significantly reduced 
expression of the sealing tight junction claudin 3, measured by immunohistochemistry, 
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has previously been reported in untreated HIV infection with resolution after ART (Kök 
et al. 2014). A recent study in ART treated patients found no alterations in Zo-1 or 
occludin distribution by immunohistochemistry but saw a significant decrease in 
transcriptional levels of Zo-1, occludin, claudin 4 and also the pore forming claudin 2 in 
the colon (Chung et al. 2014). Differences between studies may be due to patient 
groups, Kok et al included patients who had early initiation of ART (<3 months post 
diagnosis), and different methods of measuring tight junction disruption. Inflammatory 
cytokines such as IFNγ have been shown to induce macropinocytosis of tight junction 
proteins (Bruewer et al. 2005) leading to their internalisation which compromises their 
function but does not result in bulk loss of expression. 
 
In our ART cohort we saw significantly raised levels of I-FABP compared to controls but 
no rise in viraemia. I-FABP has previously been shown to be elevated in chronic HIV 
infection (Sandler et al. 2011), and a recent study found levels strongly predict mortality 
in ART-suppressed patients (Hunt et al. 2014). The lack of difference in viraemia 
compared to HC may be because our small viraemic group contained three patients with 
early infection (3, 5 and 6 months post diagnosis); a longitudinal study in acute HIV 
found I-FABP did not significantly rise until after 6 months of infection (Chevalier et al. 
2013). We found no associations between I-FABP levels and tight junction disruption. As 
we measured tight junction disruption in the sigmoid colon and I-FABP is a marker of 
small intestinal damage, the lack of correlation may suggest that different sites of the 
gastrointestinal tract are affected to a different extent at different disease stages. A recent 
study (Chung et al. 2014) found colonic tight junction transcript levels progressively 
decreased along the proximal-to-distal axis in ART patients; highlighting that even within 
the colon there is a differential degree of mucosal barrier dysregulation during HIV 
infection. We saw no correlation between I-FABP and markers of immune activation or 
microbial translocation unlike one previous study (Hunt et al. 2014).  
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Similar to other studies we found evidence of microbial translocation in viraemic HIV 
infection; including elevated LPS binding protein and increased bacterial DNA in plasma 
(Sandler et al. 2011, Brenchley et al. 2006b). We observed that ART appeared to reduce 
microbial translocation in our cohort despite the continuing mucosal damage. This is in 
contrast to other work which showed 16srDNA, although reduced in ART, were still 
elevated compared to controls (Jiang et al. 2009). The differences found in our work 
may in part be due to our control group (as discussed below). We saw no significant 
differences in levels of biologically active endotoxin in the serum. LBP has a longer half-
life than endotoxin (Schumann and Latz 2000) and high levels of LBP act to neutralize 
and remove endotoxin from circulation which may explain this disparity in results.  
 
We also saw no evidence that LPS translocation into the lamina propria was increased in 
HIV infection compared to controls. This is in contrast to work in an SIV model (Estes et 
al. 2010) and in HIV patients (Cosgrove et al. 2013) and may in part be due to our 
control cohort. These patients were receiving colonoscopy as routine screening due to a 
family history of bowel cancer or a personal history of polyps so it is possible that the 
gastrointestinal tract in these patients could have a subclinical level of inflammation and 
activation. The control population also had heterogeneous levels of endotoxin and 16s 
rDNA in circulation. Previous work has demonstrated altered gene expression (including 
the upregulation of inflammatory markers IL-8 and serum amyloid A) in patients with 
polyps (Hao et al. 2005a) and with a family history of sporadic colon cancer (Hao et al. 
2005b).  
 
We found a positive correlation between disruption to claudin 4 and microbial 
translocation measured by 16s rDNA levels in plasma. A previous study found that 
increased syndecan-1, involved in the upregulation of pore-forming claudin 2, was 
associated with bacterial dissemination into inguinal lymph nodes in HIV infection (Smith 
et al. 2010) and claudin 3 disruption has been correlated to increased LPS in the lamina 
propria in SIV infected sooty mangabeys (Estes et al. 2010) but to our knowledge ours is 
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the first study to show a direct link between levels of microbial translocation in the 
periphery and mucosal damage. Claudin 4 disruption was highest in viraemic patients 
with the highest HIV viral load supporting in vitro studies showing HIV viral components 
may directly impair the integrity of the mucosal barrier (Nazli et al. 2010). 
 
Claudin 4 disruption was also associated with elevated peripheral CD8 T cell activation. 
The significant association of 16s rDNA and systemic T cell activation with claudin-4 
breaches supports our hypothesis that disruption to the mucosal barrier leads to increased 
microbial translocation and systemic T cell activation. However whether disruption to 
the mucosal epithelial barrier is a cause or a consequence of immune activation remains 
to be elucidated. A recent SIV study found downregulation of claudin family genes as 
early as 3 days after infection but only found upregulation of inflammatory markers at 
day 12 (Barrenas et al. 2014). 
 
We found that the loss of mucosal CD4 and blood CM CD4 T cells in HIV infection was 
associated with increased claudin 1 disruption; as was loss of mucosal precursor TH17 
cells. Mucosal TH22 cell loss was also associated with breaches in claudin 1 staining but 
there was no association with TH17 cells (IL-17a+CD4+). One SIV study previously 
found loss of CD4+IL-17a+ and loss of CD4+IL-22+ in the colon inversely correlated 
with breach:intact ratios of claudin 3 (Klatt et al. 2012). In our cohort there was a trend 
for reduced mucosal CD4+IL-22+ T cells but no evidence of TH17 cell loss, we 
speculated that this in part may be due to a small viraemic cohort that included patients 
with relatively early disease; all with CD4 counts within the normal range. In this study 
we therefore demonstrate that mucosal damage occurs before peripheral CD4 counts 
decline and before the selective loss of the mucosal TH17 subset. 
 
Mucosal CD4 loss was correlated with increased levels of the microbial translocation 
markers LBP and 16s rDNA. The shift of the CD4 phenotype towards a terminally 
differentiated state in the mucosa was also associated with raised LBP. Reduced mucosal 
 155 
CD161+CD4 (precursor TH17) proportions were associated with higher levels of 
microbial translocation (16srDNA). We found a strong correlation between mucosal 
TH17 and IL-22+CD4+ reduction and increased levels of endotoxin in the serum of 
viraemic HIV patients. The loss of blood IL-22+ and IL-17f+ producing CD4 T cells and 
TH22 also correlated to increasing serum endotoxin. We therefore highlight that various 
alterations in mucosal and blood CD4 T cells percentages and phenotype are associated 
with the level of microbial translocation in HIV infection.  
 
We also found evidence that skewed mucosal T cell populations are associated with 
elevated peripheral immune activation in HIV infection; reduced mucosal central 
memory and increased terminally differentiated CD4 T cells were associated with 
increased CD4 and CD8 T cell activation. Mucosal precursor TH17 and CD4+IL-22+ T 
cell loss was also associated with increased CD4 peripheral T cell activation.  
 
Soluble CD14 is shed from activated monocytes and predicts mortality in HIV infection 
(Sandler et al. 2011). We found elevated plasma levels of sCD14 in HIV that, unlike T 
cell activation, were not reduced after ART. Levels of sCD14 were positively correlated 
to both nadir CD4 counts in ART patients and also CD4:CD8 ratios. There was also an 
inverse correlation between sCD14, blood precursor TH17 cells and mucosal effector 
memory CD4 T cells. Soluble CD163 is also shed from stimulated monocytes and has 
been identified as a marker of neurocognitive and cardiac damage in HIV infection 
(Burdo et al. 2013). We found elevated sCD163 in our ART patients compared to 
controls but saw no rise in our viraemic cohort. A previous study found sCD163 levels 
were elevated only in HIV patients who had been infected for longer than one year 
(Burdo et al. 2011) and ART did not reduce levels back to the levels of controls. We 
found no association between monocyte activation and levels of mucosal damage or 
microbial translocation in our cohort, supporting the concept that causes of immune 
activation in HIV are likely multifactorial.     
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In chapter 3 we showed that mucosal CD4 production of IFNγ, TNF and IL-2 was 
substantially blunted in viraemic HIV infection. We looked for correlations of this loss to 
markers of mucosal damage and microbial damage to assess whether mucosal CD4 
anergy is contributing to this pathway. There was no evidence that loss of the ability of 
mucosal CD4 T cells to produce IFNγ, TNF and IL-2 was associated with mucosal 
damage and we also saw no associations with markers of microbial translocation. There 
was however, an inverse association between CD4 and CD8 polyfunctional T cells in 
mucosal tissue and peripheral CD8 T cell activation possibly suggesting that CD4 T cell 
anergy contributes to immune activation via an alternative pathway.  
 
4.7.3 Limitations 
As this study was cross-sectional it was not possible to identify whether mucosal damage 
and microbial translocation are a cause or a consequence of immune activation in HIV 
infection. As discussed in chapter 3, our viraemic group was small and the study may 
have been underpowered to detect significant changes in TH17 cytokine production. As 
discussed above our control group may not represent a true ‘healthy’ control cohort.  
 
4.7.4 Future Work 
Reassessment of tight junction staining in untreated HIV patients after a period of time 
on ART is warranted, it would also be interesting to assess tight junction disruption in 
patients with acute HIV infection. More tight junctions could be assessed and 
transcription levels measured. Epithelial cell apoptosis is another mechanism resulting in 
compromised barrier function which could be assessed on our colonic biopsies.  As 
inflammatory cytokines have a role in tight junction disruption it would be of interest to 
measure cytokine production from other cells in the mucosal tissue. We found an 
association between blood viral load and tight junction disruption, as HIV antigens have 
been shown to directly damage the mucosal barrier HIV viral load in mucosal tissue 
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should be assessed.  Poor reconstitution of peripheral and mucosal CD4 T cell counts on 
ART has been linked to architectural damage (Costiniuk and Angel 2012); to assess this 
in our cohort we could measure collagen deposition in mucosal biopsies. The extent to 
which the failure of bacterial clearance mechanisms contribute to microbial translocation 
in HIV could be assessed by measuring IgA and the phagocytic ability of macrophages 
within the lamina propria.   
 
4.7.5 Conclusions 
 
In conclusion we have demonstrated significant disruption in mucosal tight junction 
proteins in HIV infection that does not fully resolve on ART. We found evidence of 
microbial translocation in untreated HIV patients but not in ART, possibly indicating that 
ART restores immune clearance of microbial products. There was a significant 
association between mucosal damage, levels of viraemia and levels of microbial 
translocation. In support of our hypothesis we saw correlations between precursor TH17 
cells, the loss of tight junctions, microbial translocation and peripheral immune 
activation and conclude that the loss of precursor TH17 cells have a role in HIV 
pathogenesis. 
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Chapter 5  T cells, microbial translocation and 
mucosal damage in ulcerative colitis 
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5.1 Introduction 
 
Ulcerative colitis involves mucosal inflammation that occurs in a continuous pattern 
restricted to the rectum and colon (Cosnes et al. 2011). UC is more common in 
developed countries and most patients are diagnosed between 30-40 years old (da Silva 
et al. 2014). There is probably an equal distribution between genders (Cosnes et al. 
2011) though perhaps an increased incidence in males after the age of 50 (Binder 2004). 
 
Non-smokers have a three-fold higher risk of developing UC and they have a more 
severe disease course compared to smokers (Binder et al. 2004). Appendectomy is also 
thought to be protective against UC with a meta-analysis concluding that removing the 
appendix reduces the chance of developing UC by 69% (Koutroubakis et al. 2002). The 
gut microbiome is dysregulated in UC with reduced Firmicutes (Clostridium spp) and 
Bacteriodetes and increased Enterobacteria (Escherichia coli) that may result in increased 
inflammation (Barnich et al. 2007).  
 
Together with many genetic polymorphisms shared with Crohn’s disease, genome-wide 
association studies (GWAS) have identified 23 UC specific gene loci (Thompson and 
Lees 2011). These genes mostly have a role in the maintenance of the epithelial barrier 
and include CDH1, HNF4α and LAMB1 (Sarlos et al. 2014). CDH1 encodes E-cadherin, 
the major component of the adherens junctions that together with tight junction proteins 
form the apical junctional complex that maintains barrier function. In healthy tissue E-
cadherin associates with hepatocyte nuclear factor-4 α (Hnf4α) to maintain barrier 
function. The lamininβ1 subunit (encoded by LAMB1) is a component of the laminins, the 
major glycoprotein component of the basement membrane that are found at reduced 
levels in inflamed UC tissue (Thompson and Lees 2011). In support of the genetic 
polymorphisms affecting barrier integrity a breakdown of tight junction barrier function 
is seen in the colon of patients with mild UC (Gitter et al. 2001). 
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UC is associated with an infiltration of activated CD4 T cells into the gut and increased 
memory T cells and activated gut homing CD4 T cells in the peripheral blood (Bouma 
and Strober 2003). Classically ulcerative colitis was thought to be mediated by TH2 cells 
but recent work has found TH17 cytokines are enriched in UC mucosal lesions and play a 
major role in inflammation (Zenewicz et al. 2009).  
 
Circulating inflammatory markers such as CRP and IL-6 are elevated in patients with 
active UC but few studies have looked for peripheral T cell activation. One study found 
an activated CD8 T cell transcription profile predicted more severe IBD/UC (Lee et al. 
2011) and Funderberg et al found increased CD4 and CD8 T cell activation in IBD that 
correlated with LPS binding protein levels (Funderburg et al. 2013).  
 
We sought to assess whether TH17 cells are raised in the periphery or the mucosa of 
patients with UC. We investigated tight junction protein expression on mucosal biopsies 
to determine if disruption to the epithelial barrier is present. We also measured 
peripheral immune activation together with markers of microbial translocation to assess 
whether the leakage of gut microbes is associated with systemic inflammation in UC. 
 
5.1.1 Aims 
• Assess differences in TH17 cell proportions and cytokine pattern in active and 
inactive UC.  
• Measure CD4 and CD8 phenotype and cytokine responses to SEB. 
• Determine the level of disruption in tight junction protein staining in active and 
inactive UC. 
• Assess the levels of microbial translocation and immune activation in UC and 
determine whether mucosal TH17 cells associate with the level of mucosal 
damage and immune dysregulation.  
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5.2 Patient Characteristics 
 
We recruited 33 ulcerative colitis patients into the study and divided them into currently 
active disease (15/33), defined as a Montreal Severity (S) score of 2 or 3, and senescent 
disease state (18/33), representing those with an S score of 0 or 1. In the active group 
we received blood samples only in 2/15 patients, and in 2/18 inactive patients we 
received biopsy samples only. 
 
Three patients were sampled twice over the recruitment period. Two patients had an 
active disease state at first sampling and returned with inactive disease 3 or 8 months 
after initial colonoscopy. The third patient had colonoscopy performed twice over 4 
months and was placed in the inactive group on both occasions. 
 
We had significantly more females in the UC groups compared to controls (p=0.0045, 
Table 5-1). Healthy controls were also significantly older than ulcerative colitis (UC) 
patients (HC= 47, Active UC= 29, Inactive UC=34 years, p=<0.0001). Absolute CD4 
counts in inactive UC (HC=524, Active UC=779, Inactive UC=892 cells/µl, 
p=0.0062) and absolute CD8 T cell counts in active UC (HC=342, Active UC=519, 
Inactive UC=481 cells/µl, p=0.0283) were significantly elevated compared to controls 
but CD4:CD8 ratios were similar across groups. Treatment was also broadly similar in 
inactive and active disease, with similar proportions on steroids and 5-ASA, although we 
did see more azathioprine use in inactive disease. Patients with inactive disease had been 
diagnosed a significantly longer time than those with active disease. 
 
We observed no correlations between absolute T cell counts or CD4:CD8 ratios and 
ulcerative colitis severity score (UCSS). 
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 HC (n=22) Active UC 
(n=15) 
Inactive UC 
(n=18) 
p value 
Age in years 47 (40–55) 29 (27-33) 34 (28-45) <0.0001a 
Gender F:M 3:19 8:7 11:7 0.0045 b 
CD4 cells/µl 524 (460 – 827) 779 (695 – 1039) 892 (677-1168) 0.0062 c 
CD8 cells/µl 342 (268 – 463) 519 (407 – 659) 481 (321 – 639) 0.0283 d 
CD4:CD8  1.60 (1.08 – 2.05) 1.70 (1.20 – 2.15) 1.80 (1.25 – 3.65) ns 
Months since 
diagnosis 
- 31.00 
(16.00-88.00) 
136.50 
(31.75-155.75) 
0.0283 
e
 
Treatment 
Steroids: n (%) 
AZA/E: n (%) 
5ASA: n (%) 
Anti-TNF: n (%) 
-  
5   (33%) 
2   (13%) 
11 (73%) 
0 
 
5   (38%) 
8   (44%) 
15 (83%) 
0 
 
IBD Score 
Montreal Severity 
0 
1 
2 
3 
Montreal Extent 
1 
2 
3 
UCSS 
≤5 
>5 
-  
 
0 
0 
7  (47%) 
8  (53%) 
 
1   (7%) 
10 (67%) 
4   (27%) 
 
0 
15  
 
 
5   (28%) 
13 (72%) 
0 
0 
 
3  (17%) 
8  (44%) 
7  (39%) 
 
17 
1 
 
 
Table 5-1 Ulcerative colitis patient characteristics. Median values with interquartile ranges are reported. p values 
from Kruskall-Wallis test or chi-squared for contingency data. aHC vs. UC S2-S3 p=<0.0001 post correction (pc), 
HC vs. UC S0-S1 p=0.0090pc. b Chi-squared 10.82, p=0.0045. c HC vs. UC S0-S1 p=0.0124pc. . d HC vs. 
UC S0-S1 p=0.0261pc. e UC S2-S3 vs. UC S0-S1 p=0.0485 Mann-Whitney test. 
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5.3 T cell subsets  
5.3.1 CD4 and CD8 Percentage and Phenotype 
 
Percentage CD4 T cells (Figure 5-1) and CD8 T cells ( 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-2) in the blood and mucosa were similar between controls and UC patients.  
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Figure 5-1 CD4 T cell percentages in the blood and mucosa of HC and UC patients. UCS2-3=active UC, UCS0-1 
= Inactive UC. Green circles=HC blood, purple triangles=Active UC blood, purple diamonds=Inactive UC blood, 
green squares=HC MMC, inverted purple triangles=Active UC MMC, purple rings=Inactive UC MMC.  Differences 
between groups were calculated using Kruskal Wallis with Dunn’s post-test correction, comparisons between PBMC 
and MMC within groups were performed using Wilcoxon matched-pairs signed rank test. MMC/PBMC ratios 
HC=0.98, Active UC=0.96, Inactive UC=0.92.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-2 CD8 T cell percentages in the blood and mucosa of HC and UC patients. UCS2-3=Active UC, UCS0-1 
= Inactive UC. Green circles=HC blood, purple triangles=Active UC blood, purple diamonds=Inactive UC blood, 
green squares=HC MMC, inverted purple triangles=Active UC MMC, purple rings=Inactive UC MMC. Differences 
between groups were calculated using Kruskal Wallis with Dunn’s post-test correction, comparisons between PBMC 
and MMC within groups were performed using Wilcoxon matched-pairs signed rank test. MMC/PBMC ratio 
HC=0.80, Active UC=0.80, Inactive UC=1.05 
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We saw increased CD45RO-CD27+ naïve CD4 T cells in the blood of UC patients 
compared to controls that lost significance post-Dunn’s correction (HC=54.60%, Active 
UC=62.50%, Inactive UC=66.60%, p=0.0389, Figure 5-3). We also found 
significantly reduced CD45RO+CD27+ central memory CD4 T cells in active UC 
compared to controls (HC=38.95%, Active UC=26.60%, Inactive UC=23.40%, 
p=0.0171).  
 
In the mucosa naïve CD4 T cells were raised in inactive UC patients compared to 
controls (HC=8.02%, Active UC=10.50%, Inactive UC=15.00%, p=0.0454, Figure 
5-3) but no other differences were seen (Table 5-2). 
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Figure 5-3 Naive and central memory CD4 T cells in blood and mucosa of HC and UC. Differences between groups 
were calculated using Kruskal-Wallis with Dunn’s post-test correction (*=<0.05, **=<0.01, ***=<0.001, 
***=<0.0001). UCS2-3=Active UC, UCS0-1 = Inactive UC. Green circles=HC blood, purple triangles=Active 
UC blood, purple diamonds=Inactive UC blood, green squares=HC MMC, inverted purple triangles=Active UC 
MMC, purple rings=Inactive UC MMC 
 
Similar to CD4 T cells blood CD8 central memory T cells were significantly reduced in 
active UC compared to controls (HC=23.00%, Active UC=10.70%, Inactive 
UC=15.00%, p=0.0034, Figure 5-4). 
 
Naïve CD8 T cells in the mucosa were significantly raised in active UC compared to 
controls. Unlike the blood we found no difference in central memory CD8 T cells in the 
mucosa but did see a significant depletion of CD8 effector memory T cells compared to 
both controls and inactive UC (HC=33.60%, Active UC=18.10%, Inactive 
UC=34.40%, p=0.0136).  
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Figure 5-4 Naive and memory CD8 T cells in blood and mucosa. Differences between groups were calculated using 
Kruskal-Wallis with Dunn’s post-test correction (*=<0.05, **=<0.01, ***=<0.001, ***=<0.0001). 
UCS2-3=Active UC, UCS0-1 = Inactive UC. Green circles=HC blood, purple triangles=Active UC blood, purple 
diamonds=Inactive UC blood, green squares=HC MMC, inverted purple triangles=Active UC MMC, purple 
rings=Inactive UC MMC 
 
 
 
 Site Subset HC Active UC Inactive UC p value 
 
T cells 
(%CD3) 
PBMC CD4 64.10 
(53.00-73.45) 
64.00 
(49.80-71.30) 
71.45 
(52.45-81.10) 
ns 
CD8 27.95 
(20.50-36.61) 
30.50 
(23.35-38.05) 
21.60 
(15.00-38.95) 
ns 
MMC CD4 64.78 
(56.66-70.59) 
65.65 
(55.65-69.43) 
62.85 
(59.31-66.13) 
ns 
CD8 22.20 
(16.99-27.95) 
24.35 
(17.73-26.08) 
21.65 
(19.21-24.54) 
ns 
 
Naïve  
 
 
PBMC %CD4 54.60 
(35.30-66.90) 
62.50 
(53.90-71.00) 
66.60 
(45.40-79.00) 
0.0389a 
%CD8 48.20 
(33.13-61.53) 
74.50 
(43.00-80.00) 
54.50 
(42.80-83.90) 
ns 
MMC %CD4 8.02 
(4.49-13.20) 
10.50 
(6.57-18.95) 
15.00 
(7.80-20.63) 
0.0454 b 
%CD8 12.10 
(5.52-17.15) 
22.90 
(16.25-34.35) 
14.40 
(7.54-26.30) 
0.0047 c 
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 Site Subset HC Active UC Inactive UC p value 
 
Terminally 
diff.  
PBMC %CD4 0.83 
(0.37-3.40) 
1.26 
(0.24-2.44) 
0.96 
(0.11-1.75) 
ns 
%CD8 9.60 
(1.59-32.05) 
11.00 
(5.75-30.00) 
12.60 
(2.24-25.00) 
ns 
MMC %CD4 4.15 
(1.63-6.81) 
2.67 
(2.32-5.33) 
3.69 
(1.48-7.29) 
ns 
%CD8 11.70 
(5.33-18.50) 
5.70 
(4.21-13.20) 
9.54 
(7.82-13.75) 
ns 
 
Central 
Memory  
PBMC %CD4 38.95 
(28.25-50.80) 
26.60 
(18.20-34.60) 
23.40 
(18.30-38.00) 
0.0171 d 
%CD8 23.00 
(13.38-38.23) 
10.70 
(9.19-15.80) 
15.00 
(6.60-19.30) 
0.0034 e 
MMC %CD4 62.00 
(52.80-74.15) 
62.70 
(56.85-67.85) 
58.75 
(46.58-65.43) 
ns 
%CD8 37.40 
(27.60-57.70) 
45.10 
(36.85-54.30) 
35.70 
(30.70-46.05) 
ns 
 
Effector 
Memory  
 
 
PBMC %CD4 3.96 
(2.83-7.42) 
3.44 
(2.21-6.50) 
3.55 
(1.44-8.78) 
ns 
%CD8 5.99 
(3.63-7.04) 
3.22 
(2.54-9.71) 
4.54 
(0.38-17.20) 
ns 
MMC %CD4 20.70 
(15.40-30.25) 
16.75 
(14.50-24.45) 
16.00 
(8.14-32.70) 
ns 
%CD8 33.60 
(24.45-43.30) 
18.10 
(15.05-26.05) 
34.40 
(16.80-46.45) 
0.0136 f 
 
Table 5-2 T cell percentage and phenotype in blood and mucosa of UC patients. Median values with interquartile 
ranges are reported, p values represent results from Kruskal-Wallis test. a p=0.0389, no significance post correction 
(pc). b p=0.0454, HC vs. UCS0-S1 p=0.0424pc. c p=0.0047, HC vs. UCS2-S3 p=0.0033pc. .d p=0.0171, 
HC vs UCS2-S3 p=0.0461pc. e p=0.0034, HC vs UCS2-S3 p=0.0037pc.  f p=0.0136, HC vs UCS2-S3 
p=0.0037pc. 
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5.4 TH17 cells 
5.4.1 Precursor TH17 cells 
 
There was a trend for reduced blood precursor TH17 cells (CD161+CD4+) in inactive 
UC compared to controls that did not reach significance (Figure 5-5).  
 
Figure 5-5 Precursor TH17 cells in blood of UC and controls. Differences between groups were calculated using 
Kruskal-Wallis with Dunn’s post-test correction. UCS2-3=Active UC, UCS0-1 = Inactive UC. Green circles=HC 
blood, purple triangles=Active UC blood, purple diamonds=Inactive UC blood.  
 
Mucosal precursor TH17 cells in active UC were reduced in UC compared to controls 
but the significance was lost after Dunn’s correction (Figure 5-6, Table 5-3). There was a 
significant reduction of CD161+ cells within the central memory T cells subset 
(HC=62.55%, Active UC=49.80%, Inactive UC=59.00%, p=0.0270). 
 
Figure 5-6 Precursor TH17 cells in mucosa of UC and controls. . Differences between groups were calculated using 
Kruskal-Wallis with Dunn’s post-test correction (*=<0.05). UCS2-3=Active UC, UCS0-1 = Inactive UC. green 
squares=HC MMC, inverted purple triangles=Active UC MMC, purple rings=Inactive UC MMC. 
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5.4.2 TH17 Frequency  
 
The frequency of IL-17a producing CD4 T cells was similar between UC patients and 
controls in the blood and the mucosa (Figure 5-7, Table 5-3). 
Figure 5-7 TH17 frequency in CD4, central and effector memory T cell in blood and mucosa of UC and HC. 
Differences between groups were calculated using Kruskal-Wallis with Dunn’s post-test correction 
 
5.4.3 TH17 Phenotype 
 
There was a significant increase in the proportion of blood TH17 cells (IL-17a+CD4+) 
with an effector memory phenotype in active UC compared to controls (HC=20.50%, 
Active UC=29.45%, Inactive UC=18.60%, p=0.0397, Figure 5-8) but we saw no 
differences in mucosal TH17 phenotype (Table 5-3). 
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Figure 5-8 Effector memory TH17 cells in PBMC of UC and HC. Differences between groups were calculated using 
Kruskal-Wallis with Dunn’s post-test correction (*=<0.05). 
 
5.4.4 TH17 Functionality 
 
We next assessed the ability of TH17 cells to produce the cytokines IFNγ, IL-2 and TNF. 
There was no significant difference in the levels of blood cytokine production (Table 5-3) 
but mucosal TH17 cells producing IL-2 were significantly reduced in active UC 
compared to inactive disease (HC=39.20%, Active UC=24.30%, Inactive UC=44.20%, 
p=0.0294). 
 
 
 
 
 
 
Figure 5-9 IL-2 production by mucosal TH17 cells in UC and HC. Differences between groups were calculated using 
Kruskal-Wallis with Dunn’s post-test correction (*=<0.05). 
 
We further assessed the polyfunctionality of TH17 cells using SPICE (Figure 5-10). In 
the blood and mucosa of both UC and controls most TH17 cells produced either IL-
2+TNF+ or TNF+ only but there was no significant difference in TH17 functional 
distribution between groups at either site.  
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Figure 5-10 TH17 polyfunctionality in UC and controls. Differences between pie charts were calculated using the 
partial permutation test in SPICE. 
 
5.4.5 TH17TH1 cells 
 
There was a significant increase in (IFNγ+IL-17a+) TH17TH1 cells in the blood of 
active UC compared to inactive disease (HC=0.03%, Active UC=0.07%, Inactive 
UC=0.02%, p=0.0418, Figure 5-11) but no differences in mucosal TH17TH1 cells. 
 
 
 
 
 
 
 
Figure 5-11 TH17TH1 frequency in blood and mucosa of UC and HC. Differences between groups were calculated 
using Kruskal-Wallis with Dunn’s post-test correction. (*=<0.05). 
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5.4.6 IL-17f+ CD4 T cells 
 
Production of the TH17-associated cytokine IL-17f by CD4 T cells (HC=0.00%, Active 
UC=0.10%, Inactive UC=0.03%, p=0.0145) and by effector memory CD4 T cells 
(HC=0.21%, Active UC=0.65%, Inactive UC=0.48%, p=0.0489) was significantly 
raised in active UC compared to controls in the blood (Figure 5-12, Table 5-3). Mucosal 
CD4 production of IL-17f was also raised in active UC (HC=0.13%, Active 
UC=0.25%, Inactive UC=0.17%, p=0.0443) and in effector memory CD4 T cells 
(HC=0.25%, Active UC=1.18%, Inactive UC=0.34%, p=0.0273). 
 
 
Figure 5-12 IL-17f production by CD4 blood and mucosal T cells in UC and controls. Differences between groups 
were calculated using Kruskal-Wallis with Dunn’s post-test correction (*=<0.05). 
 
5.4.7 Tc17 cells 
 
We found little evidence of blood CD8 T cells capable of producing either IL-17a or IL-
17f (Table 5-3). In the mucosa there was no significant difference in CD8 production of 
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IL-17a between UC patients and controls and CD8 T cells producing IL-17f were mostly 
absent.  
 
5.4.8 IL-22+ CD4 T cells 
 
There was no difference in blood CD4 production of IL-22 in UC compared to controls. 
In the mucosa however we found a significant increase in CD4 T cells (HC=0.60%, 
Active UC=0.98%, Inactive UC=0.53%, p=0.0135, Figure 5-13) and CD4 effector 
memory T cells (HC=0.98%, Active UC=2.24%, Inactive UC=1.51%, p=0.0023) 
producing IL-22 in active UC compared to controls.  
 
 
Figure 5-13 IL-22 production by blood and mucosal CD4 T cells of UC and HC patients. Differences between groups 
were calculated using Kruskal-Wallis with Dunn’s post-test correction (*=<0.05, **=<0.01) 
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5.4.9 TH22 cells 
 
We found no difference in the frequency of TH22 cells (CD161-IL-22+CD4+) in the 
blood or mucosa between UC patients or controls (Figure 5-14). 
 
 
 
 
 
 
Figure 5-14 TH22 cells in blood and mucosa of HC and UC. Differences between groups were calculated using 
Kruskal-Wallis with Dunn’s post-test correction. 
 
 
 Site Subset HC Active UC Inactive UC p value 
 
 
 
CD161 
 
PBMC %CD4 10.11 
(7.84-14.21) 
8.53 
(6.83-11.64) 
7.42 
(4.85-9.77) 
ns 
%CM 22.60 
(15.10-27.85) 
19.70 
(12.83-25.80) 
15.30 
(10.00-23.90) 
ns 
%EM 25.60 
(15.30-30.85) 
22.10 
(17.95-28.98) 
18.00 
(14.10-21.50) 
ns 
MMC %CD4 62.37 
(52.36-68.85) 
52.77 
(44.61-55.75) 
53.32 
(41.84-64.93) 
0.0377
 a
 
%CM 62.55 
(53.30-67.38) 
49.80 
(42.20-59.80) 
59.00 
(55.30-61.95) 
0.0270
 b
 
%EM 78.45 
(68.20-82.35) 
70.20 
(63.40-76.90) 
81.40 
(65.00-82.60) 
ns 
 
 
 
IL-17a 
 
PBMC %CD4 0.32 
(0.14-0.44) 
0.35 
(0.13-0.57) 
0.21 
(0.12-0.31) 
ns 
%CM 0.45 
(0.25-0.67) 
0.76 
(0.33-1.13) 
0.49 
(0.33-0.63) 
ns 
%EM 1.55 
(0.69-1.91) 
1.58 
(0.88-4.61) 
1.07 
(0.73-2.20) 
ns 
MMC %CD4 1.05 
(0.80-1.40) 
1.82 
(0.89-3.19) 
0.95 
(0.75-2.40) 
ns 
%CM 0.94 
(0.75-1.51) 
0.99 
(0.67-2.40) 
0.74 
(0.58-2.01) 
ns 
%EM 2.00 
(1.61-3.77) 
5.27 
(2.35-7.66) 
2.44 
(1.90-5.10) 
ns 
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 Site Subset HC Active UC Inactive UC p value 
 
 
 
TH17 
PBMC %Naive 8.15 
(2.79-19.85) 
6.49 
(3.08-13.06) 
15.55 
(7.05-25.25) 
ns 
%CM 60.30 
(47.40-76.10) 
58.85 
(55.68-69.38) 
59.15 
(49.70-74.25) 
ns 
%EM 20.50 
(15.60-27.40) 
29.45 
(20.75-35.25) 
18.60 
(14,55-26.25) 
0.0397
 c
 
%Term 1.18 
(0.25-4.20) 
0.58 
(0.06-3.75) 
1.36 
(0.42-4.09) 
ns 
MMC %Naive 3.85 
(2.52-9.35) 
2.27 
(0.63-4.24) 
3.64 
(1.14-7.66) 
ns 
%CM 48.10 
(38.40-66.10) 
52.40 
(34.30-57.40) 
45.00 
(29.10-61.90) 
ns 
%EM 45.20 
(28.40-52.20) 
39.20 
(34.45-64.85) 
44.20 
(28.05-60.50) 
ns 
%Term 1.85 
(0.80-3.73) 
1.14 
(0.04-2.59) 
1.82 
(0.52-3.90) 
ns 
IFNγ PBMC %TH17 9.13 
(5.55-14.25) 
14.05 
(7.37-18.55) 
8.48 
(3.66-14.20) 
ns 
IL-2 %TH17 50.20 
(43.65-64.80) 
57.95 
(48.73-62.08) 
54.45 
(48.88-60.53) 
ns 
TNF %TH17 85.70 
(74.45-90.25) 
88.45 
(77.70-93.28) 
83.90 
(77.65-86.55) 
ns 
IFNγ MMC %TH17 8.76 
(5.88-14.00) 
8.97 
(7.68-12.05) 
10.90 
(7.27-18.00) 
ns 
IL-2 %TH17 39.20 
(34.60-51.00) 
24.30 
(17.95-34.35) 
44.20 
(37.35-55.30) 
0.0294
 d
 
TNF %TH17 87.10 
(76.70-91.50) 
82.90 
(67.45-90.65) 
88.90 
(76.00-91.40) 
ns 
TH17TH1 PBMC %CD4 0.03 
(0.00-0.07) 
0.07 
(0.02-0.10) 
0.02 
(0.00-0.02) 
0.0418
 e
 
MMC %CD4 0.09 
(0.07-0.18) 
0.13 
(0.02-0.30) 
0.15 
(0.07-0.33) 
ns 
 
 
IL-17f 
 
PBMC %CD4 0.00 
(0.00-0.07) 
0.10 
(0.03-0.15) 
0.03 
(0.00-0.08) 
0.0145
 f
 
%CM 0.05 
(0.02-0.11) 
0.11 
(0.07-0.18) 
0.07 
(0.05-0.09) 
ns 
%EM 0.21 
(0.17-0.58) 
0.65 
(0.38-1.36) 
0.48 
(0.14-0.60) 
0.0489
 g
 
MMC %CD4 0.13 
(0.00-0.16) 
0.25 
(0.14-0.60) 
0.17 
(0.09-0.31) 
0.0443
 h
 
%CM 0.09 
(0.04-0.15) 
0.10 
(0.03-0.22) 
0.14 
(0.05-0.33) 
ns 
%EM 0.25 
(0.10-0.43) 
1.18 
(0.51-2.19) 
0.34 
(0.21-1.22) 
0.0273
 i
 
IL-17a PBMC %CD8 0.00 
(0.00-0.00) 
0.00 
(0.00-0.00) 
0.00 
(0.00-0.00) 
ns 
MMC %CD8 0.06 
(0.00-0.28) 
0.29 
(0.13-0.47) 
0.21 
(0.07-0.51) 
ns 
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Table 5-3 TH17 and TH22 frequency and phenotype in UC and HC. Median values with interquartile ranges are 
reported, p values represent results from Kruskal-Wallis test. 
a p=0.0377, no significance post correction (pc). b p=0.0270, HC vs. UCS2-S3 p=0.0216pc. c p=0.0397, 
UCS-S1 vs. UCS2-S3 p=0.0444pc. .d p=0.0294, UCS0-S1 vs UCS2-S3 p=0.0293pc. e p=0.0418, UCS0-S1 
vs UCS2-S3 p=0.0352pc.  f p=0.0145, HC vs UCS2-S3 p=0.0130pc. .  g p=0.0489, HC vs UCS2-S3 
p=0.0451pc. .  h p=0.0443, HC vs UCS2-S3 p=0.0454pc. .  i p=0.0273, HC vs UCS2-S3 p=0.0269pc. .  j 
p=0.0135, HC vs UCS2-S3 p=0.0113pc.k p=0.0023, HC vs UCS2-S3 p=0.0016pc. l p=0.0202, HC vs 
UCS2-S3 p=0.0446pc, UCS0-S1 vs UCS2-S3 p=0.0266. 
 
5.5 CD4 and CD8 Cytokine Response to SEB 
 
There was no difference in the secretion of IFNγ, IL-2 or TNF by blood or mucosal CD4 
T cells in controls or UC patients (Figure 5-15, Table 5-4). In the mucosa active UC 
patients had significantly reduced IL-2+CD8 T cells (HC=0.83%, Active UC=0.32%, 
Inactive UC=0.47%, p=0.0394, Figure 5-16) compared to controls. 
 Site Subset HC Active UC Inactive UC p value 
IL-17f PBMC %CD8 0.00 
(0.00-0.00) 
0.00 
(0.00-0.00) 
0.00 
(0.00-0.00) 
ns 
MMC %CD8 0.00 
(0.00-0.03) 
0.00 
(0.00-0.08) 
0.00 
(0.00-0.05) 
ns 
 
 
 
IL-22 
 
PBMC %CD4 0.12 
(0.00-0.19) 
0.17 
(0.07-0.31) 
0.09 
(0.00-0.12) 
ns 
%CM 0.18 
(0.08-0.32) 
0.26 
(0.14-0.56) 
0.20 
(0.07-0.26) 
ns 
%EM 0.50 
(0.22-0.96) 
0.95 
(0.45-1.67) 
0.63 
(0.17-1.07) 
ns 
MMC %CD4 0.60 
(0.34-0.78) 
0.98 
(0.80-1.44) 
0.53 
(0.46-0.91) 
0.0135
 j
 
%CM 0.48 
(0.31-0.64) 
0.59 
(0.44-1.16) 
0.65 
(0.37-1.09) 
ns 
%EM 0.98 
(0.61-1.24) 
2.24 
(1.81-3.83) 
1.51 
(0.66-2.38) 
0.0023
 k
 
IL-22 PBMC %CD8 0.00 
(0.00-0.00) 
0.00 
(0.00-0.00) 
0.00 
(0.00-0.00) 
ns 
MMC %CD8 0.09 
(0.00-0.14) 
0.19 
(0.10-0.35) 
0.08 
(0.00-0.12) 
0.0202
 l
 
TH22 PBMC %CD4 0.06 
(0.00-0.12) 
0.07 
(0.00-0.14) 
0.05 
(0.00-0.07) 
ns 
MMC %CD4 0.12 
(0.00-0.20) 
0.11 
(0.00-0.18) 
0.06 
(0.00-0.20) 
ns 
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Figure 5-15 Cytokine production by blood and mucosal CD4 T cells in controls and UC. Differences between groups 
were calculated using Kruskal-Wallis with Dunn’s post-test correction. 
 
 
Figure 5-16 Cytokine production by blood and mucosal CD8 T cells in controls and UC. Differences between groups 
were calculated using Kruskal-Wallis with Dunn’s post-test correction (*=<0.05). 
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 Site Subset  HC Active UC Inactive UC p value 
 
 
 
 
 
IFNγ 
PBMC  
CD4 
%CD4 1.35 
(0.50-3.13) 
1.53 
(0.99-2.76) 
1.06 
(0.36-1.55) 
ns 
%CM 1.97 
(0.75-4.62) 
3.22 
(1.66-3.96) 
2.01 
(1.54-2.32) 
ns 
%EM 6.62 
(1.89-9.62) 
4.55 
(3.52-10.26) 
3.35 
(2.33-15.00) 
ns 
 
CD8 
%CD8 2.61 
(1.16-4.97) 
2.16 
(0.90-3.80) 
1.71 
(0.56-5.18) 
ns 
%CM 3.88 
(1.92-5.60) 
5.46 
(3.18-8.29) 
4.40 
(3.65-5.36) 
ns 
%EM 4.29 
(3.18-9.69) 
7.10 
(2.75-11.80) 
4.36 
(1.93-10.77) 
ns 
MMC  
CD4 
%CD4 2.99 
(2.14-3.64) 
2.55 
(1.35-4.47) 
2.20 
(1,17-3.85) 
ns 
%CM 3.08 
(2.17-4.02) 
2.79 
(1.92-4.78) 
2.55 
(1.61-4.20) 
ns 
%EM 4.58 
(2.26-6.08) 
3.56 
(2.49-5.87) 
3.08 
(1.49-7.77) 
ns 
 
CD8 
%CD8 4.04 
(3.24-6.44) 
6.14 
(2.97-10.22) 
4.18 
(2.07-5.38) 
ns 
%CM 5.20 
(4.17-7.67) 
11.50 
(5.08-14.78) 
6.74 
(3.81-10.25) 
ns 
%EM 3.65 
(2.59-6.09 
4.93 
(2.43-8.28) 
3.33 
(1.85-5.54) 
ns 
 
 
 
 
 
IL-2 
 
 
PBMC  
CD4 
%CD4 3.39 
(1.04-4.59) 
2.21 
(1.21-3.88) 
2.07 
(1.55-2.37) 
ns 
%CM 6.41 
(2.64-7.80) 
4.95 
(2.57-10.19) 
4.61 
(3.56-5.90) 
ns 
%EM 8.72 
(3.48-12.44) 
6.66 
(4.68-13.20) 
7.96 
(4.16-10.02) 
ns 
 
CD8 
%CD8 0.83 
(0.43-1.74) 
0.32 
(0.20-0.62) 
0.47 
(0.24-0.87) 
0.0394
 a
 
%CM 2.43 
(1.01-4.15) 
1.94 
(0.77-2.33) 
2.33 
(1.23-2.80) 
ns 
%EM 1.61 
(0.53-3.22) 
0.61 
(0.10-1.95) 
1.04 
(0.54-2.70) 
ns 
MMC  
CD4 
%CD4 4.12 
(3.09-5.20) 
4.76 
(2.56-5.55) 
3.99 
(2.82-5.37) 
ns 
%CM 4.60 
(3.02-5.80) 
5.23 
(2.76-6.68) 
4.70 
(2.26-6.12) 
ns 
%EM 5.22 
(3.83-7.07) 
4.48 
(1.86-7.31) 
4.49 
(2.80-8.00) 
ns 
 
CD8 
%CD8 1.95 
(0.95-3.45) 
1.10 
(0.92-1.28) 
1.38 
(0.39-2.57) 
ns 
%CM 2.37 
(1.32-4.27) 
1.70 
(1.04-1.92) 
2.18 
(0.51-3.37) 
ns 
%EM 2.29 
(1.00-3.34) 
0.90 
(0.63-1.40) 
1.87 
(0.90-2.87) 
0.0310
 b
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 Site Subset  HC Active UC Inactive UC p value 
 
 
 
 
TNF 
 
 
PBMC  
CD4 
%CD4 6.91 
(3.87-10.65) 
5.73 
(2.69-7.56) 
5.36 
(3.40-6.62) 
ns 
%CM 11.27 
(5.22-12.87) 
8.00 
(4.63-15.41) 
8.33 
(6.54-9.23) 
ns 
%EM 16.45 
(13.03-21.45) 
17.50 
(9.11-20.80) 
12.90 
(9.90-23.42) 
ns 
 
CD8 
%CD8 5.94 
(3.20-11.05) 
3.83 
(2.37-5.14) 
4.97 
(2.39-10.82) 
ns 
%CM 9.38 
(4.84-11.80) 
9.63 
(5.21-10.90) 
9.02 
(6.20-10.50) 
ns 
%EM 17.80 
(8.27-21.15) 
12.80 
(6.86-14.80) 
9.89 
(6.78-12.00) 
ns 
MMC  
CD4 
%CD4 12.51 
(10.46-14.80) 
12.15 
(8.97-16.73) 
10.24 
(7.98-13.21) 
ns 
%CM 13.40 
(11.40-15.05) 
14.25 
(9.85-18.50) 
11.10 
(8.38-15.10) 
ns 
%EM 16.30 
(12.65-20.10) 
15.20 
(11.80-22.00) 
13.00 
(9.71-24.70) 
ns 
 
CD8 
%CD8 11.19 
(8.76-13.02) 
13.74 
(7.50-15.60) 
9.75 
(6.89-13.45) 
ns 
%CM 13.40 
(8.69-16.15) 
18.25 
(8.45-20.50) 
11.85 
(8.43-16.00) 
ns 
%EM 10.90 
(9.43-14.30) 
9.53 
(5.36-16.65) 
8.64 
(5.98-11.55) 
ns 
Table 5-4 Cytokine production by CD4 and CD8 blood and mucosal T cells in UC and HC. Values shown are 
medians with interquartile ranges. a p=0.0394, HC vs UCS2-S3 p=0.0346pc. bp=0.0310, HC vs UCS2-S3 
p=0.0288pc 
 
5.5.1 CD4 and CD8 Polyfunctional Cytokine Responses to SEB 
 
We then examined the capacity of CD4 T cells to produce the cytokines IFNγ, IL-2 and 
TNF in combination. The major responding blood and mucosal CD4 T cell subsets in 
controls and UC patients were those producing TNF alone. We found no difference in 
the pattern of mono, dual or polyfunctional cytokine expression in the blood or mucosa 
between controls and UC patients. 
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Figure 5-17 Polyfunctional CD4 T cells in blood and mucosa of UC and HC 
 
The overall pattern of polyfunctional CD8 T cells in PBMC and MMC was also similar 
across the groups. However using Mann-Whitney in SPICE we did find a significant 
reduction in IFNγ-IL-2+TNF+ (p=0.007) and IFNγ-IL-2+TNF- (p=0.010) producing 
CD8 T cells in the blood of active UC patients compared to controls and a significant 
reduction of IFNγ-IL-2+TNF+ (p=0.021) producing CD8 T cell in the mucosa of active 
disease. 
 
 
 
 
 
 
 
 
 
 
Figure 5-18 Polyfunctional CD8 T cells in blood and mucosa of UC and HC 
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5.6 Mucosal Damage in UC 
 
We found no significant difference in serum levels of intestinal fatty acid binding protein 
(I-FABP) between controls and UC patients (HC=304.61, Active UC=273.26, Inactive 
UC=372.01 ng/ml).  
 
 
 
 
 
 
Figure 5-19 Serum levels of I-FABP in controls and UC patients. Differences between groups were calculated using 
Kruskal-Wallis with Dunn’s post-test correction. 
 
Claudin 1 (HC=0.25, Active UC =3.11, Inactive UC=1.84, p=<0.0001), claudin 4 
(HC=0.64, Active UC=2.36, Inactive UC=2.66, p=0.0030) and occludin (HC=1.15, 
Active UC=2.67, Inactive UC=2.49, p=0.0170) breach:intact ratios were all raised in 
active UC compared to controls. Claudin 1 and 4 breach ratios were also significantly 
higher in inactive disease compared to controls. 
 
 
Figure 5-20 Breach:Intact ratios in UC and HC patients. Differences between groups were calculated using Kruskal-
Wallis with Dunn’s post-test correction. 
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5.7 Microbial Translocation in UC  
 
Plasma LPS binding protein (LBP) levels in active UC were significantly raised compared 
to controls and inactive UC (HC=12.42, Active UC=21.18, Inactive UC=12.44 
µg/ml, p=0.0040). However we found no evidence of increased endotoxin (HC=0.22, 
Active UC=0.11, Inactive UC=0.15 IU/ml) in serum and actually saw a significant 
reduction of plasma 16s rDNA levels in UC compared to controls (HC=24.11, Active 
UC=6.57, Inactive UC=6.01 copies/ml).  
 
Figure 5-21 Markers of microbial translocation in UC and HC patients. Differences between groups were calculated 
using Kruskal-Wallis with Dunn’s post-test correction.  
 
We found evidence of LPS translocation into the lamina propria of 36% of the active UC 
patient group (4/11) and 35% of inactive UC group (6/17) which was lower than 
healthy controls  (13/22, 59%) but not significantly different.  
 
 
 
 
 
 
 
Figure 5-22 Example LPS IHC staining in the lamina propria of a UC patient (X250 magnification). 
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5.8 Immune Activation in UC 
 
 HLA DR+CD38+ activated CD4 T cells were significantly reduced in inactive UC 
compared to both controls and active UC (HC=1.48%, Active UC=1.48%, Inactive 
UC=0.74%, p=0.0092). There were increased levels of CD38++CD8+ T cells in 
active UC that lost significance post correction but HLA DR+CD38+ CD8 T cells were 
significantly elevated in active UC compared to inactive disease (HC=3.25%, Active 
UC=3.21%, Inactive UC=1.30%, p=0.0068). Levels of sCD14 and CD163 were 
similar in controls and UC patients (Figure 5-24). 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-23 CD4 and CD8 peripheral T cell activation in UC and HC patients (*=<0.05, **=<0.01). 
 
 
 
 
 
 
 
Figure 5-24 Monocyte activation markers in controls and UC patients.  
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 Marker Site Unit HC Active UC Inactive UC p value 
Mucosal 
damage 
I-FABP serum ng/ml 304.61 
(146.40-468.27) 
273.26 
(170.30-529.10) 
372.01 
(68.33-594.05) 
ns 
Claudin 1 colon B:I ratio 0.25 
(0.11-0.52) 
3.11 
(2.19-6.17) 
1.84 
(0.45-7.18) 
<0.0001
a
 
Claudin 4 B:I ratio 0.64 
(0.47-1.79) 
2.36 
(1.43-13.24) 
2.66 
(1.42-7.79) 
0.0030
 b
 
Occludin B:I ratio 1.15 
(0.53-1.66) 
2.67 
(1.36-11.01) 
2.49 
(0.39-7.00) 
0.0170
 c
 
MT LBP plasma µg/ml 12.42 
(8.98-16.59) 
21.18 
(14.57-24.81) 
12.44 
(11.37-18.68) 
0.0040
 d
 
Endotoxin serum IU/ml 0.22 
(0.00-1.24) 
0.11 
(0.04-0.25) 
0.15 
(0.05-0.20) 
ns 
16s rDNA plasma Copies/ml 24.11 
(12.28-63.45) 
6.57 
(5.63-12.74) 
6.01 
(5.34-16.26) 
0.0012
 e
 
LPS IHC colon +ve/total 13/22, 59% 4/11, 36% 6/17, 35% - 
IA CD38++ blood %memory 
CD4 
3.77 
(2.87-6.14) 
4.82 
(3.64-7.53) 
4.52 
(2.87-6.11) 
ns 
HLA DR+ 
CD38+ 
blood %memory 
CD4 
1.48 
(1.03-2.59) 
1.48 
(0.91-3.33) 
0.74 
(0.51-1.48) 
0.0092
 f
 
CD38++ blood %memory 
CD8 
1.51 
(0.94-2.42) 
2.82 
(1.67-4.97) 
1.73 
(0.79-2.60) 
0.0429
 g
 
HLA DR+ 
CD38+ 
blood %memory 
CD8 
3.25 
(1.25-5.41) 
3.21 
(1.85-10.23) 
1.30 
(0.90-1.79) 
0.0068
 h
 
CD163 serum µg/ml 0.44 
(0.39-0.60) 
0.45 
(0.34-0.51) 
0.35 
(0.29-0.54) 
ns 
sCD14 plasma µg/ml 1.44 
(1.18-1.88) 
1.46 
(1.16-2.22) 
1.66 
(1.21-2.04) 
ns 
Table 5-5 Markers of mucosal damage, microbial translocation and immune activation in UC and HC patients. 
Values shown are medians with interquartile ranges. MT= microbial translocation, IA = immune activation. 
 
 a p=<0.0001, HC vs. UCS2-S3 p=<0.0001pc, HC vs. UCS0-S1 p=0.0002pc.  
 b p=0.0030 HC vs. UCS2-S3 p=0.0199pc, HC vs. UCS0-S1 p=0.0076pc.  
 c p=0.0170, HC vs.UCS2-S3 p=0.0178pc.  
d p=0.0040, HC vs.UCS2-S3 p=0.0040pc, UCS0-S1 vs UCS2-S3 p=0.0340pc. 
 e p=0.0012, HC vs.UCS2-S3 p=0.0057pc, UCS0-S1 vs UCS2-S3 p=0.0067pc. 
 f p=0.0092, HC vs UCS0-S1 p=0.0173pc, UCS0-S1 vs. UCS2-S3 p=0.0268pc.  
 g p=0.0489, significance lost post correction (pc) 
 h p=0.0068, UCS0-S1vs UCS2-S3 p=0.0059pc.  
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5.9 Correlations between T cells, mucosal damage, microbial 
translocation and immune activation 
 
5.9.1 Correlations with UCSS 
 
There was a positive correlation between blood IL-22 production by CD4 T cells 
(p=0.035, rs=0.407, not shown) and ulcerative colitis severity score (UCSS) but no 
other correlations between blood T cell subsets or cytokine expression and UCSS. 
Mucosal memory CD4 T cell production of the TH17 cytokines IL-17a and IL-17f 
together with IL-22 production by CD4 and CD8 T cells all correlated with UCSS 
(Figure 5-25). There was also a positive correlation between UCSS and TNF production 
by CD4 T cells and IFNγ production by CD8 mucosal T cells (Figure 5-26).  
 
 
 
  
 
 
 
 
 
 
 
 
 
Figure 5-25 Correlation between TH17 cytokines and UCSS. Correlation performed using Spearman’s Rho. 
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Figure 5-26 Correlation between inflammatory cytokines and UCSS. Correlation performed using Spearman’s Rho. 
 
Peripheral CD8 T cell activation (HLA DR+ CD38+) was also positively correlated to 
UCSS (Figure 5-27). 
 
 
 
 
 
 
 
Figure 5-27 Correlation between CD8 T cell activationa and UCSS. Correlation performed using Spearman’s Rho. 
 
We found no associations between levels of LBP, 16s rDNA or endotoxin with UCSS. 
Neither did we find associations between UCSS and mucosal damage markers. 
 
5.9.2 Correlations between mucosal damage and microbial 
translocation 
 
There was a positive correlation between the level of disruption to claudin 4 and plasma 
LBP in UC patients with active disease (Figure 5-28).  
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Figure 5-28 Correlation between claudin 4 breaches and LBP in active UC. Correlation performed using Spearman’s 
Rho. 
 
5.9.3 Correlations of mucosal damage and microbial translocation 
with immune activation 
 
Breaches in claudin 4 were also positively correlated to plasma levels of sCD14 in active 
UC (Figure 5-29) but there were no correlations between microbial translocation 
markers and immune activation. 
 
 
 
 
 
 
 
 
Figure 5-29 Correlation between claudin 4 and monocyte activation (sCD14). Correlation performed using 
Spearman’s Rho. 
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5.9.4 Correlations between mucosal damage and T cell subsets and 
cytokines 
 
Mucosal precursor TH17 cell frequency was positively correlated with disruption to all 
three tight junctions in active UC patients (Figure 5-30). Breaches in claudin 1 also 
positively correlated to mucosal CD8 EM T cells (p=0.01291, rs=0.706, not shown). 
 
Figure 5-30 Correlation between tight junction breaches and mucosal TH17 cells in active UC 
 
5.9.5 Correlations between microbial translocation and T cell subsets 
and cytokines 
 
There was a positive correlation between memory CD4 and CD8 production of TNF in 
the blood and LPS binding protein levels in active UC patients (Figure 5-31). 
  
 
 
 
 
 
Figure 5-31 Correlation between LBP and TNF production by blood T cells in active UC 
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We found a significant reduction of IL-17a+ (LPS-=1.88%, LPS+=0.73%, p=0.0020) 
and IL-17f+ (LPS- =0.25%, LPS+=0.05%, p=0.0243) mucosal CD4 cells in UC 
patients with LPS in the lamina propria (Figure 5-32). Precursor TH17 (CD161+CD4+) 
cells were, however, increased in LPS+ UC compared to LPS- UC patients (LPS-
=49.53%, LPS+=64.73%, p=0.0026).  
Figure 5-32  Mucosal precursor TH17 and TH17 cytokine freqeuency in LPS IHC positive and negative UC 
patients. Comparisons were performed using Mann-Whitney test.  
 
5.9.6 Correlations between immune activation and T cell subsets and 
cytokines 
 
There was a positive correlation between TH17 precursor cells in the blood and 
peripheral CD8 T cell activation in UC patients with active disease (Figure 5-33). We 
found no associations between mucosal T cells and peripheral immune activation. 
 
 
 
 
 
 
 
Figure 5-33 Correlation between CD8 T cell activation and blood precursor TH17 cells in active UC 
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5.10 Longitudinal UC Data 
 
Two patients with active disease had repeat colonoscopies at 3 or 8 months after their 
first visit and were in remission at second visit (Patient a; Visit 1 UCSS=10, Visit 2 
UCSS=3, Patient b UCSS=6, visit 2 UCSS=3). In these patients mucosal TH17 and 
CD8+IL-22+ T cells were reduced after remission, and we also saw a drop in serum 
levels of the mucosal damage marker, I-FABP (Figure 5-34). Levels of the microbial 
translocation marker 16s rDNA also fell in one patient. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-34 Longitudinal data for two UC patients.  
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5.11 Discussion 
 
5.11.1 Key Findings 
 
Precursor TH17 cells were lost in the mucosal CD4 central memory compartment of 
active UC but we found no difference in blood or mucosal IL-17a+CD4+ T cell 
frequency. There was however elevated production of IL-17f and IL-22 by mucosal CD4 
T cells in active disease that were associated with higher UC disease scores. We saw 
evidence of tight junction protein disruption in active UC that was partially restored in 
inactive disease patients. We found elevated levels of LPS-binding protein in active UC 
but no other evidence of increased microbial translocation. There was no evidence of 
monocyte activation but CD8 T cell activation was increased in active disease compared 
to inactive UC.  
 
Tight junction disruption was associated with LBP and sCD14 but we found no evidence 
that mucosal damage lead to increased T cell activation. In active disease levels of 
precursor TH17 cells in the mucosa were positively associated with breaches in claudin 
1, claudin 4 and occludin. We also found that blood precursor TH17 cells were 
positively associated with peripheral T cell activation.  
 
5.11.2 Discussion 
 
We observed no differences in precursor TH17 (CD4+CD161+) in the blood of UC 
patients compared to controls. In the mucosa there was a significant reduction in 
precursor TH17 cells in the central memory CD4 compartment. We saw no evidence of 
increased TH17 cells (CD4+IL-17a+) in the blood or mucosa of UC patients although 
IL-17a expression within the effector memory CD4 population was more heterogeneous 
 193 
in active UC compared to controls. We found TH17 cells with an effector memory 
phenotype were raised in the blood of active UC patients.  In the mucosa the ability of 
TH17 to produce IL-2 was reduced in active disease compared to inactive UC. There 
was a positive association between mucosal TH17 cell frequency and UC severity score. 
Previous work has shown that elevated IL-17a in the supernatant of UC (Raza and Shata 
2012) and elevated mucosal IL-17a+CD3+ T cells (Fujino et al. 2003) correlate with 
disease score. We also saw an increase in blood TH17TH1 (IL-17+IFN+CD4+) cells in 
active disease compared to inactive UC. 
 
In contrast to CD4+IL-17a+ cells we saw a significant rise in IL-17f producing CD4 T 
cells in the blood and the mucosa of active UC patients, with a significant rise within the 
CD4 effector memory subset. Elevated intestinal IL-17f mRNA expression has 
previously been reported in UC, and found to be higher than in CD patients (Seiderer et 
al. 2008). This study also found that polymorphisms in IL17F were associated with an 
earlier age of UC disease onset. We also found a significant rise in CD4+IL-22+ T cells 
in the mucosa that was strongest in the effector memory T cell subset. 
Immunohistochemical analysis of colonic mucosa has found elevated IL-22 in CD4 
positive cells in both UC and CD (Andoh et al. 2005). Similar to TH17 cells mucosal 
memory IL-17f+CD4+ and IL-22+CD4+ T cells also correlated with UCSS in our 
study. IL-22 production by CD8 T cells was also raised in the mucosa of patients with 
active UC. 
 
We found CD4 and CD8 T cell proportions in UC patients were similar to controls in 
both the blood and mucosa. Active disease was associated with reduced central memory 
CD4 and CD8 T cells in the blood and reduced effector memory CD8 and increased 
naïve CD8 T cells in the mucosa. We saw no differences between CD4 T cell production 
of IL-2, TNF and IFNγ in the blood or mucosa but patients with the highest UCSS also 
had the highest mucosal CD4 production of TNF and IFNγ.   
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There was a significant increase in breach:intact ratios of claudin 1, claudin 4 and 
occludin in active UC disease. Unlike claudin 1 and 4, occludin breach ratios were 
reduced to the level of controls in patients with inactive disease. This data supports 
Western blot analysis of biopsy specimens that found occludin, claudin 1 and claudin 4 
expression was decreased and claudin 2 increased in active UC (Heller et al. 2005), 
although this study examined tissue from the site of inflammation whereas our study 
sampled from macroscopically normal sites. A further study using IHC found claudin 4 
staining was reduced in active UC compared to controls but differences were not 
statistically significant (Prasad et al. 2005). Differences between study results may be 
explained by the method of IHC analysis, we analysed the entire surface epithelium 
whereas Prasad et al analysed expression of tight junction staining on 20 epithelial cells 
from five random fields.  
 
We found no significant increase in levels of I-FABP in active UC compared to controls. 
This is in contrast to previous work that found I-FABP concentrations were three times 
higher in UC compared to controls (Wiercinska-Drapalo et al. 2008). This study found 
I-FABP levels were highest in patients with pancolitis (Montreal classification E3) but 
patients with distal UC (Montreal classification E2) had levels similar to controls. In our 
study the active UC group was mostly comprised of patients with distal UC and only 
4/15 had pancolitis, which may explain the differences in results.  
 
We saw no increase in microbial products (measured by 16s rDNA and endotoxin) in the 
systemic circulation of active UC patients. This result supports early work in the DSS-
induced colitic mouse model (Axelsson et al. 1996) which only found low and varied 
levels of endotoxin, measured by the LAL assay, in mice with severe colitis. However 
our findings are in contrast to other work that found bacterial DNA in patients with 
active and inactive UC but no detectable levels in healthy controls (Gutiérrez et al. 
2009). Serum LPS has also been found in UC patients, though different studies report 
varying percentage positivity amongst patient groups ranging from 17% (Caradonna et 
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al. 2000) to 88% (Caradonna et al. 2000). Differences between previously published 
reports may be due to the use of the LAL assay to measure LPS, this assay has technical 
issues and is affected by interfering and enhancing factors in complex media such as 
plasma. We were unable to validate this method in our plasma samples (see appendix) 
and instead used a novel assay that utilized a TLR4/MD2/CD14 cell line to measure 
endotoxin in serum samples. 
 
We did find significantly raised levels of the acute phase reactant and indirect microbial 
translocation marker LBP in active UC. Previous studies have shown elevated LBP in the 
setting of high endotoxin concentrations in active UC patients (Pastor Rojo et al. 2007). 
Similar to our results this study found LBP and endotoxin levels were similar to controls 
in inactive disease. One other study has found raised LBP in the absence of LPS similar to 
our work (Funderburg et al. 2013). LBP binds LPS and either transfers it to high-density 
lipoproteins to decrease its bioactivity or to the TLR4/CD14/MD2 complex leading to 
LPS-mediated stimulation (Brenchley and Douek 2012). Increased levels of circulating 
LBP can protect against gram-negative septicaemia (Lamping et al. 1998). LBP has a 
longer half-life than LPS and is thought to reflect long-term exposure to endotoxin 
rather than current endotoxin exposure itself, which may explain its elevation in the 
absence of measurable bacterial product in our work. We saw no association between 
disease severity score and LBP levels in contrast to another study (Pastor Rojo et al. 
2007) which may be due to the use of different UC scoring systems. 
 
To assess localised microbial translocation we stained our biopsies with an anti-LPS 
antibody and assessed its expression in the lamina propria. We found LPS in the lamina 
propria of 35% of our UC group compared to 59% of our controls. However, TLR4 
expression is known to be upregulated on IBD intraepithelial lymphocytes and TLR4+ 
marcophages are increased in the lamina propria, so it is possible that there is increased 
recognition of LPS leading to increased immune activation in the IBD setting (Cario and 
Podolsky 2000).  
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Similar to other studies we saw no increase in sCD14 in active UC (Pasternak et al. 
2010, Funderburg et al. 2013). We also found no difference in sCD163 levels, which is 
shed from activated tissue macrophages and monocytes and functions to inhibit T cell 
activation. An earlier study found elevated CD163+ cells at the site of active 
inflammation in IBD and elevated expression on circulating monocytes (Franzè et al. 
2013). Recently CD163 has been shown to bind both gram-positive and negative bacteria 
and induce proinflammatory cytokine production (Fabriek et al. 2009). Although soluble 
CD163 has been identified as a useful indicator of histological lesions in coeliac disease 
(Daly et al. 2006) it has not been widely studied in IBD.  
 
We observed raised HLA DR+CD38+ expression on peripheral CD8 T cells in active 
disease supporting previous work (Funderburg et al. 2013). In contrast we saw 
significantly reduced CD4 T cell activation in inactive disease compared to controls and 
active disease, perhaps as a result of effective immune suppression. CD8 T cell activation 
was positively associated with UCSS. 
 
There was a positive association between disruption in claudin 4 staining and LBP levels 
in active UC patients. Claudin 4 disruption was also associated with sCD14 levels, 
although this marker was not elevated compared to controls. Together these results 
support a role for tight junction dysregulation in microbial translocation and peripheral 
immune activation in UC. 
 
We saw a significant positive association between precursor TH17 cells in the mucosa of 
active UC patients with disruption to all tight junctions measured, there was also a 
positive correlation between blood precursor TH17 with CD8 T cell activation. This 
data suggests a role for the precursor TH17 cell in mucosal damage and peripheral 
immune activation. In support of the association between TH17 cells and mucosal 
damage we found evidence from longitudinal data in two patients that IL-17a and IL-17f 
together with I-FABP reduce after successful treatment. LBP levels also correlated with 
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production of TNF by blood CD4 and CD8 T cells in active disease supporting a role for 
this inflammatory cytokine in disease pathogenesis. This data is supported by clinical 
studies demonstrating the successful use of anti-TNF monoclonals in the treatment of 
UC. 
 
5.11.3 Limitations 
 
In addition to the general limitations discussed in previous chapters, as most of our UC 
patients were on immunosuppressive treatment it is unclear to what extent therapy is 
altering or repairing T cell subset and cytokine dysregulation compared to controls.  
 
5.11.4 Future Work 
 
Future studies would examine the extent other TH subsets play in UC pathogenesis such 
as TH2 (IL-13) and TH9 (IL-9) compared to TH17 cells. Other mucosal cells capable of 
producing TH17 cytokines should also be examined. More tight junctions could be 
assessed and their transcription levels measured. 
 
5.11.5 Conclusions 
 
In conclusion we found elevated TH17-associated cytokines in the mucosa of UC patients 
that positively correlated with disease state. We found evidence of disruption to tight 
junction proteins, which correlated to the microbial translocation marker LBP as well as 
to precursor TH17 frequency. This supports a role for precursor TH17 cells in mucosal 
damage, elevated microbial translocation and immune activation. 
 198 
Chapter 6  T cells, microbial translocation and 
mucosal damage in Crohn’s disease 
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6.1 Introduction 
 
Crohn’s disease (CD) involves discrete patches of gut inflammation that can occur in any 
region of the gastrointestinal tract but are usually seen in the ileum and colon. Unlike 
UC, CD inflammation is transmural and associated with intestinal granulomas, fistulas 
and strictures. In the UK the prevalence of CD is around 145 per 100 000 adults (Rubin 
et al. 2000). CD is usually diagnosed when a patient is 20-30 years old, a decade younger 
than UC, and it is more common in females (Cosnes et al. 2011). 
 
In contrast to UC, smoking and appendectomy are risk factors for the development of 
CD together with a western diet and social stress. The gut microbiome has been 
implicated in both UC and CD pathogenesis with mouse models only developing 
intestinal inflammation in the presence of bacteria. In support of this, probiotics and 
antibiotics have been shown to ameliorate IBD in some cases (Corridoni et al. 2014).   
 
Genetic mutations specific for CD include those involved in phagocytosis, innate 
immunity and autophagy. NOD2 polymorphisms in CD patients may enhance gut 
inflammation by reducing antibacterial peptide production. Other NOD2 mutants may 
reduce inhibition of TLR2 resulting in increased TH1 responses, or inhibit IL-10 and 
immune regulation (Geremia et al. 2014). Defects in mucosal barrier defense including 
reduced secretory IgA, reduced mucin production and reduced expression of the 
antimicrobial peptides β-defensins have been found in CD. Increased paracellular 
permeability, a measure of barrier disruption, is seen in CD patients and in their first-
degree unaffected relatives (Peeters et al. 1997). The increased intestinal permeability in 
CD is accompanied by increased bacterial translocation to mesenteric lymph nodes 
(Matricon et al. 2010) and into systemic circulation (Pastor Rojo et al. 2007, Pasternak 
et al. 2010). 
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GWAS studies have identified polymorphisms in genes associated with the TH17 subset 
in both CD and UC. However the role of this subset in IBD is controversial, with some 
studies showing a pathogenic role and others demonstrating a protective role (Gálvez 
2014). 
 
In this chapter we sought to investigate the relationship between TH17 cells, tight 
junction disruption, the translocation of bacterial products and systemic immune 
activation in CD patients.  
 
6.1.1 Aims 
• Assess differences in TH17 cell proportions and cytokine pattern in active and 
inactive CD.  
• Measure CD4 and CD8 phenotype and cytokine responses to SEB. 
• Determine the level of disruption in tight junction protein staining in active and 
inactive CD. 
• Assess the levels of microbial translocation and immune activation in CD and 
determine whether mucosal TH17 cells associate with the level of mucosal 
damage and immune dysregulation.  
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6.2 Patient Characteristics 
 
We divided our Crohn’s disease patients into two groups using the Harvey-Bradshaw 
Index (HBI). Patients with a HBI score greater than 5 were assigned into the Active CD 
group, patients with a score less than 5 were identified as Inactive CD patients. In our 
Active CD group we had 6/8 patients with rectal involvement, in the Inactive CD group 
we included 5/12 patients who had never experienced rectal involvement (nriCD). One 
patient in the Active CD group provided blood but not mucosal samples. 
 
We included repeat data from a patient who was sampled a year after the first 
colonoscopy. The first visit was classified in the Active CD group (HBI=6) and the 
second sample into the Inactive CD group with a HBI score of 4 after TNF therapy. We 
also included repeat data from a patient in remission on the initial visit (HBI=0) and then 
1.5 years later with active disease (HBI=8). 
 
3 of our active CD cohort had been treated with both azathioprine and anti-TNF therapy, 
2 patients had never been treated. In the inactive CD group 3 patients had been treated 
with anti-TNF, 3 different patients treated with azathioprine and 5 patients had never 
been treated. The age of our active CD cohort was similar to the inactive CD group but 
both groups were significantly younger than our control cohort. We also had 
significantly more females in both our CD group compared to controls. 
 
Blood CD4 absolute counts were significantly elevated in the Inactive CD group 
compared to controls (HC=524, Active CD=851, Inactive CD=935 cells/µl, 
p=0.0298) but we observed no difference in absolute CD8 counts (HC=342, Active 
CD=341, Inactive CD=444 cells/µl). There was a trend for increased CD4/CD8 ratios 
in the Active CD group compared to controls that did not reach significance (HC=1.60, 
Active CD=2.60, Inactive CD=2.00, p=0.0871).    
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 HC (n=22) Active CD  
(n=8) 
Inactive CD 
(n=12) 
p value 
Age in years 47 (40–55) 29 (24-34) 35 (27-39) <0.0001a 
Gender F:M 3:19 6:2 7:5 0.0029 b 
CD4 cells/µl 524 (460 - 827) 851 (579 - 963) 935 (617 - 1073) 0.0298 c 
CD8 cells/µl 342 (268 - 463) 341 (247 - 403) 444 (279 - 586) ns 
CD4:CD8  1.60 (1.08 - 2.05) 2.60 (1.90 - 3.50) 2.00 (1.45 - 2.70) ns 
Months since 
diagnosis 
- 82.00  
(32.25-117.75) 
108.00 
(46.00-140.75) 
ns 
Treatment 
Steroids: n (%) 
AZA/E: n (%) 
5ASA: n (%) 
Anti-TNF: n (%) 
-  
0  
4 (50%) 
2 (25%) 
4 (50%) 
 
0  
2 (17%) 
3 (25%) 
3 (25%) 
 
IBD Score 
HBI 
Active/Inactive 
Colon 
Montreal A 
A1 
A2 
A3 
Montreal L 
L2  
L3 
L4 
Montreal 
B1 
B2 
B3 
-  
>5 
6/2 
 
0 
0 
8  
 
5 
2 
1 
 
4  
2 
2 
 
<5 
1/11 
 
1 
10 
1 
 
6 
6 
0 
 
8 
2 
2 
 
Table 6-1 CD patient characteristics. Median values with interquartile results are shown 
 
a HC vs. Active CD p=<0.0001post correction, HC vs. Inactive CD p=0.0028. b Chi-squared 11.66, p=0.0029. 
c HC vs. Inactive CD p=0.0290. 
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6.3 T cell Subsets  
6.3.1 CD4 and CD8 Percentage and Phenotype 
 
Percentage CD4 T cells in blood and mucosa were similar between HC and CD groups 
(Figure 6-1). In active CD we saw significantly reduced CD4 T cells in the mucosa 
compared to the blood (p=0.0156). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6-1 CD4 T cell percentages in the blood and mucosa of HC and CD patients. Green circles=HC blood, pink 
triangles=Active CD blood, pink diamonds=Inactive CD blood, green squares=HC MMC, inverted pink 
triangles=Active CD MMC, pink rings=Inactive CD MMC. Differences between groups were calculated using 
Kruskal Wallis with Dunn’s post-test correction, comparisons between PBMC and MMC within groups were 
performed using Wilcoxon matched-pairs signed rank test. MMC/PBMC ratios HC=0.98, Active CD=0.84, 
Inactive CD=0.94). 
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We also found no differences in the frequency of CD8 T cells in the blood or mucosa 
between controls and CD patients (Figure 6-2). Healthy controls had significantly 
reduced CD8 T cells in the mucosa compared to blood (p=0.0172) but this pattern was 
reversed in active CD (p=0.0156) and the MMC/PBMC ratio of CD8 T cells was 
significantly raised in Active CD compared to controls (HC=0.80, Active CD=1.39, 
Inactive CD=0.83, p=0.0069). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6-2 CD8 T cell percentages in the blood and mucosa of HC and CD patients. Green circles=HC blood, pink 
triangles=Active CD blood, pink diamonds=Inactive CD blood, green squares=HC MMC, inverted pink 
triangles=Active CD MMC, pink rings=Inactive CD MMC. Differences between groups were calculated using 
Kruskal Wallis with Dunn’s post-test correction, comparisons between PBMC and MMC within groups were 
performed using Wilcoxon matched-pairs signed rank test  (**=<0.01). 
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Active CD patients had significantly raised naïve CD4 T cells in the blood (HC=54.60%, 
Active CD=69.05%, Inactive CD=65.10%, p=0.0187, Figure 6-3) and we saw reduced 
central memory T cells in CD that lost significance post correction. There was no 
difference between groups in the proportion of effector memory or terminally 
differentiated CD4 T cells (Table 6-2). In the mucosa we observed a trend for increased 
naïve CD4 T cells in CD that did not reach significance (HC=8.02%, Active 
CD=16.00%, Inactive CD=21.00%, p=0.0579) but saw no differences between 
proportions of central memory, effector memory or terminally differentiated CD4 T 
cells (Table 6-2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6-3 Naïve and central memory CD4 percentages in blood and mucosa of HC and CD. Differences between 
groups were calculated using Kruskal-Wallis with Dunn’s post-test correction (*=<0.05). 
 
Blood naïve CD8 T cells were significantly increased in both active and inactive CD 
patients compared to controls (HC=48.20%, Active CD=79.60%, Inactive 
CD=68.90%, p=0.0004, Figure 6-4) and central memory CD8 proportions were 
significantly reduced in CD compared to controls (HC=23.00%, Active CD=10.23%, 
Inactive CD=10.75%, p=0.0026). There was a trend for reduced effector memory CD8 
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T cells that did not reach significance. In the mucosa we found a significant reduction in 
central memory CD8 T cells in inactive CD compared to controls (HC=37.40%, Active 
CD=30.80%, Inactive CD=24.35%, p=0.0229). 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6-4 Naïve and central memory CD8 percentages in blood and mucosa of HC and CD. Differences between 
groups were calculated using Kruskal-Wallis with Dunn’s post-test correction (*=<0.05, **=<0.01). 
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 Site Subset HC Active CD Inactive CD p value 
 
T cells 
(%CD3) 
PBMC CD4 64.10 
(53.00-74.45) 
72.95 
(61.94-82.71) 
63.20 
(59.50-75.06) 
ns 
CD8 27.95 
(20.50-36.61) 
21.30 
(14.14-29.55) 
29.25 
(20.66-33.79) 
ns 
MMC CD4 64.78 
(56.66-70.59) 
62.40 
(44.15-74.50) 
61.53 
(53.98-65.81) 
ns 
CD8 22.20 
(16.99-27.95) 
25.05 
(20.80-34.75) 
24.85 
(18.18-32.56) 
ns 
 
Naïve  
PBMC %CD4 54.60 
(35.30-66.90) 
69.05 
(63.60-82.78) 
65.10 
(52.35-76.68) 
0.0187
a
 
%CD8 48.20 
(33.13-61.53) 
79.60 
(72.15-86.18) 
68.90 
(46.13-84.43) 
0.0004
 b
 
MMC %CD4 8.02 
(4.49-13.20) 
16.00 
(12.50-24.70) 
21.00 
(3.61-26.60) 
ns 
%CD8 12.10 
(5.52-17.15) 
16.40 
(9.99-38.30) 
19.90 
(8.38-26.00) 
ns 
 
Terminally 
diff.  
PBMC %CD4 0.83 
(0.37-3.40) 
0.41 
(0.22-0.75) 
0.43 
(0.27-2.27) 
ns 
%CD8 9.60 
(1.59-32.05) 
5.87 
(3.38-11.59) 
6.87 
(2.77-17.53) 
ns 
MMC %CD4 4.15 
(1.63-6.81) 
4.19 
(2.14-12.60) 
5.54 
(2.49-6.09) 
ns 
%CD8 11.70 
(5.33-18.50) 
9.45 
(8.15-30.20) 
16.20 
(12.00-23.70) 
ns 
 
Central 
Memory  
PBMC %CD4 38.95 
(28.25-50.80) 
28.25 
(15.43-32.45) 
31.80 
(16.10-37.98) 
0.0413
 c
 
%CD8 23.00 
(13.38-38.23) 
10.23 
(9.29-14.15) 
10.75 
(6.59-20.38) 
0.0026
 d
 
MMC %CD4 62.00 
(52.80-74.15) 
53.80 
(42.90-59.20) 
53.30 
(43.90-68.30) 
ns 
%CD8 37.40 
(27.60-57.70) 
30.80 
(20.20-33.90) 
24.35 
(16.13-34.20) 
0.0229
 e
 
 
Effector 
Memory  
PBMC %CD4 3.96 
(2.83-7.42) 
2.86 
(1.59-4.67) 
3.52 
(1.52-5.38) 
ns 
%CD8 5.99 
(3.63-7.04) 
2.78 
(0.87-3.56) 
2.62 
(1.37-8.85) 
0.0442
 f
 
MMC %CD4 20.70 
(15.40-30.25) 
22.50 
(19.80-28.50) 
21.90 
(8.47-41.90) 
ns 
%CD8 33.60 
(24.45-43.30) 
34.70 
(22.40-48.30) 
27.85 
(7.92-52.63) 
ns 
Table 6-2 T cell percentages and phenotype in controls and CD patients. Median values with interquartile ranges 
are reported, p values represent results from Kruskal-Wallis test. 
a HC vs. active CD p=0.0390post correction(pc). b HC vs. active CD p=0.0011pc, HC vs. inactive CD 
p=0.0218pc. c no significance post correction. d HC vs. active CD p=0.00202pc, HC vs. inactive CD 
p=0.0122pc. e HC vs. Inactive CD p=0.0266pc. f no significance post correction. 
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6.4 TH17 cells 
6.4.1 Precursor TH17 and TH17 cells 
 
Precursor TH17 levels in the blood and in the mucosa were similar across the groups 
(Figure 6-5). There was also no difference between groups in the frequency of TH17 
(CD4+IL-17a+) in the blood and mucosa of CD patients and controls (Figure 6-6). 
 
 
 
 
 
Figure 6-5 Precursor TH17 cells in the blood and mucosa of controls and CD patients. 
 
 
Figure 6-6 TH17 frequency in the blood and mucosa of controls and CD patients. Differences between groups were 
calculated using Kruskal-Wallis with Dunn’s post-test correction. 
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6.4.2 TH17 Phenotype 
 
The proportion of TH17 cells with memory, naïve and terminally differentiated 
phenotype was similar in CD patients and controls in the blood and the mucosa (Table 
6-3).  
 
6.4.3 TH17 Functionality 
 
The majority of TH17 cells in the blood and mucosa of HC and CD patients produced 
either IL-2 with TNF or TNF only. We found no significant differences between groups 
in the pattern of cytokine production by TH17 cells in the blood and mucosa (Figure 
6-7).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6-7 SPICE plots showing polyfunctional TH17 cells in the blood and mucosa of controls and CD patients 
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6.4.4 TH17TH1 cells 
 
The frequency of CD4 T cells capable of producing IL-17a with IFNγ was similar in CD 
patients and controls in both the blood and mucosa (Figure 6-8).   
 
 
 
 
 
 
Figure 6-8 TH17TH1 frequency in blood and mucosa of CD and HC patients. Differences between groups were 
calculated using Kruskal-Wallis with Dunn’s post-test correction 
 
6.4.5 IL-17f+ CD4 T cells 
 
IL-17f+CD4+ percentages were significantly raised in the blood of inactive CD patients 
compared to controls (HC=0.00%, Active CD=0.03%, Inactive CD=0.11%, 
p=0.0251). This was also found in the CD4 effector memory subset (Table 6-3) but we 
observed no differences between groups in the mucosa (Figure 6-9). 
 
 
 
 
 
 
Figure 6-9 IL-17f production by CD4 T cells in the blood and mucosa of CD patients and controls. Differences 
between groups were calculated using Kruskal-Wallis with Dunn’s post-test correction 
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6.4.6 Tc17 cells 
 
CD8 production of IL-17a and IL-17f was mostly absent in controls and CD patients. In 
the mucosa we saw more IL-17a production by CD8 T cells compared to blood but no 
significant differences between groups (Table 6-3). 
 
6.5 IL-22+ CD4 and TH22 cells 
 
We found no differences in IL-22 production by CD4 T cells between controls and CD 
patients in the blood or mucosa. Neither did we find differences in the proportion of 
CD161-IL-22+ CD4 T cells (TH22) between groups in mucosal or blood CD4 T cells 
(Figure 6-10). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6-10  IL-22+CD4+ and TH22 production in PBMC and MMC of controls and CD patients. Differences 
between groups were calculated using Kruskal-Wallis with Dunn’s post-test correction 
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 Site Subset HC Active CD Inactive CD p value 
 
 
 
CD161 
 
PBMC %CD4 10.11 
(7.84-14.21) 
7.01 
(6.89-12.97) 
9.47 
(4.77-16.41) 
ns 
%CM 22.60 
(15.10-27.85) 
20.05 
(16.25-33.25) 
24.00 
(14.00-33.20) 
ns 
%EM 25.60 
(15.30-30.85) 
28.80 
(17.18-33.50) 
32.60 
(17.20-38.60) 
ns 
MMC %CD4 62.37 
(52.36-68.85) 
45.52 
(43.54-69.19) 
63.52 
(50.79-69.80) 
ns 
%CM 62.55 
(53.30-67.38) 
58.60 
(51.60-68.10) 
64.30 
(54.75-68.45) 
ns 
%EM 78.45 
(68.20-82.35) 
79.60 
(65.50-83.90) 
78.45 
(76.75) 
ns 
 
 
 
IL-17a 
 
PBMC %CD4 0.32 
(0.14-0.44) 
0.25 
(0.08-0.34) 
0.32 
(0.13-0.40) 
ns 
%CM 0.45 
(0.25-0.67) 
0.46 
(0.24-0.87) 
0.62 
90.44-0.72) 
ns 
%EM 1.55 
(0.69-1.91) 
1.40 
(0.92-4.68) 
1.81 
(0.76-3.00) 
ns 
MMC %CD4 1.05 
(0.80-1.40) 
0.79 
(0.60-1.57) 
1.16 
(0.47-1.79) 
ns 
%CM 0.94 
(0.75-1.51) 
1.02 
(0.44-1.56) 
1.43 
(0.74-2.03) 
ns 
%EM 2.00 
(1.61-3.77) 
1.52 
(1.19-5.07) 
3.26 
(1.03-4.90) 
ns 
IFNγ PBMC %TH17 9.13 
(5.55-14.25) 
8.65 
(4.66-18.00) 
10.45 
(7.64-17.83) 
ns 
IL-2 %TH17 50.20 
(43.65-64.80) 
54.50 
(42.50-57.90) 
52.50 
(43.68-63.28) 
ns 
TNF %TH17 85.70 
(74.45-90.25) 
85.00 
(74.60-94.10) 
85.10 
(82.48-86.40) 
ns 
IFNγ MMC %TH17 8.76 
(5.88-14.00) 
8.09 
(4.61-18.20) 
5.24 
(2.78-22.00) 
ns 
IL-2 %TH17 39.20 
(34.60-51.00) 
50.80 
(21.00-53.45) 
25.55 
(15.88-47.13) 
ns 
TNF %TH17 87.10 
(76.70-91.50) 
82.60 
(67.20-87.45) 
68.20 
(55.53-83.73) 
ns 
TH17TH1 PBMC %CD4 0.03 
(0.00-0.07) 
0.03 
(0.01-0.10) 
0.03 
(0.02-0.06) 
ns 
MMC %CD4 0.09 
(0.07-0.18) 
0.07 
(0.03-0.17) 
0.19 
(0.03-0.57) 
ns 
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Table 6-3 TH17 and TH22 frequency in CD and HC. Medians with interquartile ranges are reported.  a HC vs. 
Inactive CD p=0.0218 post correction (pc).   b HC vs. Inactive CD p=0.0178 pc.     
 Site Subset HC Active CD Inactive CD p value 
 
 
IL-17f 
 
PBMC %CD4 0.00 
(0.00-0.07) 
0.03 
(0.00-0.16) 
0.11 
(0.05-0.15) 
0.0251
a
 
%CM 0.05 
(0.02-0.11) 
0.12 
(0.03-0.25) 
0.08 
(0.06-0.16) 
ns 
%EM 0.21 
(0.17-0.58) 
0.47 
(0.14-1.24) 
1.00 
(0.52-1.44) 
0.0225
 b
 
MMC %CD4 0.13 
(0.00-0.16) 
0.14 
(0.09-0.26) 
0.06 
(0.00-0.13) 
ns 
%CM 0.09 
(0.04-0.15) 
0.15 
(0.00-0.22) 
0.04 
(0.00-0.13) 
ns 
%EM 0.25 
(0.10-0.43) 
0.26 
(0.16-0.88) 
0.30 
(0.11-0.41) 
ns 
IL-17a PBMC %CD8 0.00 
(0.00-0.00) 
0.00 
(0.00-0.00) 
0.00 
(0.00-0.05) 
ns 
MMC %CD8 0.06 
(0.00-0.28) 
0.21 
(0.00-1.77) 
0.10 
(0.00-0.40) 
ns 
IL-17f PBMC %CD8 0.00 
(0.00-0.00) 
0.00 
(0.00-0.00) 
0.00 
(0.00-0.00) 
ns 
MMC %CD8 0.00 
(0.00-0.03) 
0.00 
(0.00-0.06) 
0.00 
(0.00-0.00) 
ns 
 
 
 
IL-22 
 
PBMC %CD4 0.12 
(0.00-0.19) 
0.09 
(0.02-0.25) 
0.14 
(0.06-0.23) 
ns 
%CM 0.18 
(0.08-0.32) 
0.24 
(0.12-0.62) 
0.24 
(0.10-0.33) 
ns 
%EM 0.50 
(0.22-0.96) 
0.74 
(0.44-1.38) 
1.27 
(0.42-1.57) 
ns 
MMC %CD4 0.60 
(0.34-0.78) 
0.75 
(0.49-1.03) 
0.63 
(0.17-1.33) 
ns 
%CM 0.48 
(0.31-0.64) 
0.33 
(0.07-0.91) 
0.35 
(0.15-1.35) 
ns 
%EM 0.98 
(0.61-1.24) 
1.99 
(0.89-2.40) 
1.59 
(0.71-2.04) 
ns 
IL-22 PBMC %CD8 0.00 
(0.00-0.00) 
0.00 
(0.00-0.00) 
0.00 
(0.00-0.05) 
ns 
MMC %CD8 0.09 
(0.00-0.14) 
0.16 
(0.10-0.69) 
0.05 
(0.00-0.09) 
ns 
TH22 PBMC %CD4 0.06 
(0.00-0.12) 
0.03 
(0.00-0.09) 
0.06 
(0.00-0.11) 
ns 
MMC %CD4 0.12 
(0.00-0.20) 
0.16 
(0.00-0.39) 
0.08 
(0.00-0.12) 
ns 
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6.6 CD4 and CD8 Cytokine Responses to SEB 
 
We saw no difference in the ability of CD4 T cells to secrete IFNγ or IL-2 in the blood of 
CD patients compared to controls. There was reduced TNF secretion by CD4 T cells in 
CD that lost significance post correction (HC=6.91%, Active CD=3.86%, Inactive 
CD=3.69%, p=0.0392, Figure 6-11). 
 
 
Figure 6-11 Cytokine production by blood CD4 T cells in HC and CD. Differences between groups were calculated 
using Kruskal-Wallis with Dunn’s post-test correction. 
 
In the mucosa TNF production by CD4 T cells was also reduced in CD patients but 
similar to the blood this lost significance post correction (HC=12.51%, Active 
CD=8.68%, Inactive CD=9.05%, p=0.0326, Figure 6-12). We found no differences in 
mucosal in IFNγ or IL-2 production by CD4 T cells (Table 6-4).  
 
Figure 6-12 Cytokine produciton by mucosal CD4 T cells in HC and CD. 
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Blood and mucosal CD8 production of IFNγ, IL-2 and TNF was similar between CD 
patients and controls (Figure 6-13).  
 
 
Figure 6-13 Blood and mucosal CD8 production of inflammatory cytokines in HC and CD patients. Differences 
between groups were calculated using Kruskal-Wallis with Dunn’s post-test correction 
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 Site Subset  HC Active CD Inactive 
CD 
p Value 
 
 
 
 
IFNγ 
PBMC  
CD4 
%CD4 1.35 
(0.50-3.13) 
0.66 
(0.20-1.17) 
1.06 
(0.34-1.39) 
ns 
%CM 1.97 
(0.75-4.62) 
1.77 
(0.49-2.12) 
1.51 
(1.19-2.82) 
ns 
%EM 6.62 
(1.89-9.62) 
2.70 
(1.61-11.18) 
6.92 
(2.07-10.19) 
ns 
 
CD8 
%CD8 2.61 
(1.16-4.97) 
2.66 
(0.89-3.64) 
3.19 
(1.26-4.84) 
ns 
%CM 3.88 
(1.92-5.60) 
4.95 
(1.41-6.63) 
7.14 
(3.12-11.50) 
ns 
%EM 4.29 
(3.18-9.69) 
5.10 
(1.49-9.55) 
7.06 
(3.93-29.98) 
ns 
MMC  
CD4 
%CD4 2.99 
(2.14-3.64) 
1.49 
(1.18-2.39) 
2.75 
(1.74-5.63) 
ns 
%CM 3.08 
(2.17-4.02) 
2.23 
(1.01-2.89) 
3.36 
(1.63-5.91) 
ns 
%EM 4.58 
(2.26-6.08) 
2.27 
(1.12-6.67) 
6.53 
(1.94-8.52) 
ns 
 
CD8 
%CD8 4.04 
(3.24-6.44) 
2.63 
(1.51-7.39) 
5.58 
(3.84-6.55) 
ns 
%CM 5.20 
(4.17-7.67) 
5.26 
(2.86-15.10) 
7.46 
(4.26-9.04) 
ns 
%EM 3.65 
(2.59-6.09) 
2.14 
(0.96-3.68) 
6.36 
(2.63-11.51) 
ns 
 
 
 
 
IL-2 
 
 
PBMC  
CD4 
%CD4 3.39 
(1.04-4.59) 
1.83 
(0.82-3.09) 
2.02 
(0.87-2.57) 
ns 
%CM 6.41 
(2.64-7.80) 
4.76 
(2.22-5.97) 
4.51 
(3.11-5.21) 
ns 
%EM 8.72 
(3.48-12.44) 
7.50 
(5.01-12.62) 
7.31 
(4.31-11.53) 
ns 
 
CD8 
%CD8 0.83 
(0.43-1.74) 
0.47 
(0.08-0.88) 
0.63 
(0.20-1.33) 
ns 
%CM 2.43 
(1.01-4.15) 
2.60 
(0.64-3.94) 
2.68 
(1.07-4.50) 
ns 
%EM 1.61 
(0.53-3.22) 
0.88 
(0.35-2.78) 
1.72 
(0.47-5.27) 
ns 
MMC  
CD4 
%CD4 4.12 
(3.09-5.20) 
2.98 
(0.91-3.54) 
2.68 
(2.01-5.43) 
ns 
%CM 4.60 
(3.02-5.80) 
4.30 
(1.02-4.57) 
2.76 
(2.32-4.44) 
ns 
%EM 5.22 
(3.83-7.07) 
2.54 
(1.52-8.14) 
5.09 
(2.51-6.72) 
ns 
 
CD8 
%CD8 1.95 
(0.95-3.45) 
1.12 
(0.53-4.00) 
0.99 
(0.48-2.31) 
ns 
%CM 2.37 
(1.32-4.27) 
1.95 
(0.77-6.43) 
1.48 
(0.32-3.11) 
ns 
%EM 2.29 
(1.00-3.34) 
0.96 
(0.84-3.25) 
1.69 
(0.64-3.22) 
ns 
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TNF 
 
 
PBMC  
CD4 
%CD4 6.91 
(3.87-10.65) 
3.86 
(1.62-6.17) 
3.67 
(2.37-5.45) 
0.0392a 
%CM 11.27 
(5.22-12.87) 
7.80 
(4.13-9.27) 
7.85 
(5.31-8.95) 
ns 
%EM 16.45 
(13.03-21.45) 
10.65 
(8.03-23.60) 
13.95 
(10.12-23.17) 
ns 
 
CD8 
%CD8 5.94 
(3.20-11.05) 
3.91 
(1.24-6.67) 
5.03 
(1.58-7.41) 
ns 
%CM 9.38 
(4.84-11.80) 
8.67 
(3.95-12.95) 
10.39 
(5.82-16.08) 
ns 
%EM 17.80 
(8.27-21.15) 
5.49 
(3.43-17.15) 
12.10 
(9.31-39.98) 
ns 
MMC  
CD4 
%CD4 12.51 
(10.46-14.80) 
8.68 
(5.05-12.02) 
9.05 
(6.07-14.48) 
0.0326 b 
%CM 13.40 
(11.40-15.05) 
10.60 
(4.42-12.50) 
10.80 
(5.91-13.50) 
ns 
%EM 16.30 
(12.65-20.10) 
16.00 
(7.58-18.30) 
15.90 
(7.68-24.60) 
ns 
 
CD8 
%CD8 11.19 
(8.76-13.02) 
8.18 
(3.22-9.36) 
10.26 
(7.10-11.62) 
ns 
%CM 13.40 
(8.69-16.15) 
12.70 
(4.92-15.80) 
10.70 
(6.97-16.20) 
ns 
%EM 10.90 
(9.43-14.30) 
6.43 
(5.88-11.90) 
11.05 
(6.72-19.43) 
ns 
Table 6-4 Cytokine production by blood and mucosal T cell subsets of HC and CD patients. Median values with 
interquartile ranges are reported. aNo significance post correction. bNo significance post correction. 
 
6.6.1 CD4 and CD8 polyfunctional cytokine responses to SEB 
 
We next assessed the ability of responding T cells to produce IFNγ, IL-2 and TNF 
together. In the blood we found no difference between proportions of polyfunctional 
CD4 between groups (HC=0.74%, Active CD=0.50%, Inactive CD=0.53%, Figure 
6-14) but we saw a significant reduction in mucosal polyfunctional CD4 T cells 
(HC=1.65%, Active CD=0.84%, Inactive CD=1.15%, p=0.0419). There was no 
difference between groups in blood (HC=0.31%, Active CD=0.30%, Inactive 
CD=0.36%) or mucosal (HC=1.18%, Active CD=0.41%, Inactive CD=0.89%) CD8 
polyfunctional T cells. 
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Figure 6-14 Polyfunctional T cells in blood and mucosa of HC and CD patients. Differences between groups were 
calculated using Kruskal-Wallis with Dunn’s post-test correction (*=p<0.05). 
 
Using SPICE we looked at the distribution of responding T cells producing combinations 
of IFNγ, IL-2 and TNF. We found no difference in the overall responding CD4 T cell 
cytokine pattern in blood or mucosa between groups (Figure 6-15). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6-15 SPICE pie charts showing polyfunctional CD4 cytokines in blood and mucosa of CD patients and HC. 
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We did see a significant difference in the pattern of cytokine production in responding 
CD8 T cells in the blood between groups that was associated with reduced CD8 T cells 
solely producing TNF in both CD groups and reduced IFNγ-IL-2+TNF+ CD8 T cells in 
inactive disease compared to controls (p=0.0013, Figure 6-16). Mucosal CD8 cytokine 
patterns of production were similar across groups.  
 
 
 
 
 
 
 
 
 
 
 
Figure 6-16 SPICE pie charts showing polyfucntional CD8 cytokine response in blood and mucosa of controls and 
CD patients. 
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6.7 Mucosal Damage in CD 
 
We found no significant differences between serum intestinal fatty acid binding protein 
levels and CD patients or controls (HC=304.61, Active CD=199.97, Inactive 
CD=170.77 ng/ml, Figure 6-17).  
 
 
 
 
 
 
Figure 6-17 I-FABP levels in CD patients and HC. Differences between groups were calculated using Kruskal-Wallis 
with Dunn’s post-test correction 
 
We did see significant increases in breach:intact ratios of the tight junction protein 
Claudin 1 in both CD groups compared to controls (HC=0.25, Active CD=1.83, 
Inactive CD=1.50, p=0.0003, Figure 6-18) but there was no significant evidence of 
disruption to claudin 4 or occludin. I-FABP and Claudin 4 B:I ratios were correlated in 
CD (p=0.019, rs=0.560, not shown). 
 
Figure 6-18 Tight junction disruption in CD patients and healthy controls. Comparisons between groups were 
performed using Kruskal-Wallis with Dunn’s post-test correction (*=p<0.05, ***=p<0.001). 
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6.8 Microbial Translocation in CD  
 
Plasma LPS binding protein (LBP) was raised in active CD compared to controls 
(HC=12.42, Active CD=18.37, Inactive CD=19.30, p=0.0110) but in contrast we 
found significantly less 16s rDNA in the plasma of CD patients (HC=24.11, Active 
CD=4.63, Inactive CD=11.70 copies/ml, p=0.0089) and no difference between serum 
levels of endotoxin between groups (HC=0.22, Active CD=0.12, Inactive CD=0.13 
IU/ml, Figure 6-19).  
 
Figure 6-19 Microbial translocation markers in CD. Differences between groups were calculated using Kruskal-
Wallis with Dunn’s post-test correction (*=p<0.05). 
 
There was evidence of LPS translocation into the lamina propria in 11/18 CD patients 
studied (61%, Figure 6-20), a similar proportion to healthy controls (13/22, 59%). 
There was no difference in LPS translocation between the active and inactive CD groups 
and no association between LPS staining and other markers of microbial translocation.  
 
 
 
 
 
 
 
Figure 6-20 Example LPS staining in CD lamina propria by immunohistochemistry (x250 magnification) 
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6.9 Immune Activation in CD 
 
We found no evidence of elevated peripheral CD4 or CD8 T cell activation in active or 
inactive CD compared to controls (Figure 6-21). We also found no evidence of increased 
monocyte activation in CD patients compared to controls (Figure 6-22). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6-21 Peripheral T cell activation in controls and CD patients. Differences between groups were calculated 
using Kruskal-Wallis with Dunn’s post-test correction 
 
 
 
 
 
 
 
Figure 6-22 Monocyte activation markers in controls and CD patients. Differences between groups were calculated 
using Kruskal-Wallis with Dunn’s post-test correction 
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 Marker Site Unit HC Active CD Inactive CD p value 
Mucosal 
damage 
I-FABP serum ng/ml 304.61 
(146.40-468.27) 
199.97 
(87.72-527.02) 
170.77 
(51.03-568.57 
ns 
Claudin 1 colon B:I ratio 0.25 
(0.11-0.52) 
1.83 
(1.17-8.12) 
1.50 
(0.23-5.18) 
0.0003
 a
 
Claudin 4 B:I ratio 0.64 
(0.47-1.79) 
3.12 
(1.63-9.37) 
1.21 
(0.67-5.83) 
ns 
Occludin B:I ratio 1.15 
(0.53-1.66) 
3.03 
(0.86-9.80) 
3.83 
(0.53-7.45) 
ns 
MT LBP plasma µg/ml 12.42 
(8.98-16.59) 
18.37 
(16.26-21.02) 
19.30 
(11.85-21.73) 
0.0110
 b
 
Endotoxin serum IU/ml 0.22 
(0.00-1.24) 
0.12 
(0.02-0.19) 
0.13 
(0.10-0.26) 
ns 
16s rDNA plasma Copies/ml 24.11 
(12.28-63.45) 
4.63 
(2.05-27.70) 
11.70 
(5.76-17.55) 
0.0089
 c
 
LPS IHC colon +ve/total 
%pos 
13/22, 59% 
 
5/8, 63% 6/10, 60% ns 
IA CD38++ blood % Memory 
CD4 
3.77 
(2.87-6.14) 
4.37 
(3.01-6.22) 
4.56 
(3.85-7.96) 
ns 
HLA DR+ 
CD38+ 
blood % Memory 
CD4 
1.48 
(1.03-2.59) 
1.13 
(0.76-4.03) 
1.26 
(0.68-2.15) 
ns 
CD38++ blood % Memory 
CD8 
1.51 
(0.94-2.42) 
1.99 
(1.73-6.19) 
2.17 
(0.97-4.78) 
ns 
HLA DR+ 
CD38+ 
blood % Memory 
CD8 
3.25 
(1.25-5.41) 
2.53 
(1.26-9.37) 
2.39 
(0.54-4.69) 
ns 
sCD163 serum µg/ml 0.44 
(0.39-0.60) 
0.50 
(0.39-0.72) 
0.40 
(0.28-0.60) 
ns 
sCD14 plasma µg/ml 1.44 
(1.18-1.88) 
1.61 
(1.33-2.58) 
1.29 
(1.14-1.72) 
ns 
Table 6-5 Markers of mucosal damage, microbial translocation and immune activation in CD and HC patients. 
Values shown are medians with interquartile ranges. MT= microbial translocation, IA = immune activation. aHC 
vs. active CD p=0.0010 post correction(pc), HC vs. inactive CD p=0.0123pc. bHC vs. active CD p=0.0245pc. 
cHC vs. active CD p=0.0208pc. 
 
6.10 Correlations between T cells, mucosal damage, 
microbial translocation and immune activation 
 
We saw no correlations between Harvey-Bradshaw Index scores and mucosal damage, 
microbial translocation, immune activation or mucosal T cell subsets. In the peripheral 
 224 
blood more severe CD was associated with lower percentage CD8 T cells (rs=-0.4856, 
p=0.0300, not shown).  
 
6.10.1 Correlations between mucosal damage, microbial 
translocation and immune activation 
 
There were no correlations between markers of mucosal damage (I-FABP, tight junction 
disruption) with markers of microbial translocation (LBP, 16s rDNA, endotoxin) or 
immune activation in CD. 
 
6.10.2 Correlations between mucosal damage and T cell subsets 
and cytokines 
 
We found a positive correlation between I-FABP and mucosal CD4 production of IL-2 
and IFNγ in CD (Figure 6-23). I-FABP also positively correlated to mucosal CD4 central 
memory T cells (p=0.0030, rs=0.6574, not shown).  
 
 
 
 
 
 
 
Figure 6-23 Correlation between I-FABP and mucosal CD4 cytokine production 
 
We found an inverse correlation between mucosal precursor TH17 cells and breaches in 
Claudin 4 and Occludin but not Claudin 1 in our CD patients (Figure 6-24). 
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Figure 6-24 Correlation of mucosal precursor TH17 cells and tight junction breaches. 
 
In contrast we saw a positive correlation between the frequency of mucosal TH17 cells 
(Il-17a+CD4+) and disruption to claudin 1 and occludin in CD patients (Figure 6-25).  
 
 
 
 
 
 
Figure 6-25 Correlation between tight junction breaches and mucosal TH17. 
 
There was also a strong correlation between all tight junction protein breach:intact ratios 
and TNF production by CD8 central memory T cells in the mucosa (Figure 6-26). 
 
 
Figure 6-26 Correlation between mucosal CD8 TNF production and tight junction disruption. 
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6.10.3 Correlations between immune activation and T cell 
subsets  
 
We found a positive association between plasma sCD14 levels and mucosal CD4 T cell 
secretion of IL-17f (Figure 6-27). 
 
 
 
 
 
 
 
 
Figure 6-27 Correlation between plasma sCD14 and mucosal IL-17f+CD4+ T cells in CD. 
 
Finally peripheral CD8 T cell activation was associated with CD4 memory T cell 
production of both IL-17a and TNF in the mucosa (Figure 6-28).   
 
 
 
 
 
 
 
 
 
Figure 6-28 correlation between T cell activation and mucosal CD4 cytokine production. Correlations were 
performed using Spearman’s Rho. 
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6.11 Discussion 
 
6.11.1 Key Findings 
 
We found significant breaches of claudin 1 staining in patients with active and inactive 
CD. There was a trend for increased disruption in claudin 4 and occludin in our patients 
that did not reach significance. There was elevated LPS binding protein in our active CD 
cohort but no other evidence of microbial translocation. We also found no evidence of 
peripheral T cell or monocyte activation in our patients. Finally we saw no rise in 
mucosal TH17 cells or cytokines in active CD. 
 
6.11.2 Discussion 
 
Crohn’s disease was associated with significant breaches in the pore-sealing tight junction 
claudin 1. This disruption was still evident, though reduced, in patients with inactive 
disease. We also saw a trend for increased disruption in claudin 4 and occludin tight 
junction staining in our patients that did not reach significance. Overall disruption to 
tight junctions was quite heterogeneous in both CD groups. Reduced occludin protein 
and mRNA expression in active CD has previously been reported (Kucharzik et al. 2001) 
and more recently CD was associated with a down regulation of occludin, claudin 5 and 
claudin 8, and unchanged levels of claudin1 and claudin 4 (Zeissig et al. 2007). 
Differences between our study and others may be due to the method of tight junction 
protein detection. We used immunohistochemical staining but other groups have 
quantified mRNA using PCR and protein levels using Western blot.  
 
Similar to other studies, and to our UC cohort, we saw elevated LBP in active CD 
(Funderburg et al. 2013) but we found no direct evidence of microbial product in the 
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circulation of our CD patients. This may be due to efficient immune clearance of LBP-
LPS complexes. Also similar to Funderburg et al we saw no evidence of increased T cell 
or monocyte activation (sCD14) in the circulation of our CD cohort.  There was also no 
associations between mucosal damage markers and markers of microbial translocation or 
peripheral immune activation. 
 
We observed no significant difference in blood or mucosal frequencies of precursor 
TH17 cells or TH17 cells in our CD patients. We also found no evidence that TH17 cells 
in Crohn’s disease had altered phenotype or ability to produce IFNγ, IL-2 or TNF 
compared to controls. There was also no difference in TH22 frequency or IL-22 
production by CD4 T cells in the blood or mucosa of our disease cohort. Our results are 
in contrast to other work that showed increased precursor TH17 in the mucosa of CD 
patients (Kleinschek et al. 2009) and increased mucosal IL-17a together with reduced IL-
22 (Leung et al. 2014). However it is important to clarify that our biopsies were all 
taken from macroscopically normal regions and other studies examined tissue from the 
inflamed lesions of patients. A recent study found elevated IL-17a production in inflamed 
regions of CD patients but no significant rise in non-inflamed CD tissue compared to 
controls (Leung et al. 2014). Also IL-23 driven inflammation in IBD has primarily been 
linked to TH17 but there are other cells capable of producing IL-17a, IL-17f and IL-22 
including CD3 negative innate lymphoid cells (ILC). These cells respond to IL-23 and 
have been found in elevated numbers in the inflamed mucosa of CD patients (Geremia et 
al. 2011). In support of our findings Geremia et al found no difference in TH17 gene 
expression in lamina propria T cells of CD patients compared to controls.  
 
We did see elevated IL-17f production by CD4 T cells in the blood of patients with 
inactive disease compared to controls though no differences in mucosal tissue. Other 
work has shown CD patients have 4-fold increased IL-17f mRNA expression in inflamed 
tissue compared to noninflamed regions (Seiderer et al. 2008). We found a correlation 
between mucosal CD4 IL-17f production and sCD14 levels (although neither was 
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elevated in our cohort) in CD, supporting a role for this subset in peripheral immune 
activation.  
 
Naïve CD4 and CD8 T cells were significantly elevated in the blood of our CD patients 
compared to controls. This is probably because our CD patients were significantly 
younger than our control cohort. In support of this we found a significant correlation 
between naïve T cells and the age of our CD and control patients (Naïve CD4: 
p=0.0003, rs=-0.5322. Naïve CD8: p=<0.0001, rs=-0.6238). Blood central memory 
CD8 T cells were significantly reduced in CD patients, although this too was associated 
with the age of the cohort (p=0.0025, rs=0.4541).  
 
Patients with active CD had elevated CD8 T cells in the mucosa compared to the blood 
and loss of blood CD8 T cells was associated with higher CD HBI disease score. Unlike 
the blood, mucosal naïve T cells were similar between controls and CD patients 
suggesting well established age-related T cell phenotype changes are not as distinct in 
mucosal compartments. Similar to the blood, mucosal central memory CD8 T cells were 
reduced in inactive CD compared to controls but this was not related to the age of our 
groups (p=0.1349, rs=0.2405) and so loss of CD8 central memory T cells appears to be 
a feature of Crohn’s disease.  
 
We saw a trend for reduced blood and mucosal CD4 T cell production of TNF in 
response to SEB stimulation that lost significance post correction. This is likely as a result 
of CD therapy; half of our active group and a third of our inactive patients were on anti-
TNF monoclonal treatment. There was however no significant difference in CD8 
production of TNF in the blood or mucosa of CD patients compared to controls. We 
also found no significant differences in the production of IFNγ or IL-2 by blood or 
mucosal T cells. This finding challenges the concept that CD is primarily a TH1 driven 
disease and is also in contrast to other work. Previous studies found elevated IFNγ 
production by CD4 lamina propria T cells (Fuss et al. 1996) and CD4 and CD8 T cells in 
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the blood (Funderburg et al. 2013). However other work has shown that mucosal 
cytokine profiles alter during disease progression, with IFNγ overproduction lost in long-
standing CD (Kugathasan et al. 2007) and no evidence of elevated TNF production in 
mucosal specimens with established lesions (Zorzi et al. 2013). Our CD cohort had been 
diagnosed a median of 8 years.  
 
Mucosal loss of precursor TH17 cells was inversely correlated with disruption to claudin 
4 and occludin staining. Conversely mucosal TH17 (CD4+IL-17a+) cells were highest in 
patients with the most disruption to claudin 1 and occludin staining supporting a 
pathogenic role for TH17 cells in CD. There was no correlation between precursor 
TH17 and TH17 cells in mucosal tissue and it is unclear why one subset appears to be 
involved in the protection of tight junctions and the other implicated in pathology. T 
helper cell plasticity is widely reported and it is possible that the CD161+CD4+ subset 
under different cytokine environments may mature into functional subsets distinct from 
TH17 cells.   
 
We found mucosal CD4 T cell production of IFNγ and IL-2 was associated with elevated 
serum levels of the mucosal damage marker I-FABP. We also found a positive correlation 
between tight junction disruption and production of TNF by CD8 central memory T 
cells in the mucosa. This supports mechanistic studies that showed IFNγ treatment 
decreases barrier function in T84 cell lines by reducing Zo-1 expression (Youakim and 
Ahdieh 1999) and by redistributing occludin, claudin 1 and claudin 4 away from the tight 
junction (Bruewer et al. 2003). TNF with IFNγ can also down regulate the occludin 
promoter, leading to reduced expression (Mankertz et al. 2000).  
 
 
6.11.3 Limitations 
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A limitation of this study is the relatively small sample size and the heterogeneous nature 
of the disease group. Due to the small numbers we were unable to divide our CD group 
into those with and without colonic involvement. Also as most patients were on 
immunosuppressive treatment it is unclear whether the lack of differences in cytokine 
production in CD compared to controls is due to successful therapy. As our control 
group was significantly older than our disease group it is also difficult to distinguish 
pathogenic changes in T cell phenotype from normal age-related changes.  
 
6.11.4 Future Work 
 
Further work would involve the measurement of other mucosal immune subsets, such as 
innate lymphoid cells and the assessment of TH17 associated cytokine production in 
biopsies taken from inflamed regions. We saw little evidence of microbial translocation 
in our cohort and although we demonstrated some disruption to tight junction staining 
we have not demonstrated that this leads to increased mucosal barrier impairment. Gut 
permeability could be assessed in vivo using the lactulose-mannitol intestinal permeability 
test. 
 
6.11.5 Conclusions 
 
We found significant breaches of claudin 1 staining and a trend for increased disruption 
in claudin 4 and occludin in our CD patients. There was limited evidence of microbial 
translocation and no evidence of peripheral T cell or monocyte activation in our patients. 
We also saw no rise in mucosal TH17 cells or associated cytokines in active CD, neither 
did we see elevated TH1 associated cytokines. There was however a positive correlation 
between mucosal damage and TH17 and TH1 mucosal cytokines supporting their 
previously described pathogenic role in Crohn’s disease.  
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Chapter 7  Conclusion: Comparisons between 
HIV and the inflamed colon (IBD) 
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7.1 Summary of Results 
 
We have demonstrated significant disruption of mucosal tight junction proteins in HIV 
infection that do not resolve on ART. We found evidence of microbial translocation in 
untreated HIV patients but not in ART, possibly indicating that ART restores immune 
clearance of microbial products. There was a significant association between mucosal 
damage, levels of viraemia and levels of microbial translocation in HIV. We saw a 
significant reduction in precursor (CD4+CD161+) TH17 cells but no significant 
depletion in expression of IL-17A or IL-22 by mucosal CD4 T cells.   In support of our 
hypothesis that the loss of mucosal TH17 cells is associated with impairment of the 
mucosal barrier we found an inverse correlation between precursor CD161+ TH17 cells 
and disruption to tight junctions. We also saw an inverse correlation between mucosal 
TH17 precursor frequency with microbial translocation and peripheral immune 
activation and conclude that precursor TH17 cell loss has a role in HIV pathogenesis. We 
further found evidence of CD4 and CD8 T cell dysregulation in the blood and mucosa of 
HIV infected patients including increased terminally differentiated cells and the loss of 
TH1 cells and MAIT cells.  
 
We found evidence of disruption to tight junction proteins, which positively correlated 
to the microbial translocation marker LBP as well as to precursor TH17 in patients with 
UC. In contrast to HIV we found elevated TH17-associated cytokines in the mucosa of 
UC patients that positively correlated with disease state. Although LBP was raised in 
active UC, we found no elevation of direct markers of microbial translocation (16rDNA, 
endotoxin) suggesting microbial immune clearance mechanisms are intact.  Our data 
supports a role for precursor TH17 cells in mucosal damage, elevated microbial 
translocation and immune activation within the setting of ulcerative colitis. 
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In Crohn’s disease we found significant breaches of claudin 1 staining and a trend for 
increased disruption in claudin 4 and occludin. There was however limited evidence of 
microbial translocation and no evidence of peripheral T cell or monocyte activation. We 
also saw no rise in mucosal precursor TH17, TH17 cells or associated cytokines in active 
CD compared to controls, although there was a positive correlation between mucosal 
damage and TH17 mucosal cytokines supporting their potential pathogenic role in 
Crohn’s disease.  
 
7.2 Comparisons between HIV and IBD 
 
We next compared our viraemic HIV patients to IBD patients with active disease 
activity. We found a number of differences in mucosal T cell phenotype and cytokine 
production. In the mucosa there was reduced central memory and increased terminally 
differentiated CD4 T cells in viraemic HIV compared to UC patients (Figure 7-1). 
 
 
 
 
 
 
 
Figure 7-1 Mucosal CD4 T cell phenotype in viraemic HIV and active IBD. Comparisons between groups were 
performed using Kruskal-Wallis with Dunn’s post-test correction (***=p<0.001). 
 
The ability of CD4 T cells to respond to SEB in the mucosa of viraemic infection was 
compromised compared to controls (Chapter 3) and also to active UC patients, (Figure 
7-2). There was less evidence of differences in mucosal CD8 responses to SEB but TNF 
was significantly reduced in viraemic HIV compared to active UC. Active CD patients 
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had similar SEB-induced cytokine production to controls and no significant differences to 
either UC or HIV patients.  
 
 
Figure 7-2 Mucosal CD4 T cell responses to SEB in viraemic HIV compared to active IBD. Comparisons between 
groups were performed using Kruskal-Wallis with Dunn’s post-test correction (**=p<0.01, ***=p<0.001). 
 
Viraemic HIV patients also had significantly reduced levels of precursor TH17 
(CD161+CD4+) cells and TH17 (IL-17a+CD4+) cells compared to active UC patients. 
The TH17/TH22 cytokine IL-22 was also significantly elevated in UC compared to 
viraemic HIV patients but we saw no differences in CD4 T cell production of IL-17f 
between groups.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7-3 Precursor TH17, TH17 and associated cytokines in viraemic HIV compared to active IBD 
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Similar to T cell production of IFNγ, TNF and IL-2 we saw no significant differences in 
TH17 cells and associated cytokines between our active CD patients with UC or HIV 
patients. 
 
Viraemic HIV was associated with elevated microbial translocation compared to active 
IBD. LPS-Binding protein levels were raised in active IBD and viraemic HIV infection 
compared to controls but were not significantly different to each other. However 16s 
rDNA levels in viraemic HIV plasma was significantly raised compared to active IBD and 
endotoxin significantly raised compared to active UC (Figure 7-4). 
 
Figure 7-4 Microbial translocation markers in active IBD and viraemic HIV infection. Comparisons between groups 
were performed using Kruskal-Wallis with Dunn’s post-test correction (*=p<0.05, **=p<0.01). 
 
Peripheral CD4 and CD8 T cell activation, measured by bright CD38 expression, was 
significantly raised in viraemic HIV compared to both active CD and active UC (Figure 
7-5). T cell activation measured by dual expression of HLA DR and CD38 was also 
raised in HIV infection on CD8 T cells compared to active CD and there was increased 
CD4 HLA DR+CD38+ T cells in viraemic HIV that lost significance post correction. 
 
Soluble CD14 levels in the plasma of viraemic HIV patients were similar to those in 
active IBD but we found a significant increase in serum levels of soluble CD163 in 
viraemia compared to active UC (not shown). 
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Figure 7-5 Peripheral T cell activation in viraemic HIV and active IBD. Comparisons between groups were performed 
using Kruskal-Wallis with Dunn’s post-test correction  (*=p<0.05, **=p<0.01). 
 
Viraemic HIV patients had increased levels of serum intestinal acid fatty acid binding 
protein compared to active UC and active CD that lost significance post correction 
(Figure 7-6). Finally, although we found less disruption to tight junctions in CD patients 
compared to controls we found no significant differences when we compared the level of 
tight junction protein disruption between active IBD groups and viraemic HIV infection 
(Figure 7-7).  
 
 
 
 
 
 
 
Figure 7-6 I-FABP in Active IBD and viraemic HIV infection. Comparisons between groups were performed using 
Kruskal-Wallis with Dunn’s post-test correction. 
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Figure 7-7 Tight junction protein Breach: Intact ratios in active IBD and Viraemic HIV infection. Comparisons 
between groups were performed using Kruskal-Wallis with Dunn’s post-test correction. 
 
7.3 Discussion 
Epithelial barrier dysregulation, measured by disruption to tight junction protein 
staining, is common in viraemic HIV infection and in patients with active IBD. In our 
patient cohort it appears to occur to a similar extent in these disease groups. Disruption 
to the epithelial barrier is not thought to be sufficient to cause disease in IBD, as 
unaffected first-degree relatives of CD patients have increased levels of paracellular 
permeability. The extent to which disruption of tight junction proteins contributes to 
intestinal permeability in IBD is also unclear. Our biopsies were collected from areas of 
the sigmoid colon without evidence of inflammation, and it is likely that inflamed regions 
in IBD have more significant structural damage allowing more pronounced translocation 
of microbial products. To confirm the role of the subtle tight junction disruptions we 
observed we would need to assess physiological markers of increased intestinal 
permeability and look for correlations.  
 
Although tight junction disruption was similar between groups we saw no evidence of 
circulating microbial products (measured by 16srDNA and endotoxin levels) in our IBD 
group in contrast to viraemic HIV patients. LPS-binding protein, an indirect marker of 
bacterial translocation, was however raised equally in all groups suggesting IBD patients 
are effectively clearing microbial product compared to viraemic HIV patients. Chronic 
HIV patients have significantly reduced IgA levels and reduced phagocytic macrophage 
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function in the lamina propria and hence microbial clearance may be compromised (Klatt 
et al. 2013). In health bacterial products from the intestine translocate into the portal 
system where they are cleared by Kupffer cells. In liver disease there is increased LPS 
found in systemic circulation, and excessive LPS translocation to the liver accelerates 
liver fibrosis and the release of proinflammatory cytokines (Marchetti et al. 2013). Thus 
in HIV infection an excess of LPS may contribute to liver damage which eventually leads 
to reduced ability to clear LPS hence increased levels in systemic circulation.  
 
Whether tight junction disruption is a cause or effect of mucosal inflammation in IBD 
and HIV still requires elucidation. In this study we examined T cell production of the 
pro-inflammatory cytokines IFNγ and TNF in the mucosa. Both UC and CD patients had 
similar levels to controls but we found significantly reduced mucosal CD4 T cell 
cytokine production in viraemic HIV. We could not find any correlations between this 
blunted response and mucosal damage. However future work would involve measuring 
inflammatory cytokines from other cell sources in the mucosa, as both TNF and IFNγ are 
known to be capable of directly damaging the mucosal epithelial barrier.  
 
In support of our hypothesis that microbial translocation is a cause of systemic immune 
activation we found a significant correlation between LBP and 16s rDNA with CD8 T 
cell activation and endotoxin with CD4 T cell activation in HIV infection (chapter 4). 
We also found significantly reduced T cell activation in our IBD patients, who had no 
evidence of increased microbial product in blood, compared to HIV, although the extent 
to which IBD therapy is affecting this measurement needs to be further studied.  
 
We found significantly reduced precursor TH17, IL-17a+CD4+ and IL-22+CD4+ T 
cells in HIV compared to UC. Claudin 1 disruption in HIV was associated with loss of 
mucosal precursor TH17 cells and loss of TH22 cells. However in UC disruption to all 
tight junction proteins was associated with elevated precursor TH17 cells. In CD loss of 
precursor TH17 and increased TH17 cells was associated with increased disruption to 
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tight junctions. Why the precursor TH17 subset is pathogenic in HIV but potentially 
protective in UC is unclear. It is possible that precursor TH17 cell recruitment occurs in 
UC in response to mucosal damage but the bulk loss of CD4 cells in HIV mucosa 
prevents this enrichment to sites of damage. Although interestingly, multivariate analysis 
in IBD patients with HIV infection has shown that HIV status was associated with 
reduced risk of IBD disease relapse (Viazis et al. 2010), perhaps as a result of the reduced 
mucosal CD4 T cell pool. In vitro studies investigating the effect of addition of TH17 
cytokines to polarised epithelial cell systems may help elucidate their role in both IBD 
and HIV. 
 
In conclusion we have demonstrated that microbial translocation is a feature of HIV 
infection and is associated with mucosal damage and peripheral immune activation. We 
also found some evidence that loss of precursor TH17 cells and TH17 cytokines 
contribute to immune activation and are associated with mucosal damage and microbial 
translocation. Comparing our HIV cohort to patients with an inflamed bowel (IBD) we 
found a similar level of tight junction disruption despite significantly different mucosal 
TH17 frequencies and hence could not establish that alterations in mucosal TH17 
cytokine secretions account for differences in gap junction protein expression.  
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3. Patient information sheet 	  PATIENT	  INFORMATION	  SHEET	  and	  CONSENT	  FORM	  
 
 
1. Study title 
 
Is depletion of CD4 TH17 lymphocytes in the gastrointestinal tract associated with 
microbial translocation and systemic immune activation in adult HIV-1 infection 
 
2. Invitation paragraph 
 
You are being invited to take part in a research study.  Before you decide it is important for 
you to understand why the research is being done and what it will involve.  Please take time 
to read the following information carefully and discuss it with friends, relatives and your GP if 
you wish.  Ask us if there is anything that is not clear or if you would like more information.  
Take time to decide whether or not you wish to take part. 
 
3. What is the purpose of the study? 
 
The purpose of this study is to investigate whether a breakdown in immune function in the 
gut is associated with widespread activation of the immune system which is known to be 
harmful in HIV infection. This information will be used to guide further research into mucosal 
immune function. Participation in the study will involve a single donation of 50 to 60mL 
blood, taken at the time of your endoscopic examination. Furthermore during your 
endoscopic examination extra biopsies will be taken in addition to any biopsies taken as part 
of your clinical care.  
  
4. Why have I been chosen? 
 
You have been chosen because you are attending Chelsea and Westminster Hospital for an 
endoscopic examination of your bowel. The study will be comparing immune cells in different 
patient populations. You fall into one of the following four categories: 
1) HIV infection not on antiretroviral therapy 
2) HIV infection on antiretroviral therapy with suppressed viral replication 
3) A family or personal history of colon polyps requiring surveillance by means of endoscopy 
4) known Inflammatory Bowel Disease requiring endoscopic examination to stage or assess 
your known disease or as part of a surveillance program for long standing disease 
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It is up to you to decide whether or not to take part.  If you do decide to take part you will be 
given this information sheet to keep and be asked to sign a consent form.  If you decide to 
take part you are still free to withdraw at any time and without giving a reason. Refusal to 
participate or subsequent withdrawal will not affect the standard of care you receive. 
 
5. What will happen to me if I take part? 
 
There are no extra visits associated with this study. Blood will be drawn at the same time as 
your endoscopic examination In addition during your routine endoscopic examination 10 
extra biopsies will be taken. Up to 40 biopsies of the large bowel are routinely taken at 
endoscopic examination. Taking the extra biopsies will add less than 5 minutes to your total 
procedure time, which typically takes about 30 minutes. No changes will be made to any of 
your routine clinical care. The extra blood taken will be no more than 60mls and will take no 
more than a few minutes to take.  
 
6. What do I have to do? 
 
After giving your consent, the blood for research will be drawn. During your endoscopic 
examination extra biopsies will be taken. There are no restrictions to taking medication or 
any other aspect of your lifestyle. 
7. What is the procedure that is being tested? 
The blood that is drawn for research purposes will be analysed for the presence and function 
of white blood cells, in particular the T cells. Analysis will be performed on the same day as 
the blood is drawn or may be prepared and frozen for analysis at another date. The extra 
biopsies that will be taken will be analysed for the presence and function of similar T cells, 
furthermore specialised proteins that are responsible for maintaining gut integrity will be 
analysed by specialised microscopic techniques. 
 
8. What are the side effects of taking part? 
As with all blood letting there can be some discomfort at the site of puncture. Taking 60 mls 
of blood will have no discernable effect on your total blood volume. Taking the extra biopsies 
will add less than 5 minutes to the total procedure time of your endoscopic examination, 
without significantly changing the risks of the procedure. 
9. What are the possible disadvantages and risks of taking part? 
Blood taking may be associated with discomfort and may leave a temporary bruise. Every 
effort will be made to minimise this. A slightly longer endoscopic procedure. 
10. What are the possible benefits of taking part? 
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There is no clinical benefit to you in taking part in this study. 
11. What if something goes wrong? 
If you are harmed by taking part in this research project, there are no special compensation 
arrangements.  If you are harmed due to someone’s negligence, then you may have 
grounds for legal action but you may have to pay for it.  Regardless of this, if you wish to 
complain about any aspect of the way you have been approached or treated during the 
course of this study, the normal NHS complaints mechanisms may be available to you. 
15. Will my taking part in this study be kept confidential? 
All information which is collected about you during the course of the research will be kept 
strictly confidential.  A member of the clinical team of the clinic you are attending will access 
your current medical notes and may also access future medical notes to check your health 
status over time for follow up data. Any information about you which leaves the 
hospital/surgery will have your name and address removed so that you cannot be 
recognised from it. Blood samples will be assigned an anonymous code on reaching the 
laboratory. This code will be used at all subsequent stages in the laboratory and in recording 
data. You will not be identified in any way.   
16. What will happen to the results of the research study? 
The study results will be presented at research conferences and published in research 
journals. You will not be identified in any way.  
17. Who is organising and funding the research? 
This research project is organised by the Department of Immunology at Chelsea and 
Westminster Hospital and funded by the St Stephens AIDS Trust and Pfizer UK. 
18. Who has reviewed this study? 
This study has been reviewed and approved by the Riverside Research Ethics Committee. 
The committee consists of medical staff and lay members. 
19.  Contact for further information 
In case of further questions regarding the study please speak to the study doctor. The study 
doctor is Dr Alan Steel. 
Thank you for reading this information sheet and taking part in this research.  
You will be given a copy of this information sheet and signed consent form to keep. 
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4. Patient consent form 
 
RESEARCH CONSENT FORM 
 
 
Title of Project: Is depletion of CD4 TH17 lymphocytes in the gastrointestinal tract 
associated with microbial translocation and systemic immune activation in adult HIV-
1 infection 
 
(The patient/volunteer should complete the whole of this sheet him/herself) 
 
 
Have you read the Information Sheet?     Yes No 
 
Have you had the opportunity to ask questions  
and discuss the study?       Yes No 
 
Have you received satisfactory answers to all of your questions?  Yes No 
 
Have you received enough information about the study?   Yes No 
 
Whom have you spoken to? (write name)      
 
 
Do you understand that you are free to withdraw from the study,  
at any time, without having to give a reason, and without affecting 
the quality of your present or future medical care?    Yes No 
 
Do you agree to take part in this study?     Yes No 
 
 
I understand that the Local Ethics Committee may review this form as part of a monitoring 
process. 
 
 
NAME IN BLOCK LETTERS: 
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Signature:       Date:  
 
 
SIGNATURE OF PERSON OBTAINING CONSENT 
 
 
Signature:       Date: 
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5. LAL assay validation 
 
Despite heat treatment of plasma samples prior to testing we found a significant 
inhibition of endotoxin recovery from spiked plasma controls, even when plasma was 
diluted to 2% (recommended dilution is 20%). 
 
 
 
 
 
 
 
 
We further recognised that reading the endotoxin plate at 405nm may lead to 
inaccuracies because plasma samples are yellow-coloured. As expected we found the OD 
of plasma samples with and without LAL reagent were highly correlated. 
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To overcome these difficulties we performed diazo-coupling and measured the final 
purple product at 540nm after diluting plasma samples to 1%. Unfortunately we still 
could not fully recover spiked controls and most patients measured at this concentration 
had OD values <0.01. We then moved on to develop a more robust way of measuring 
endotoxin (TLR4 assay). 
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6.  HIV T cell and TH17 phenotype in SPICE 
 
In SPICE we found a significant difference in blood CD4 phenotype between viraemic 
and ART patients (p=0.0213) due to the lower percentages of central memory T cells in 
viraemia (see below). Phenotypic shifts of CD4 T cells were more pronounced across 
groups in the mucosa with significant differences seen between controls, viraemia 
(p=<0.0001) and ART (p=0.0019) pie charts.  
 
 
 
 
 
 
 
 
 
 
 
 
 
SPICE pie charts showing CD4 T cell phenotype in blood and mucosa of controls and HIV patients. Pink = naïve, 
beige = terminally differentiated, purple= effector memory, green= central memory. Comparisons between pie charts 
were performed in SPICE using a partial permutation test. 
 
CD8 phenotype in the blood was significantly different between controls and both HIV 
groups.   
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We further looked at the ability of TH17 to secrete the pro-inflammatory cytokines 
IFNγ, IL-2 and TNF (see across). We found no difference in the cytokine production of 
TH17 cells in the blood (IFNγ; HC=9.13%, Viraemic=9.71%, ART=9.45%. IL-2; 
HC=50.20%, Viraemic=55.45%, ART=56.00%. TNF; HC=85.70%, 
Viraemic=85.40%, ART=86.35%). In the mucosa we also found no difference in TH17 
production of IFNγ (HC=8.76%, Viraemic=9.17%, ART=6.43%) or IL-2 
(HC=39.20%, Viraemic=26.90%, ART=33.15%) by TH17 cells. But we did find 
reduced TNF producing TH17 cells in viraemic infection compared to controls 
(HC=87.10%, Viraemic=66.40%, ART=79.05%, p=0.0268).  
SPICE pie charts CD8 memory phenotype MMC and PBMC. pink= naïve, beige = terminally 
differentiated, purple= effector memory, green= central memory. Comparisons between pie charts 
were performed in SPICE using a partial permutation test. 
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Cytokine production by blood and mucosal TH17 cells in controls and HIV patients 
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7. Further correlations in HIV-1 infection 
 
Further correlations between mucosal damage and blood T cell subsets 
 
Claudin 1 was inversely correlated to blood CD4 IL-2 production (p=0.010, rs=-0.409) 
and Claudin 1 and 4 inversely correlated to polyfunctional CD8 (Claudin 1; p=0.025, 
rs=-0.359. Claudin 4; p=0.004, rs=-0.456) T cells in the blood.  
 
Further correlations between microbial translocation and T cell subsets 
 
16s RNA was correlated to blood CD4 and CD8 production of IL-2 (CD4 p=0.020, 
rs=-0.372; CD8 p=0.004, rs=-0.447) and TNF (CD4 p=0.023, rs=-0.364; CD8 
p=0.022, rs=-0.365). There was also a strong inverse association between 
polyfunctional CD4 (p=0.007, rs=-0.424) and polyfunctional CD8 (p=0.001, rs=-
0.496) blood T cell percentages with 16s RNA plasma levels.  
 
Serum endotoxin levels were inversely correlated to CD8 TNF production in the blood 
of HIV-1 patients  (p=0.009, rs=-0.406). We also found an inverse correlation between 
mucosal CD4 IL-2 production and endotoxin levels  (p=0.025, rs=-0.362). 
 
Further correlations between immune activation and T cell subsets 
 
Plasma16s RNA levels and serum endotoxin levels were positively correlated to 
percentage terminally differentiated CD8 T cells in the blood (16s p=0.004, rs=0.455; 
Endotoxin p=0.027, rs=0.350). 
 
Levels of sCD14 were negatively correlated to IFNγ (p=0.014, rs=-0.384) and IL-2  
(p=0.034, rs=-0.335) production by CD4 T cells in the blood. We found no 
associations between sCD163 and CD4 or CD8 inflammatory cytokines in blood but saw 
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an inverse correlation between sCD163 and mucosal CD8 IL-2 production (p=0.019, 
rs=-0.399). 
 
Inflammatory cytokine production by blood CD4 T cells were not correlated to T cell 
activation markers.  There was an inverse association between CD8 T cell activation 
(CD38++) and CD8 IL-2 production in the blood (p=0.005, rs=-0.434). 
 
Similar to the blood, mucosal IL-2 production by CD8 T cells was also inversely 
correlated to CD8 CD38 bright activation (p=0.016, rs=-0.388) together with CD4 
activation (p=0.001, rs=-0.512). CD38++ CD8 T cell activation was also correlated to 
mucosal CD8 TNF production (p=0.010, rs=-0.410). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 276 
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Abstract 
  
Mucosal-associated invariant T (MAIT) cells are tissue-homing T cells recently implicated in HIV 
pathogenesis. We found that the proportion of MAIT cell in blood and colon of HIV+ patients are reduced in 
untreated infection. Antiretroviral therapy restored colonic but not blood MAIT cell percentages. We observed 
a negative correlation between colonic MAIT cells and T-cell activation in blood and suggest mucosal MAIT cell 
depletion may contribute to systemic immune activation in HIV infection. 
  
 
 
  
Mucosal-associated invariant T (MAIT) cells are a recently described innate-like mucosal-homing T cell 
subset which express the semi-invariant T cell receptor V[alpha]7.2, interleukin-18R and are strongly positive 
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for CD161 [1]. MAIT cells play a key role in host immunity against bacteria and fungi by recognition of vitamin 
B metabolites presented by the MHC class 1b-related protein MR1 [2]. Two recent studies have shown that 
antiretroviral therapy (ART) fails to restore MAIT cell percentages in the blood [3,4]. Damage to the mucosal 
epithelium resulting in microbial translocation has been proposed as a mechanism for the immune activation 
seen in HIV+ patients [5]. We hypothesized that depletion of MAIT cells in the colon of HIV+ patients would 
correlate with increased immune activation and markers of microbial translocation. 
  
We analysed paired blood and colonic samples from 37 HIV-1-infected patients (12 with detectable 
viraemia and 25 on suppressive ART) and 22 HIV-uninfected controls. The control patients were undergoing 
colonoscopy at Chelsea & Westminster NHS Trust due to a personal or family history of large bowel polyps or 
cancer. 
Biopsies were collected 25–30 cm from the anal verge of the sigmoid colon using Jumbo EndoJaw 3.7 
mm forceps (Olympus) and processed as previously described to obtain mucosal mononuclear cells (MMCs) [6]. 
Peripheral blood mononuclear cells and MMCs were stained with Violet Dead Cell Stain (Invitrogen) and the 
following antibodies: CD16-FITC, CD3-V500, CD8-AF700, CD19-V450, CD14-V450, CD161-PE-CY5, HLADR-FITC, 
CD38-PE (all BD Bioscience); CD45RO-PE-TR (Beckman Coulter); CD27-APC-Efluor780 (eBioscience); and CD4-
QDot605 (Invitrogen). The cells were acquired on an LSRII (BD Bioscience) and analysed in FlowJo v8.8.6 
(TreeStar). After gating to exclude doublets, aggregates, and dead cells, MAIT cells were identified as 
CD3+CD4-CD8+ lymphocytes with bright expression of CD161. To exclude NKT cells, we confirmed that the 
population was CD16-negative. T-cell activation was identified on memory CD8+ cells by bright CD38 
expression. 
  
Quantitative real-time PCR was performed using Platinum Syber Green Supermix (Invitrogen) in an 
Applied Biosystems ABI PRISM 7000 with a standard curve made from purified Escherichia coli (Affymetrix). 
Primers used were: forward (5'-3'-TGG AGC ATG TGG TTT AAT TCG A), reverse (5'-3'-TGC GGG ACT TAA CCC 
AAC A) (Eurofins MWG Operon), and PCR conditions were: 10 min 95oC, 40× 40 s 94oC, 45 s 60oC, 45 s 72oC. A 
PCR run was accepted if the slope of the standard fell between -3.6 and -3.3, and the curve fit was greater 
than 0.985. The samples were run in duplicate and repeated if the SD of the quantification cycle (Cq) was 
greater than 0.500. Soluble CD14 (R&D Systems) was measured in plasma according to the manufacturers’ 
instructions. Kruskal–Wallis test with Dunns multiple correction was used to compare groups and correlations 
were performed using Spearman's rho in Prism 4 (GraphPad). 
  
We saw a significant reduction in the proportion of blood CD8+ T cells that express CD161++ in ART-naive 
and ART-treated HIV patients compared to healthy controls (Table 1; P < 0.001). The expression of CD161++ on 
CD8+ T cells isolated from colon samples was also significantly reduced in viraemic HIV (P = 0.005), but was 
similar to controls in patients receiving ART. We found no correlation between MAIT cell proportions in the 
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blood compared to the colon in our control or HIV groups. We also found no correlation between mucosal 
MAIT cells and the time since diagnosis in ART-naive patients group or time on treatment in the ART-treated 
cohort. 
  
Table 1 Patient demographics and results. 
 
CD8+ T-cell activation was significantly increased in both the HIV groups (Table 1; P < 0.001) compared 
to controls, and levels of activation were significantly higher in viraemic compared to aviraemic HIV (P < 
0.001). We found a significant inverse correlation between mucosal MAIT cell proportions and levels of 
CD8+ T-cell activation in both the HIV and control groups (HIV Spearman's rho = -0.434, P = 0.008; controls 
Spearman's rho = -0.512, P = 0.018). We also found significantly raised levels of sCD14 in the plasma of both 
HIV groups compared to controls (P = 0.006), but this did not correlate with MAIT cell levels. There was a 
trend for increased bacterial 16s rDNA in viraemic patients (Table 1; P = 0.051), but we found no correlations 
with blood or colonic MAIT cells. 
  
Our data confirm results of recent studies showing a significant reduction in the proportion of blood 
CD161++CD8+T cells in viraemic and ART-treated HIV patients compared to healthy controls [3,4]. However, in 
contrast to the study by Leeansyahet al.[3], we found a significant depletion of MAIT cells isolated from colon 
biopsies in viraemic HIV patients compared to controls. Differences in sampling sites, markers used to identify 
MAIT cells and patient characteristics may in part account for discrepancy between the two studies. It has 
been proposed that the rate of loss of MAIT cells in mucosal tissues is much slower than that seen in blood 
and the failure of ART to restore this lymphocyte subset in blood argues for treatment of HIV as early as 
possible to preserve host immunity against bacterial and fungal infections [7]. Our results show that the 
kinetics of MAIT cell loss in untreated HIV infection appears to be similar in the blood and mucosa, and we 
demonstrate that ART appears to be effective in restoring the MAIT cell population. Although we did find a 
negative correlation between T-cell activation and mucosal MAIT cell proportions in both our HIV and control 
populations, we did not find any associations with evidence of microbial translocation. However, microbial 
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translocation is more frequently seen in patients with advanced chronic disease [8]and our cohort included 
patients with more recent infection. It is possible that the relationship between colonic MAIT cell proportions 
and microbial translocation may be more apparent if one were to evaluate bacterial translocation directly at 
mucosal sites [4]. 
  
In conclusion, we show that, although MAIT cells remain diminished in blood even during ART, colonic 
MAIT cell populations restore to normal levels and negatively correlate with CD8+ T-cell immune activation in 
HIV infection. We suggest that this correlation with immune activation, identified as a better marker of HIV 
disease progression than CD4+ cell counts and viral loads [9], implies an important regulatory function for 
MAIT cells located in the gastrointestinal tract. 
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